QUARTERLY REPORT
Q1 2022 — Quarterly report (10-Q)
Q1 2022PDF · 139 pages1.3 MB
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________________________________
FORM 10-Q
_____________________________________________
(Mark One)
☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended March 31, 2022
OR
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from to
____________________________________________
Marsh & McLennan Companies, Inc.
1166 Avenue of the Americas
New York, New York 10036
(212) 345-5000
_____________________________________________
Commission file number 1-5998
State of Incorporation: Delaware
I.R.S. Employer Identification No. 36-2668272
_____________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol(s) Name of exchange on which registered
Common Stock, par value $1.00 per share MMC New York Stock Exchange
Chicago Stock Exchange
London Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to
be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to
submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an
emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule
12b-2 of the Exchange Act.
Large Accelerated Filer ☒ Accelerated Filer ☐
Non-Accelerated Filer ☐(Do not check if a smaller reporting company) Smaller Reporting Company ☐
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of April 18, 2022, there were outstanding 501,913,724 shares of common stock, par value $1.00 per share, of the registrant.
-- 1 of 139 --
INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains "forward-looking statements," as defined in the Private Securities Litigation Reform Act of 1995. These
statements, which express management's current views concerning future events or results, use words like "anticipate," "assume," "believe," "continue,"
"estimate," "expect," "intend," "plan," "project" and similar terms, and future or conditional tense verbs like "could," "may," "might," "should," "will" and
"would".
Forward-looking statements are subject to inherent risks and uncertainties that could cause actual results to differ materially from those expressed or
implied in our forward-looking statements. Factors that could materially affect our future results include, among other things:
• the impact of geopolitical or macroeconomic conditions on us, our clients and the countries and industries in which we operate, including from
conflicts such as the war in Ukraine, capital markets volatility and inflation;
• the increasing prevalence of ransomware, supply chain and other forms of cyber attacks, and their potential to disrupt our operations and result in
the disclosure of confidential client or company information;
• the impact from lawsuits or investigations arising from errors and omissions, breaches of fiduciary duty or other claims against us in our capacity
as a broker or investment advisor, including claims related to our investment business’ ability to execute timely trades in light of increased trading
volume;
• the financial and operational impact of complying with laws and regulations, including domestic and international sanctions regimes, anti-corruption
laws such as the U.S. Foreign Corrupt Practices Act, U.K. Anti Bribery Act and cybersecurity and data privacy regulations;
• our ability to attract, retain and develop industry leading talent;
• our ability to compete effectively and adapt to competitive pressures in each of our businesses, including from disintermediation as well as
technological change, digital disruption and other types of innovation;
• our ability to manage potential conflicts of interest that may arise across our businesses given our expanding client base, the broad scope of our
work and the significant volume of our engagements;
• the impact of changes in tax laws, guidance and interpretations, or disagreements with tax authorities; and
• the regulatory, contractual and reputational risks that arise based on insurance placement activities and insurer revenue streams.
The factors identified above are not exhaustive. Marsh McLennan and its subsidiaries (collectively, the "Company") operate in a dynamic business
environment in which new risks emerge frequently. Accordingly, we caution readers not to place undue reliance on any forward-looking statements, which
are based only on information currently available to us and speak only as of the dates on which they are made. The Company undertakes no obligation to
update or revise any forward-looking statement to reflect events or circumstances arising after the date on which it is made.
Further information concerning Marsh McLennan and its businesses, including information about factors that could materially affect our results of
operations and financial condition, is contained in the Company's filings with the Securities and Exchange Commission, including the "Risk Factors" section
and the "Management’s Discussion and Analysis of Financial Condition and Results of Operations" section of this Quarterly Report on Form 10-Q and our
most recently filed Annual Report on Form 10-K.
2
-- 2 of 139 --
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION 4
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) 4
CONSOLIDATED STATEMENTS OF INCOME 4
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 5
CONSOLIDATED BALANCE SHEETS 6
CONSOLIDATED STATEMENTS OF CASH FLOWS 8
CONSOLIDATED STATEMENTS OF EQUITY 9
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 10
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS 32
OF OPERATIONS
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 44
ITEM 4. CONTROLS & PROCEDURES 45
PART II. OTHER INFORMATION 46
ITEM 1. LEGAL PROCEEDINGS 46
ITEM 1A. RISK FACTORS 46
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 46
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 46
ITEM 4. MINE SAFETY DISCLOSURE 46
ITEM 5. OTHER INFORMATION 46
ITEM 6. EXHIBITS 46
3
-- 3 of 139 --
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.
MARSH & McLENNAN COMPANIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Three Months Ended
March 31,
(In millions, except per share data) 2022 2021
Revenue $ 5,549 $ 5,083
Expense:
Compensation and benefits 3,100 2,807
Other operating expenses 1,004 918
Operating expenses 4,104 3,725
Operating income 1,445 1,358
Other net benefit credits 62 71
Interest income 1 —
Interest expense (110) (118)
Investment income 26 11
Income before income taxes 1,424 1,322
Income tax expense 338 324
Net income before non-controlling interests 1,086 998
Less: Net income attributable to non-controlling interests 15 15
Net income attributable to the Company $ 1,071 $ 983
Net income per share attributable to the Company:
- Basic $ 2.13 $ 1.93
- Diluted $ 2.10 $ 1.91
Average number of shares outstanding:
- Basic 503 509
- Diluted 509 514
Shares outstanding at March 31, 502 509
The accompanying notes are an integral part of these unaudited consolidated statements.
4
-- 4 of 139 --
MARSH & McLENNAN COMPANIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
Three Months Ended
March 31,
(In millions) 2022 2021
Net income before non-controlling interests $ 1,086 $ 998
Other comprehensive (loss) income, before tax:
Foreign currency translation adjustments (169) (91)
Gain related to pension/post-retirement plans 86 6
Other comprehensive loss, before tax (83) (85)
Income tax expense on other comprehensive income 21 2
Other comprehensive loss, net of tax (104) (87)
Comprehensive income 982 911
Less: comprehensive income attributable to non-controlling interest 15 15
Comprehensive income attributable to the Company $ 967 $ 896
The accompanying notes are an integral part of these unaudited consolidated statements.
5
-- 5 of 139 --
MARSH & McLENNAN COMPANIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In millions, except share data)
(Unaudited)
March 31,
2022 December 31,
2021
ASSETS
Current assets:
Cash and cash equivalents $ 772 $ 1,752
Receivables
Commissions and fees 5,503 5,093
Advanced premiums and claims 139 136
Other 494 523
6,136 5,752
Less-allowance for credit losses (173) (166)
Net receivables 5,963 5,586
Other current assets 1,053 926
Total current assets 7,788 8,264
Goodwill 16,254 16,317
Other intangible assets 2,720 2,810
Fixed assets (net of accumulated depreciation and amortization of $1,679 at March 31, 2022
and $1,589 at December 31, 2021) 865 847
Pension related assets 2,246 2,270
Right of use assets 1,825 1,868
Deferred tax assets 530 551
Other assets 1,460 1,461
$ 33,688 $ 34,388
The accompanying notes are an integral part of these unaudited consolidated statements.
6
-- 6 of 139 --
MARSH & McLENNAN COMPANIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (Continued)
(In millions, except share data)
(Unaudited)
March 31,
2022 December 31,
2021
LIABILITIES AND EQUITY
Current liabilities:
Short-term debt $ 1,191 $ 17
Accounts payable and accrued liabilities 3,084 3,165
Accrued compensation and employee benefits 1,400 2,942
Current lease liabilities 331 332
Accrued income taxes 308 198
Dividends payable 273 —
Total current liabilities 6,587 6,654
Fiduciary liabilities 10,461 9,622
Less – cash and cash equivalents held in a fiduciary capacity (10,461) (9,622)
— —
Long-term debt 10,552 10,933
Pension, post-retirement and post-employment benefits 1,515 1,632
Long-term lease liabilities 1,831 1,880
Liabilities for errors and omissions 352 355
Other liabilities 1,695 1,712
Commitments and contingencies — —
Equity:
Preferred stock, $1 par value, authorized 6,000,000 shares, none issued — —
Common stock, $1 par value, authorized 1,600,000,000 shares, issued 560,641,640 shares at
March 31, 2022 and December 31, 2021 561 561
Additional paid-in capital 1,026 1,112
Retained earnings 18,916 18,389
Accumulated other comprehensive loss (4,679) (4,575)
Non-controlling interests 219 213
16,043 15,700
Less – treasury shares, at cost, 58,524,983 shares at March 31, 2022
and 57,105,619 shares at December 31, 2021 (4,887) (4,478)
Total equity 11,156 11,222
$ 33,688 $ 34,388
The accompanying notes are an integral part of these unaudited consolidated statements.
7
-- 7 of 139 --
MARSH & McLENNAN COMPANIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
For the Three Months Ended March 31,
(In millions) 2022 2021
Operating cash flows:
Net income before non-controlling interests $ 1,086 $ 998
Adjustments to reconcile net income used for operations:
Depreciation and amortization of fixed assets and capitalized software 89 97
Amortization of intangible assets 91 100
Non cash lease expense 77 79
Adjustments and payments related to contingent consideration assets and liabilities 10 (1)
Deconsolidation of Russian businesses 39 —
Net gain on investments (26) (11)
Net (gain) loss on disposition of assets (1) 3
Share-based compensation expense 105 78
Changes in assets and liabilities:
Net receivables (429) (404)
Other assets (117) (116)
Accrued compensation and employee benefits (1,528) (1,167)
Provision for taxes, net of payments and refunds 144 198
Contributions to pension and other benefit plans in excess of current year credit (125) (102)
Other liabilities (33) (78)
Operating lease liabilities (84) (82)
Net cash used for operations (702) (408)
Financing cash flows:
Purchase of treasury shares (500) (112)
Net proceeds from issuance of commercial paper 825 —
Repayments of debt (4) (4)
Shares withheld for taxes on vested units – treasury shares (134) (93)
Issuance of common stock from treasury shares 34 35
Payments of deferred and contingent consideration for acquisitions (16) (32)
Receipts of contingent consideration for dispositions 3 —
Distributions of non-controlling interests (7) (8)
Dividends paid (272) (237)
Change in fiduciary liabilities 926 190
Net cash provided by (used for) financing activities 855 (261)
Investing cash flows:
Capital expenditures (122) (69)
Net (purchases) sale of long term investments (8) 4
Dispositions (4) —
Acquisitions (24) —
Other, net (1) (2)
Net cash used for investing activities (159) (67)
Effect of exchange rate changes on cash, cash equivalents, and cash and cash equivalents held in a fiduciary capacity (136) (36)
Decrease in cash, cash equivalents, and cash and cash equivalents held in a fiduciary capacity (142) (772)
Cash, cash equivalents, and cash and cash equivalents held in a fiduciary capacity at beginning of period 11,375 10,674
Cash, cash equivalents, and cash and cash equivalents held in a fiduciary capacity at end of period $ 11,233 $ 9,902
Reconciliation of cash, cash equivalents, and cash and cash equivalents held in a fiduciary capacity to the Consolidated Balance Sheets
Three Months Ended March 31, 2022 2021
(In millions)
Cash and cash equivalents $ 772 $ 1,120
Cash and cash equivalents held in a fiduciary capacity 10,461 8,782
Total cash, cash equivalents, and cash and cash equivalents held in a fiduciary capacity $ 11,233 $ 9,902
The accompanying notes are an integral part of these unaudited consolidated statements.
8
-- 8 of 139 --
MARSH & McLENNAN COMPANIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited)
Three Months Ended
March 31,
(In millions, except per share data) 2022 2021
COMMON STOCK
Balance, beginning and end of period $ 561 $ 561
ADDITIONAL PAID-IN CAPITAL
Balance, beginning of period $ 1,112 $ 943
Change in accrued stock compensation costs (145) (133)
Issuance of shares under stock compensation plans and employee stock purchase plans 59 41
Balance, end of period $ 1,026 $ 851
RETAINED EARNINGS
Balance, beginning of period $ 18,389 $ 16,272
Net income attributable to the Company 1,071 983
Dividend equivalents declared (4) (3)
Dividends declared (540) (472)
Balance, end of period $ 18,916 $ 16,780
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME
Balance, beginning of period $ (4,575) $ (5,110)
Other comprehensive (loss) income, net of tax (104) (87)
Balance, end of period $ (4,679) $ (5,197)
TREASURY SHARES
Balance, beginning of period $ (4,478) $ (3,562)
Issuance of shares under stock compensation plans and employee stock purchase plans 91 113
Purchase of treasury shares (500) (112)
Balance, end of period $ (4,887) $ (3,561)
NON-CONTROLLING INTERESTS
Balance, beginning of period $ 213 $ 156
Net income attributable to non-controlling interests 15 15
Distributions and other changes (9) (9)
Balance, end of period $ 219 $ 162
TOTAL EQUITY $ 11,156 $ 9,596
Dividends declared per share $ 1.07 $ 0.93
The accompanying notes are an integral part of these unaudited consolidated statements.
9
-- 9 of 139 --
MARSH & McLENNAN COMPANIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Nature of Operations
Marsh & McLennan Companies, Inc. (the "Company"), a global professional services firm, is organized based on the different services that it offers.
Under this structure, the Company’s two business segments are Risk and Insurance Services and Consulting.
The Risk and Insurance Services segment ("RIS") provides risk management solutions (risk advice, risk transfer and risk control and mitigation) as
well as insurance and reinsurance broking and services for businesses, public entities, insurance companies, associations, professional services
organizations, and private clients. The Company conducts business in this segment through Marsh and Guy Carpenter. Marsh provides data-driven
risk advisory services and solutions to commercial and consumer clients. Guy Carpenter develops advanced risk, reinsurance and capital strategies
that help clients grow profitably and identify and capitalize on emerging opportunities.
The Company conducts business in its Consulting segment through Mercer and Oliver Wyman Group. Mercer delivers advice and solutions that
help organizations create a dynamic world of work, shape retirement and investment outcomes, and unlock health and well being for a changing
workforce. Oliver Wyman Group serves as critical strategic, economic and brand advisor to private sector and governmental clients.
Deconsolidation of Russia
On February 24, 2022, Russian forces launched a military invasion of Ukraine. In response, the United States, the European Union, United
Kingdom and other governments have imposed significant economic sanctions on Russia, and Russia has responded with counter-sanctions. The
war in Ukraine has disrupted international commerce and the global economy.
On March 10, 2022, the Company announced it would exit its businesses in Russia and transfer ownership of its Russian businesses to local
management who will operate independently in the Russian market.
In the first quarter of 2022, the Company concluded that it does not meet the accounting criteria for control over its wholly-owned Russian
businesses due to the evolving trade and economic sanctions against Russia and related Russian counter-sanctions. These sanctions include
restrictions on payments to and from Russian companies and reduced currency access through official exchange markets that have significantly
impacted the Company's ability to effectively manage and operate its Russian businesses. For the three months ended March 31, 2022, the
Company recorded a loss of $52 million on the deconsolidation of the Russian businesses and other related charges. Refer to Note 8, Acquisitions
and Dispositions, for additional information on the deconsolidation of the Russian businesses.
The Company continues to monitor the ongoing situation and its potential impact on our business, financial condition, results of operations and
cash flows.
Business Update Related To COVID-19
For over two years, the COVID-19 pandemic has impacted businesses globally including in every geography in which the Company operates. Our
businesses have remained resilient throughout the pandemic and demand for our advice and services remains strong.
The Company had strong revenue growth the first three months of 2022. However, uncertainty remains in the economic outlook, and the ultimate
extent of the impact of COVID-19 to the Company will depend on future developments that it is unable to predict, including new "waves" of infection
from emerging variants of the virus and potential renewed restrictions and mandates by various governments or agencies.
2. Principles of Consolidation and Other Matters
The Company prepared the consolidated financial statements included herein pursuant to the rules and regulations of the Securities and Exchange
Commission. For interim filings, certain information and disclosures normally included in financial statements prepared in accordance with
accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. The Company
believes that the information and disclosures presented are adequate to make such information and disclosures not misleading. These consolidated
financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Form 10-K").
10
-- 10 of 139 --
The financial information contained herein reflects all normal recurring adjustments which are, in the opinion of management, necessary for a fair
presentation of the Company’s consolidated financial statements as of and for the three months ended March 31, 2022 and 2021.
Estimates: The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosures of assets and liabilities at the date of the financial statements, and the reported amounts
of revenue and expense during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies.
The estimates are based on historical experience and on various other assumptions that the Company believes are reasonable.
Such matters include:
• estimates of revenue;
• impairment assessments and charges;
• recoverability of long-lived assets;
• liabilities for errors and omissions;
• deferred tax assets, uncertain tax positions and income tax expense;
• share-based and incentive compensation expense;
• the allowance for current expected credit losses on receivables;
• useful lives assigned to long-lived assets, and depreciation and amortization; and
• fair value estimates of contingent consideration receivable or payable related to acquisitions or dispositions.
The Company believes these estimates are reasonable based on information currently available at the time they are made. The Company also
considered the potential impact of COVID-19 and the war in Ukraine to its customer base in various industries and geographies. Insurance
exposures subject to variable factors are subject to mid-term and end of term adjustments, as well as policy audits, which may reduce premiums
and corresponding commissions. Estimates were updated based on internal and industry specific economic data. The ultimate extent to which
COVID-19 will directly or indirectly impact the Company’s businesses, results of operations and financial condition will depend on numerous
evolving factors and future developments that it is not able to predict. Actual results may differ from these estimates.
Cash and Cash Equivalents
Cash and cash equivalents primarily consist of certificates of deposit and time deposits, with original maturities of three months or less, and money
market funds. The estimated fair value of the Company's cash and cash equivalents approximates their carrying value. The Company is required to
maintain operating funds primarily related to regulatory requirements outside of the United States or as collateral under captive insurance
arrangements. At March 31, 2022, the Company maintained $304 million compared to $303 million at December 31, 2021 related to these
regulatory requirements.
Allowance for Credit Losses on Accounts Receivable
The Company’s policy for providing an allowance for credit losses on its accounts receivable is based on a combination of factors, including
historical write-offs, aging of balances, and other qualitative and quantitative analyses. The charge related to expected credit losses was immaterial
to the consolidated statements of income for the three months ended March 31, 2022 and 2021,respectively.
Investments
The caption "Investment income" in the consolidated statements of income comprises realized and unrealized gains and losses from investments
recognized in earnings. It includes, when applicable, other than temporary declines in the value of securities, mark-to-market increases or
decreases in equity investments with readily determinable fair values and equity method gains or losses on the Company's investments in private
equity funds.
The Company holds investments in certain private equity funds. Investments in private equity funds are accounted for in accordance with the equity
method of accounting using a consistently applied three-month lag period adjusted for any known significant changes from the lag period to the
reporting date of the Company. The underlying private equity funds follow investment company accounting, where investments within the fund are
carried at fair value. Investment gains or losses for its proportionate share of the change in fair value of the funds are recorded in earnings.
Investments using the equity method of accounting are included in "other assets" in the consolidated balance sheets.
11
-- 11 of 139 --
The Company recorded investment income of $26 million for the three months ended March 31, 2022 compared to investment income of $11
million for the same period last year. The increase in 2022 is primarily driven by higher mark to market gains in the Company's private equity
investments and its investment in Alexander Forbes ("AF").
Income Taxes
The Company's effective tax rate in the first quarter of 2022 was 23.7% compared with 24.5% in the first quarter of 2021.
The tax rates in both periods reflect the impact of discrete tax matters such as excess tax benefits related to share-based compensation, enacted
tax legislation, changes in uncertain tax positions, deferred tax adjustments and nontaxable adjustments to contingent acquisition consideration.
The excess tax benefit related to share-based payments is the most significant discrete item, as it normally is in the first quarter because that is
when most share-based compensation vests, reducing the effective tax rate by 1.8% and 1.1% in the first quarters of 2022 and 2021, respectively.
The rate in the first quarter of 2022 also reflects tax benefits from planning implemented in the period that postponed the utilization of current year
losses in the U.K. to a future year when the tax rate will be 25%.
The Company's tax rate reflects its income, statutory tax rates, and tax planning in the various jurisdictions in which it operates. Significant
judgment is required in determining the annual effective tax rate and in evaluating uncertain tax positions.
Losses in one jurisdiction, generally, cannot offset earnings in another, and within certain jurisdictions profits and losses may not offset between
entities. Consequently, losses in certain jurisdictions may require valuation allowances affecting the effective tax rate, depending on estimates of
the realizability of associated deferred tax assets. The tax rate is also sensitive to changes in unrecognized tax benefits, including the impact of
settled tax audits and expired statutes of limitation.
Changes in tax laws or tax rulings may have a significant impact on our effective tax rate. The Company reports a liability for unrecognized tax
benefits resulting from uncertain tax positions taken or expected to be taken in tax returns. The Company's gross unrecognized tax benefits was
$94 million at March 31, 2022 and December 31, 2021. It is reasonably possible that the total amount of unrecognized tax benefits will decrease
between zero and approximately $49 million within the next twelve months due to settlements of audits and expirations of statutes of limitation.
Integration and Restructuring Charges
Severance and related costs are recognized based on amounts due under established severance plans or estimates of one-time benefits that will
be provided. Typically, severance benefits are recognized when the impacted colleagues are notified of their expected termination and such
termination is expected to occur within the legally required notification period. These costs are included in compensation and benefits in the
consolidated statements of income.
Costs for real estate consolidation are recognized based on the type of cost, and the expected future use of the facility. For locations where the
Company does not expect to sub-lease the property, the amortization of any Right-of-use ("ROU") asset is accelerated from the decision date to the
cease use date. For locations where the Company expects to sub-lease the properties subsequent to its vacating the property, the ROU asset is
reviewed for potential impairment at the earlier of the cease use date or the date a sub-lease is signed. To determine the amount of impairment, the
fair value of the ROU asset is determined based on the present value of the estimated net cash flows related to the property. Contractual costs
outside of the ROU asset are recognized based on the net present value of expected future cash outflows for which the Company will not receive
any benefit. Such amounts are reliant on estimates of future sub-lease income to be received and future contractual costs to be incurred. These
costs are included in other operating expenses in the consolidated statements of income.
Other costs related to integration and restructuring, such as moving, legal or consulting costs are recognized as incurred. These costs are included
in other operating expenses in the consolidated statements of income.
3. Revenue
The core principle of the revenue recognition guidance is that an entity should recognize revenue to depict the transfer of promised goods or
services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or
services. To achieve this principle, the entity applies the following steps: identify the contract(s) with the customer, identify the performance
obligations in the contract(s), determine the transaction price, allocate the transaction price to the performance obligations in the contract and
recognize revenue when (or as) the entity satisfies a performance obligation.
12
-- 12 of 139 --
In accordance with accounting guidance, a performance obligation is satisfied either at a “point in time” or “over time” depending on the nature of
the product or service provided, and the specific terms of the contract with customers.
Other revenue included in the consolidated statements of income that is not from contracts with customers is less than 2% of total revenue, and
therefore, is not presented as a separate line item.
The Company's revenue recognition guidance is provided in more detail in Note 2, Revenue, in the Form 10-K for the year ended December 31,
2021.
The following table disaggregates components of the Company's revenue:
Three Months Ended
March 31,
(In millions) 2022 2021
Marsh:
EMEA $ 842 $ 837
Asia Pacific 321 274
Latin America 104 90
Total International 1,267 1,201
U.S./Canada 1,279 1,124
Total Marsh 2,546 2,325
Guy Carpenter 999 895
Subtotal 3,545 3,220
Fiduciary interest income 4 5
Total Risk and Insurance Services $ 3,549 $ 3,225
Mercer:
Wealth $ 617 $ 623
Health 524 487
Career 202 178
Total Mercer 1,343 1,288
Oliver Wyman Group 667 585
Total Consulting $ 2,010 $ 1,873
The Company recognizes commission revenue for a significant portion of its brokerage arrangements at a point in time on the effective date of the
underlying policy. Commission revenue is estimated using historical information about the risks to be covered over the policy period, some of which
are dependent on variable factors such as number of employees covered, covered payroll, airline passenger miles flown, shipped tonnage of
marine cargo and others.
The following table provides contract assets and contract liabilities information from contracts with customers:
(In millions) March 31, 2022 December 31, 2021
Contract assets $ 357 $ 290
Contract liabilities $ 824 $ 776
The Company records accounts receivable when the right to consideration is unconditional, subject only to the passage of time. Contract assets
primarily relate to quota share reinsurance brokerage and contingent insurer revenue. The Company does not have the right to bill and collect
revenue for quota share brokerage until the underlying policies written by the ceding insurer attach to the treaty. Estimated revenue related to
achievement of volume or loss ratio metrics cannot be billed or collected until all related policy placements are completed and the contingency is
resolved. Contract assets are included in other current assets in the Company's consolidated balance sheets. Contract liabilities primarily relate to
the advance consideration received from customers. Contract liabilities are included in current liabilities in the Company's consolidated balance
sheets. Revenue recognized in the first three months of 2022 and 2021 that was included in the contract liability balance at the beginning of each of
those years was $280 million and $238 million, respectively.
13
-- 13 of 139 --
The amount of revenue recognized in the first three months of 2022 and 2021 from performance obligations satisfied in previous periods, mainly
due to variable consideration from contracts with insurers, quota share business and consulting contracts previously considered constrained was
$24 million and $34 million, respectively.
The Company applies the practical expedient and does not disclose the value of unsatisfied performance obligations for (1) contracts with original
contract terms of one year or less and (2) contracts where the Company has the right to invoice for services performed. The revenue expected to
be recognized in future periods during the non-cancellable term of existing contracts greater than one year that is related to performance
obligations that are unsatisfied or partially satisfied at the end of the reporting period is approximately $187 million, primarily related to Mercer. The
Company expects revenue in 2023, 2024, 2025, 2026 and 2027 and beyond of $78 million, $61 million, $28 million, $12 million and $8 million,
respectively, related to these performance obligations.
4. Fiduciary Assets and Liabilities
In its capacity as an insurance broker or agent, generally the Company collects premiums from insureds and after deducting its commissions,
remits the premiums to the respective insurance underwriters. The Company also collects claims or refunds from underwriters on behalf of
insureds. Un-remitted insurance premiums and claims proceeds are held by the Company in a fiduciary capacity. The Company's fiduciary assets
primarily include bank or short term time deposits and liquid money market funds, and are classified as cash and cash equivalents. Risk and
Insurance Services revenue includes interest on fiduciary funds of $4 million and $5 million for the three months ended March 31, 2022 and 2021,
respectively. Since cash and cash equivalents held in a fiduciary capacity are not available for corporate use, they are shown in the consolidated
balance sheets as an offset to fiduciary liabilities.
Net uncollected premiums and claims and the related payables amounted to $13.0 billion at March 31, 2022 and at December 31, 2021
respectively. The Company is not a principal to the contracts under which the right to receive premiums or the right to receive reimbursement of
insured losses arises.
Accordingly, net uncollected premiums and claims and the related payables are not assets and liabilities of the Company and are not included in
the accompanying consolidated balance sheets. In certain instances, the Company advances premiums, refunds or claims to insurance
underwriters or insureds prior to collection. These advances are made from corporate funds and are reflected in the accompanying consolidated
balance sheets as receivables.
The Company, through its Mercer subsidiary, manages assets in trusts or funds for which Mercer’s management or trustee fee is not considered a
variable interest, since the fees are commensurate with the level of effort required to provide those services. Mercer is not the primary beneficiary of
these trusts or funds. Mercer’s maximum exposure to loss of its interests is, therefore, limited to collection of its fees.
5. Per Share Data
Basic net income per share attributable to the Company is calculated by dividing the after-tax income attributable to the Company by the weighted
average number of outstanding shares of the Company’s common stock.
Diluted net income per share attributable to the Company is calculated by dividing the after-tax income attributable to the Company by the weighted
average number of outstanding shares of the Company’s common stock, which have been adjusted for the dilutive effect of potentially issuable
common shares.
Basic and Diluted EPS Calculation
Three Months Ended
March 31,
(In millions, except per share data) 2022 2021
Net income before non-controlling interests $ 1,086 $ 998
Less: Net income attributable to non-controlling interests 15 15
Net income attributable to the Company $ 1,071 $ 983
Basic weighted average common shares outstanding 503 509
Dilutive effect of potentially issuable common shares 6 5
Diluted weighted average common shares outstanding 509 514
Average stock price used to calculate common stock equivalents $ 157.49 $ 114.96
14
-- 14 of 139 --
6. Supplemental Disclosures to the Consolidated Statements of Cash Flows
The following table provides additional information concerning acquisitions, interest and income taxes paid for the three month periods ended
March 31, 2022 and 2021.
(In millions) 2022 2021
Assets acquired, excluding cash $ 30 $ —
Liabilities assumed (2) —
Contingent/deferred purchase consideration (4) —
Net cash outflow for current year acquisitions $ 24 $ —
(In millions) 2022 2021
Interest paid $ 171 $ 191
Income taxes paid, net of refunds $ 201 $ 122
The classification of contingent consideration payments in the consolidated statements of cash flows is dependent upon whether receipt, payment
or adjustment was part of the initial liability established on the acquisition date (financing) or an adjustment to the acquisition date liability
(operating).
The following amounts are included in the consolidated statements of cash flows as operating and financing activities:
For the Three Months Ended March 31,
(In millions) 2022 2021
Operating:
Contingent consideration payments $ — $ (1)
Acquisition/disposition related net charges for adjustments 10 —
Adjustments and payments related to contingent consideration $ 10 $ (1)
Financing:
Contingent purchase consideration $ (4) $ (10)
Deferred purchase consideration related to prior years' acquisitions (12) (27)
Payments of deferred and contingent consideration for acquisitions $ (16) $ (37)
Receipt of contingent consideration related to prior year dispositions $ 3 $ 5
The Company had non-cash issuances of common stock under its share-based payment plan of $250 million and $212 million for the three months
ended March 31, 2022 and 2021, respectively. The Company recorded share-based compensation expense related to restricted stock units,
performance stock units and stock options of $105 million and $78 million for the three months ended March 31, 2022 and 2021, respectively.
Statement of Cash Flows Reclassifications
In the first quarter of 2022, the Company refined the statements of cash flows presentation to combine and reclassify certain line items within the
operating cash flows section. The prior year's presentation was conformed to the current presentation and had no impact on operating cash flows.
15
-- 15 of 139 --
7. Other Comprehensive Income (Loss)
The changes, net of tax, in the balances of each component of Accumulated Other Comprehensive Income ("AOCI") for the three months ended
March 31, 2022 and 2021, including amounts reclassified out of AOCI, are as follows:
(In millions)
Pension/Post-
Retirement Plans
Gains (Losses)
Foreign Currency
Translation Gains
(Losses)
Total Gains
(Losses)
Balance as of December 31, 2021 $ (3,202) $ (1,373) $ (4,575)
Other comprehensive income (loss) before reclassifications 35 (169) (134)
Amounts reclassified from accumulated other comprehensive income 30 — 30
Net current period other comprehensive income (loss) 65 (169) (104)
Balance as of March 31, 2022 $ (3,137) $ (1,542) $ (4,679)
(In millions)
Pension/Post-
Retirement Plans
Gains (Losses)
Foreign Currency
Translation Gains
(Losses) Total Gains
(Losses)
Balance as of December 31, 2020 $ (4,126) $ (984) $ (5,110)
Other comprehensive income (loss) before reclassifications (36) (91) (127)
Amounts reclassified from accumulated other comprehensive income 40 — 40
Net current period other comprehensive income (loss) 4 (91) (87)
Balance as of March 31, 2021 $ (4,122) $ (1,075) $ (5,197)
The components of other comprehensive income (loss) for the three month periods ended March 31, 2022 and 2021 are as follows:
Three Months Ended March 31, 2022 2021
(In millions) Pre-Tax Tax (Credit) Net of Tax Pre-Tax Tax (Credit) Net of Tax
Foreign currency translation adjustments $ (169) $ — $ (169) $ (91) $ — $ (91)
Pension/post-retirement plans:
Amortization of gains included in net periodic
pension cost:
Net actuarial losses 39 9 30 52 12 40
Subtotal 39 9 30 52 12 40
Foreign currency translation adjustments 65 16 49 (37) (8) (29)
Other adjustments (18) (4) (14) (7) (2) (5)
Effect of re-measurement — — — (2) — (2)
Pension/post-retirement plans gains 86 21 65 6 2 4
Other comprehensive (loss) income $ (83) $ 21 $ (104) $ (85) $ 2 $ (87)
Components of net periodic pension cost are included in other net benefit credits in the consolidated statements of income. Income tax expense on net actuarial
losses are included in income tax expense.
(a)
(a)
16
-- 16 of 139 --
8. Acquisitions and Dispositions
The Company’s acquisitions have been accounted for as business combinations. Net assets and results of operations are included in the
Company’s consolidated financial statements commencing at the respective purchase closing dates. In connection with acquisitions, the Company
records the estimated values of the net tangible assets and the identifiable intangible assets purchased, which typically consist of customer
relationships, developed technology, trademarks and non-compete agreements. The valuation of purchased intangible assets involves significant
estimates and assumptions. The Company estimates the fair value of purchased intangible assets, primarily using the income approach, by
determining the present value of future cash flows over the remaining economic life of the respective assets. The significant estimates and
assumptions used in this approach include the determination of the discount rate, economic life, future revenue growth rates, expected account
attrition rates and earnings margins. Refinement and completion of final valuation of net assets acquired could affect the carrying value of tangible
assets, goodwill and identifiable intangible assets.
The Risk and Insurance Services segment completed one acquisition during the three months ended March 31, 2022:
• January – Marsh McLennan Agency ("MMA") acquired Heil & Kay Insurance Agency Inc., an Illinois-based full-service independent
insurance agency providing business insurance, employee health benefits services and personal lines insurance.
The Consulting segment completed two acquisitions during the three months ended March 31, 2022:
• February – Oliver Wyman acquired Azure Consulting, an Australia-based management consulting firm with expertise in strategy
development, organizational design and operations in the industrials, energy and natural resources sectors.
• March – Mercer acquired GeFi Assurances, a France-based brokerage and consulting firm specializing in collective corporate social
protection.
Total purchase consideration for acquisitions made during the three months ended March 31, 2022 was $28 million, which consisted of cash paid of
$24 million and deferred purchase consideration and estimated contingent consideration of $4 million. Contingent consideration arrangements are
based primarily on earnings before interest, tax, depreciation and amortization ("EBITDA") or revenue targets over a period of two to four years.
During the three months ended March 31, 2022, the Company also paid $12 million of deferred purchase consideration and $4 million of contingent
consideration related to acquisitions made in prior years. Estimated fair values of assets acquired and liabilities assumed are subject to adjustment
until purchase accounting is finalized.
The following table presents the preliminary allocation of purchase consideration to the assets acquired and liabilities assumed during 2022 based
on the estimated fair values for the acquisitions as of their respective acquisition dates:
Acquisitions through March 31, 2022
(In millions)
Cash $ 24
Estimated fair value of deferred/contingent consideration 4
Total consideration $ 28
Allocation of purchase price:
Net receivables 1
Other current assets 2
Goodwill 17
Other intangible assets 10
Total assets acquired 30
Current liabilities 1
Other liabilities 1
Total liabilities assumed 2
Net assets acquired $ 28
17
-- 17 of 139 --
The purchase price allocation for assets acquired and liabilities assumed is based on estimates that are preliminary in nature and subject to
adjustments, which could be material. Any necessary adjustments must be finalized during the measurement period, which for a particular asset,
liability, or non-controlling interest ends once the acquirer determines that either (1) the necessary information has been obtained or (2) the
information is not available. However, the measurement period for all items is limited to one year from the acquisition date.
Items subject to change include:
• amounts of intangible assets, fixed assets, capitalized software assets and right-of-use assets, subject to finalization of valuation efforts;
• amounts for contingencies, pending the finalization of the Company’s assessment of the portfolio of contingencies;
• amounts for deferred tax assets and liabilities, pending the finalization of valuations of the assets acquired, liabilities assumed and
associated goodwill discussed below; and
• amounts for income tax assets, receivables and liabilities, pending the filing of the acquired companies' pre-acquisition income tax returns
and receipt of information from taxing authorities which may change certain estimates and assumptions used.
The estimation of fair value requires numerous judgments, assumptions and estimates about future events and uncertainties, which could materially
impact these values, and the related amortization, where applicable, in the Company’s results of operations.
The following table provides information about intangible assets acquired during 2022:
Intangible assets through March 31, 2022
(In millions) Amount
Weighted Average
Amortization Period
Client relationships $ 10 10.4 years
The consolidated statements of income include the results of operations of acquired companies since their respective acquisition dates. The
Company had no acquisitions during the first three months of 2021.
Dispositions
During the first three months of 2022, Mercer sold its retirement plan administration and call center operations in Brazil for cash proceeds of
approximately $4 million.
Prior-Year Acquisitions
The Risk and Insurance Services segment completed eight acquisitions during 2021:
• April – MMA acquired PayneWest Insurance, Inc., a Montana-based full-service broker providing business insurance, surety, employee
benefits and personal insurance services to companies and individuals, and The Pryor Group, LLC, a Texas-based full-service broker
providing business insurance with a specialty in quick service restaurants and the personal lines of franchise owners.
• September – MMA acquired Vaaler Insurance, Inc., a North Dakota-based insurance broker providing business insurance, employee health
and benefits, and personal lines solutions, with specialized expertise in the construction, education, and healthcare industries.
• November – MMA acquired Pelnik Insurance, a North Carolina-based full-service broker providing business insurance, employee health
and benefits, and private client services to midsize businesses and individuals throughout the Mid-Atlantic, Southwest Truck Insurance
Agency, Inc., a Texas-based broker providing business insurance for the trucking industry, serving clients in the U.S., and Mexico and
InSource Insurance Group LLC, a Texas-based full-service broker providing business insurance, employee health and benefits, private
client and surety services to the oil and gas, construction, manufacturing, and transportation industries.
• December – Marsh acquired Services Assurance Monétique (SAM), a France-based affinity insurance broker specializing in bank and retail
insurance markets and increased its ownership interest in Marsh India Insurance Broker Private Limited ("Marsh India") from 49% to 92%.
The Consulting segment completed one acquisition during 2021:
• November – Oliver Wyman Group acquired Huron Consulting Group’s life sciences strategy consulting practice in the U.S. and the U.K.,
which assists clients in addressing their most important commercial strategy, marketing, pricing, market access and research and
development challenges.
18
-- 18 of 139 --
Prior year dispositions
There were no dispositions during the first three months of 2021.
Deconsolidation of Russia
In the first quarter of 2022, the Company concluded that it does not meet the accounting criteria for control over its wholly-owned Russian
subsidiaries, and therefore, deconsolidated the businesses effective as of the end of the first quarter.
For the three months ended March 31, 2022, the Company recorded a loss of $39 million on the deconsolidation of the Russian businesses
included in revenue in the consolidated statements of income. The loss consisted of the reclassification of cumulative translation losses from
accumulated other comprehensive income and a charge for the write-off of the Russia businesses' net assets.
On March 10, 2022, the Company announced it would exit its businesses in Russia and transfer ownership of its Russian entities to local
management who will operate independently in the Russian market. The closing of the transaction is subject to approval from the Russian
regulators.
Subsequent event
On April 1, 2022, Mercer sold its U.S. affinity business that provides insurance marketing, brokerage and administration to association and affinity
groups for cash proceeds of approximately $145 million and a net gain of approximately $110 million.
Pro-Forma Information
The following unaudited pro-forma financial data gives effect to the acquisitions made by the Company during 2022 and 2021. In accordance with
accounting guidance related to pro-forma disclosures, the information presented for acquisitions made in 2022 is as if they occurred on January 1,
2021 and reflects acquisitions made in 2021 as if they occurred on January 1, 2020. The unaudited pro-forma information includes the effects of
amortization of acquired intangibles. The unaudited pro-forma financial data is presented for illustrative purposes only and is not necessarily
indicative of the operating results that would have been achieved if such acquisitions had occurred on the dates indicated, nor is it necessarily
indicative of future consolidated results.
Three Months Ended
March 31,
(In millions, except per share data) 2022 2021
Revenue $ 5,550 $ 5,156
Net income attributable to the Company $ 1,071 $ 987
Basic net income per share attributable to the Company $ 2.13 $ 1.94
Diluted net income per share attributable to the Company $ 2.10 $ 1.92
9. Goodwill and Other Intangibles
The Company is required to assess goodwill and any indefinite-lived intangible assets for impairment annually, or more frequently if circumstances
indicate impairment may have occurred. The Company performs the annual impairment assessment for each of its reporting units during the third
quarter of each year. In accordance with applicable accounting guidance, a company can assess qualitative factors to determine whether it is
necessary to perform a quantitative goodwill impairment test. Alternatively, the Company may elect to proceed directly to the quantitative goodwill
impairment test. In 2021, the Company elected to perform a qualitative impairment assessment. As part of its assessment, the Company
considered numerous factors, including:
• that the fair value of each reporting unit exceeds its carrying value by a substantial margin based on its most recent quantitative
assessment in 2019;
• whether significant acquisitions or dispositions occurred which might alter the fair value of its reporting units;
• macroeconomic conditions and their potential impact on reporting unit fair values;
• actual performance compared with budget and prior projections used in its estimation of reporting unit fair values;
• industry and market conditions; and
• the year-over-year change in the Company’s share price.
19
-- 19 of 139 --
The Company completed its qualitative assessment in the third quarter of 2021 and concluded that goodwill was not impaired.
Other intangible assets that are not deemed to have an indefinite life are amortized over their estimated lives and assessed for impairment upon the
occurrence of certain triggering events in accordance with applicable accounting literature. Based on its assessment, the Company concluded that
other intangible assets were not impaired. The Company does not have any indefinite lived intangible assets.
Changes in the carrying amount of goodwill are as follows:
March 31,
(In millions) 2022 2021
Balance as of January 1, $ 16,317 $ 15,517
Goodwill acquired 17 —
Other adjustments (80) (59)
Balance at March 31, $ 16,254 $ 15,458
Primarily reflects the impact of foreign exchange.
The goodwill arising from the acquisitions in 2022 and 2021 consists largely of the synergies and economies of scale expected from combining the
operations of the Company and the acquired entities and the trained and assembled workforce acquired.
The goodwill acquired in 2022 was $17 million, of which approximately $1.6 million is deductible for tax purposes, and is primarily related to the
Risk and Insurance Services segment.
Goodwill allocable to the Company’s reportable segments at March 31, 2022 is as follows: Risk and Insurance Services, $12.5 billion and
Consulting, $3.8 billion.
The gross cost and accumulated amortization of identified intangible assets at March 31, 2022 and December 31, 2021 are as follows:
March 31, 2022 December 31, 2021
(In millions)
Gross
Cost Accumulated
Amortization
Net
Carrying
Amount Gross
Cost Accumulated
Amortization
Net
Carrying
Amount
Client relationships $ 4,041 $ 1,389 $ 2,652 $ 4,066 $ 1,334 $ 2,732
Other 362 294 68 365 287 78
Amortized intangibles $ 4,403 $ 1,683 $ 2,720 $ 4,431 $ 1,621 $ 2,810
Primarily non-compete agreements, trade names and developed technology.
Aggregate amortization expense for the three months ended March 31, 2022 and 2021 was $91 million and $100 million, respectively. The
estimated future aggregate amortization expense is as follows:
For the Years Ending December 31,
(In millions) Estimated Expense
2022 (excludes amortization through March 31, 2022) $ 261
2023 328
2024 308
2025 269
2026 248
Subsequent years 1,306
Total future amortization $ 2,720
(a)
(a)
(a)
(a)
20
-- 20 of 139 --
10. Fair Value Measurements
Fair Value Hierarchy
The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as
defined by the FASB. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1)
and lowest priority to unobservable inputs (Level 3). In some cases, the inputs used to measure fair value might fall into different levels of the fair
value hierarchy. In such cases, the level in the fair value hierarchy, for disclosure purposes, is determined based on the lowest level input that is
significant to the fair value measurement. Assets and liabilities recorded in the consolidated balance sheets at fair value are categorized based on
the inputs in the valuation techniques as follows:
Level 1. Assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market
(examples include active exchange-traded equity securities and exchange-traded money market mutual funds).
Assets and liabilities measured using Level 1 inputs include exchange-traded equity securities, exchange-traded mutual funds and money market
funds.
Level 2. Assets and liabilities whose values are based on the following:
a) Quoted prices for similar assets or liabilities in active markets;
b) Quoted prices for identical or similar assets or liabilities in non-active markets (examples include corporate and municipal
bonds, which trade infrequently);
c) Pricing models whose inputs are observable for substantially the full term of the asset or liability (examples include most
over-the-counter derivatives, including interest rate and currency swaps); and
d) Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or
other means for substantially the full asset or liability (for example, certain mortgage loans).
Assets and liabilities using Level 2 inputs are related to an equity security.
Level 3. Assets and liabilities whose values are based on prices, or valuation techniques that require inputs that are both unobservable and
significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a
market participant would use in pricing the asset or liability.
Assets and liabilities measured using Level 3 inputs relate to assets and liabilities for contingent purchase consideration.
Valuation Techniques
Equity Securities, Money Market Mutual Funds and Mutual Funds – Level 1
Investments for which market quotations are readily available are valued at the sale price on their principal exchange or, for certain markets, official
closing bid price. Money market mutual funds are valued using a valuation technique that results in price per share at $1.00.
Contingent Purchase Consideration Assets and Liabilities – Level 3
Purchase consideration for some acquisitions and dispositions made by the Company include contingent consideration arrangements. Contingent
consideration arrangements are based primarily on EBITDA or revenue targets over a period of two to four years. The fair value of the contingent
purchase consideration asset and liability is estimated as the present value of future cash flows to be paid, based on projections of revenue and
earnings and related targets of the acquired and disposed entities.
21
-- 21 of 139 --
The following fair value hierarchy table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis
as of March 31, 2022 and December 31, 2021:
Identical Assets
(Level 1)
Observable Inputs
(Level 2)
Unobservable
Inputs
(Level 3) Total
(In millions) 03/31/22 12/31/21 03/31/22 12/31/21 03/31/22 12/31/21 03/31/22 12/31/21
Assets:
Financial instruments owned:
Exchange traded equity securities $ 69 $ 61 $ — $ — $ — $ — $ 69 $ 61
Mutual funds 179 192 — — — — 179 192
Money market funds 82 425 — — — — 82 425
Other equity investment — — 8 8 — — 8 8
Contingent purchase consideration assets
— — — — 2 5 2 5
Total assets measured at fair value $ 330 $ 678 $ 8 $ 8 $ 2 $ 5 $ 340 $ 691
Fiduciary Assets:
U.S. treasury bills $ 30 $ 55 $ — $ — $ — $ — $ 30 $ 55
Money market funds 205 527 — — — — 205 527
Total fiduciary assets measured
at fair value $ 235 $ 582 $ — $ — $ — $ — $ 235 $ 582
Liabilities:
Contingent purchase
consideration liability $ — $ — $ — $ — $ 358 $ 352 $ 358 $ 352
Total liabilities measured at fair value $ — $ — $ — $ — $ 358 $ 352 $ 358 $ 352
Included in other assets in the consolidated balance sheets.
Included in cash and cash equivalents in the consolidated balance sheets.
Included in other receivables in the consolidated balance sheets.
Included in accounts payable and accrued liabilities and other liabilities in the consolidated balance sheets.
Maturity dates of three months or less.
The Level 3 assets in the table reflect contingent purchase consideration from the sale of businesses. The change in the contingent purchase
consideration assets from December 31, 2021 is driven primarily by cash receipts.
During the three months ended March 31, 2022, there were no assets or liabilities that were transferred between levels.
The following table sets forth a summary of the changes in fair value of the Company’s Level 3 liabilities for the three month periods ended
March 31, 2022 and 2021:
Three Months Ended
March 31,
(In millions) 2022 2021
Balance at beginning of period $ 352 $ 243
Payments (4) (11)
Revaluation impact 10 1
Balance at March 31, $ 358 $ 233
Long-Term Investments
The Company holds investments in public and private companies as well as certain private equity investments that are accounted for using the
equity method of accounting. The carrying value of these investments was $224 million and $207 million at March 31, 2022 and December 31,
2021, respectively.
(a)
(a)
(b)
(a)
(c)
(e)
(d)
(a)
(b)
(c)
(d)
(e)
22
-- 22 of 139 --
Investments in Public and Private Companies
The Company has investments in private insurance and consulting companies with a carrying value of $51 million and $58 million at March 31,
2022 and December 31, 2021, respectively. These investments are accounted for using the equity method of accounting, the results of which are
included in revenue in the consolidated statements of income and the carrying value of which is included in other assets in the consolidated
balance sheets. The Company records its share of income or loss on its equity method investments, some of which are on a one quarter lag basis.
Private Equity Investments
The Company's investments in private equity funds were $173 million and $149 million at March 31, 2022 and December 31, 2021, respectively.
The carrying values of these private equity investments approximate fair value. The underlying private equity funds follow investment company
accounting, where investments within the fund are carried at fair value. The Company records in earnings its proportionate share of the change in
fair value of the funds on the investment income (loss) line in the consolidated statements of income. These investments are included in other
assets in the consolidated balance sheets. The Company recorded net investment gains of $17 million for the three month period ended March 31,
2022, and gains of $10 million from these investments for the same period in 2021.
Other Investments
At March 31, 2022 and December 31, 2021, the Company held certain equity investments with readily determinable market values of $82 million
and $75 million, respectively, including an investment in the common stock of Alexander Forbes ("AF") of $64 million at March 31, 2022 and $57
million at December 31, 2021. At March 31, 2022 and December 31, 2021, the Company recorded investment gains on these investments of $9
million and $5 million, respectively. The Company also held investments without readily determinable market values of $39 million and $36 million
at March 31, 2022 and December 31, 2021, respectively.
11. Derivatives
Net Investment Hedge
The Company has investments in various subsidiaries with Euro functional currencies. As a result, the Company is exposed to the risk of
fluctuations between the Euro and U.S. dollar exchange rates. The Company designated its €1.1 billion senior note debt instruments ("euro notes")
as a net investment hedge (the "hedge") of its Euro denominated subsidiaries. The hedge effectiveness is re-assessed each quarter to confirm that
the designated equity balance at the beginning of each period continues to equal or exceed 80% of the outstanding balance of the Euro debt
instrument and that all the critical terms of the hedging instrument and the hedged net investment continue to match. If the Company concludes that
the hedge is highly effective, the change in the debt balance related to foreign exchange fluctuations is recorded in foreign currency translation
gains (losses) in the consolidated balance sheets. The Company concluded that the hedge continues to be highly effective as of March 31, 2022.
The U.S. dollar value of the euro notes decreased $29 million through March 31, 2022 due to the impact of foreign exchange rates, with a
corresponding decrease to accumulated other comprehensive loss.
12. Leases
The Company leases office facilities under non-cancelable operating leases with terms generally ranging between 10 and 25 years. The Company
utilizes these leased office facilities for use by its employees in countries in which the Company conducts its business. None of the Company’s
leases restrict the payment of dividends or the incurrence of debt or additional lease obligations, or contain significant purchase options.
Operating leases are recognized on the balance sheet as ROU assets and operating lease liabilities based on the present value of the remaining
future minimum payments over the lease term at commencement date of the lease.
23
-- 23 of 139 --
The following table provides additional information about the Company’s property leases:
Three Months Ended
March 31,
(In millions) 2022 2021
Lease Cost:
Operating lease cost $ 90 $ 94
Short-term lease cost 1 1
Variable lease cost 34 37
Sublease income (5) (8)
Net lease cost $ 120 $ 124
Other information:
Operating cash outflows from operating leases $ 99 $ 99
Right of use assets obtained in exchange for new operating lease liabilities $ 51 $ 22
Weighted-average remaining lease term – real estate 8.7 years 8.3 years
Weighted-average discount rate – real estate leases 2.75% 2.93%
Excludes ROU asset impairment charges.
Future minimum lease payments for the Company’s operating leases as of March 31, 2022 are as follows:
Payment Dates (In millions) Real Estate Leases
Remainder of 2022 $ 290
2023 356
2024 314
2025 282
2026 258
2027 223
Subsequent years 710
Total future lease payments 2,433
Less: Imputed interest (271)
Total $ 2,162
Current lease liabilities $ 331
Long-term lease liabilities 1,831
Total lease liabilities $ 2,162
Note: Table excludes obligations for leases with original terms of 12 months or less which have not been recognized as a ROU asset or liability in the consolidated
balance sheets.
As of March 31, 2022, the Company had additional operating real estate leases that had not yet commenced of $41 million. These operating leases
will commence over the next 12 months.
13. Retirement Benefits
The Company maintains qualified and non-qualified defined benefit pension plans for some of its U.S. and non-U.S. eligible employees. The
Company’s policy for funding its tax-qualified defined benefit pension plans is to contribute amounts at least sufficient to meet the funding
requirements set forth in accordance with applicable law.
The target asset allocation for the Company's U.S. plans is 60% equities and equity alternatives and 40% fixed income. At March 31, 2022 the
actual allocation for the Company's U.S. Plan was 62% equities and equity alternatives and 38% fixed income. The target allocation for the U.K.
Plans at March 31, 2022 is 22% equities and equity alternatives and 78% fixed income. At March 31, 2022, the actual allocation for the U.K. Plans
was 24% equities and equity alternatives and 76% fixed income. The Company's U.K. Plans comprised approximately 81% of non-U.S. plan assets
at December 31, 2021. The assets of the Company's defined benefit plans are diversified and are managed in accordance with applicable laws and
with the goal of maximizing the plans' real return within acceptable risk parameters. The Company generally uses threshold-based portfolio re-
balancing to ensure the actual portfolio remains consistent with target asset allocation ranges.
(a)
(a)
24
-- 24 of 139 --
The components of the net periodic benefit cost for defined benefit plans are as follows:
Combined U.S. and significant non-U.S. Plans Pension
Benefits For the Three Months Ended March 31,
(In millions) 2022 2021
Service cost $ 8 $ 10
Interest cost 100 85
Expected return on plan assets (202) (208)
Recognized actuarial loss 39 52
Net periodic credit $ (55) $ (61)
Amounts Recorded in the Consolidated Statement of Income
Combined U.S. and significant non-U.S. Plans Pension
Benefits For the Three Months Ended March 31,
(In millions) 2022 2021
Compensation and benefits expense $ 8 $ 10
Other net benefit credit (63) (71)
Total credit $ (55) $ (61)
U.S. Plans only Pension
Benefits For the Three Months Ended March 31,
(In millions) 2022 2021
Interest cost $ 48 $ 46
Expected return on plan assets (84) (82)
Recognized actuarial loss 19 23
Net periodic credit $ (17) $ (13)
Significant non-U.S. Plans only Pension
Benefits For the Three Months Ended March 31,
(In millions) 2022 2021
Service cost $ 8 $ 10
Interest cost 52 39
Expected return on plan assets (118) (126)
Recognized actuarial loss 20 29
Net periodic credit $ (38) $ (48)
The weighted average actuarial assumptions utilized to calculate the net periodic benefit costs for the U.S. and significant non-U.S. defined benefit
plans are as follows:
Combined U.S. and significant non-U.S. Plans
Pension
Benefits
For the Three Months Ended March 31, 2022 2021
Weighted average assumptions:
Expected return on plan assets 4.56 % 4.72 %
Discount rate 2.28 % 1.92 %
Rate of compensation increase 2.16 % 1.85 %
The Company made approximately $68 million of contributions to its U.S. and non-U.S. defined benefit pension plans for the three months ended
March 31, 2022. The Company expects to contribute approximately $110 million to its U.S. and non-U.S. defined benefit pension plans during the
remainder of 2022.
25
-- 25 of 139 --
Defined Contribution Plans
The Company maintains certain defined contribution plans ("DC Plans") for its employees, the most significant being in the U.S. and the U.K. The
cost of the U.S. DC Plans was $43 million and $39 million for the three months ended March 31, 2022 and 2021, respectively. The cost of the U.K.
DC Plans was $44 million and $39 million for the three months ended March 31, 2022 and 2021, respectively.
14. Debt
The Company’s outstanding debt is as follows:
(In millions)
March 31,
2022 December 31,
2021
Short-term:
Commercial paper $ 825 $ —
Current portion of long-term debt 366 17
1,191 17
Long-term:
Senior notes – 3.30% due 2023 350 349
Senior notes – 4.05% due 2023 250 249
Senior notes – 3.50% due 2024 599 599
Senior notes – 3.875% due 2024 997 997
Senior notes – 3.50% due 2025 498 498
Senior notes – 1.349% due 2026 615 629
Senior notes – 3.75% due 2026 598 598
Senior notes – 4.375% due 2029 1,499 1,499
Senior notes – 1.979% due 2030 600 614
Senior notes – 2.250% due 2030 739 739
Senior notes – 2.375% due 2031 396 397
Senior notes – 5.875% due 2033 298 298
Senior notes – 4.75% due 2039 495 495
Senior notes – 4.35% due 2047 493 493
Senior notes – 4.20% due 2048 593 593
Senior notes – 4.90% due 2049 1,238 1,238
Senior notes – 2.90% due 2051 346 346
Mortgage – 5.70% due 2035 312 316
Other 2 3
10,918 10,950
Less current portion 366 17
$ 10,552 $ 10,933
The senior notes in the table above are registered by the Company with the Securities and Exchange Commission and are not guaranteed.
On April 9, 2021, the Company increased its short-term commercial paper financing program to $2.0 billion from $1.5 billion. The Company had
$825 million of commercial paper outstanding at March 31, 2022 at an average effective interest rate of 0.91%.
Credit Facilities
On April 2, 2021, the Company entered into an amended and restated multi-currency unsecured $2.8 billion five- year revolving credit facility ("New
Facility"). The interest rate on the New Facility is based on LIBOR plus a fixed margin which varies with the Company’s credit ratings. The New
Facility expires in April 2026 and requires the Company to maintain certain coverage and leverage ratios which are tested quarterly. The New
Facility includes provisions for determining a LIBOR successor rate in the event LIBOR reference rates are no longer available or in certain other
circumstances which are determined to make using an alternative rate desirable. As of March 31, 2022, the Company had no borrowings under this
facility.
26
-- 26 of 139 --
In connection with the New Facility, the Company terminated its previous multi-currency unsecured $1.8 billion five-year revolving credit facility and
its unsecured $1 billion 364-days unsecured revolving credit facility ("364-day Facility").
Additional credit facilities, guarantees and letters of credit are maintained with various banks aggregating $483 million at March 31, 2022 and $508
million at December 31, 2021. There were no outstanding borrowings under these facilities at March 31, 2022 and December 31, 2021.
Senior Notes
In December 2021, the Company issued $400 million of 2.375% senior notes due 2031 and $350 million of 2.90% senior notes due 2051. The
Company used the net proceeds from these issuances for general corporate purposes, and repaid $500 million of 2.75% senior notes with an
original maturity date of January 2022 in December 2021.
On April 15, 2021, the Company repaid $500 million of senior notes maturing in July 2021.
Fair Value of Short-term and Long-term Debt
The estimated fair value of the Company's short-term and long-term debt is provided below. Certain estimates and judgments were required to
develop the fair value amounts. The fair value amounts are not necessarily indicative of the amounts that the Company would realize upon
disposition, nor do they indicate the Company’s intent or need to dispose of the financial instrument.
March 31, 2022 December 31, 2021
(In millions)
Carrying
Amount
Fair
Value
Carrying
Amount
Fair
Value
Short-term debt $ 1,191 $ 1,195 $ 17 $ 17
Long-term debt $ 10,552 $ 11,004 $ 10,933 $ 12,466
The fair value of the Company's short-term debt consists primarily of commercial paper and term debt maturing within the next year and its fair
value approximates its carrying value. The estimated fair value of a primary portion of the Company's long-term debt is based on discounted future
cash flows using current interest rates available for debt with similar terms and remaining maturities. Short-term and long-term debt would be
classified as Level 2 in the fair value hierarchy.
15. Restructuring Costs
Restructuring costs include Company initiated actions related to improving and streamlining the Company's global information technology and HR
functions, JLT integration costs, improving efficiencies and client services related to Marsh's operational excellence program, and real estate related
costs for exiting leased facilities.
For the three months ended March 31, 2022, the Company incurred costs of $30 million, reflecting $16 million in RIS, $6 million in Consulting, and
$8 million in Corporate related to these initiatives.
Details of the restructuring activity from January 1, 2021 through March 31, 2022, are as follows:
(In millions) Severance
Real Estate Related
Costs
Information
Technology
Consulting and Other
Outside Services Total
Liability at 1/1/21 $ 52 $ 51 $ 2 $ 1 $ 106
2021 charges 38 31 23 71 163
Cash payments (55) (26) (25) (72) (178)
Non-cash charges — (22) — — (22)
Liability at 12/31/21 $ 35 $ 34 $ — $ — $ 69
2022 charges 3 6 5 16 30
Cash payments (16) (4) (3) (16) (39)
Non-cash charges — (4) (2) — (6)
Liability at 3/31/22 $ 22 $ 32 $ — $ — $ 54
Includes ROU and fixed asset impairments and other real estate related costs.
The expenses associated with these initiatives are included in compensation and benefits and other operating expenses in the consolidated
statements of income. The liabilities associated with these initiatives are classified on the consolidated balance sheets as accounts payable and
accrued liabilities, other liabilities or accrued compensation and employee benefits, depending on the nature of the items.
(a)
(a)
27
-- 27 of 139 --
16. Common Stock
On March 23, 2022, the Board of Directors of the Company authorized an additional $5 billion in share repurchases. This is in addition to the
Company's existing share repurchase program, which had approximately $1.3 billion of remaining authorization as of December 31, 2021. During
the first three months of 2022, the Company repurchased 3.2 million shares of its common stock for $500 million. As of March 31, 2022, the
Company remained authorized to repurchase up to approximately $5.8 billion in shares of its common stock. There is no time limit on the
authorization.
During the first three months of 2021, the Company repurchased 1.0 million shares of its common stock for $119 million, of which approximately
$112 million was paid in the first quarter of 2021.
The Company issued approximately 1.8 million and 2.0 million shares related to stock compensation and employee stock purchase plans during the
first three months of 2022 and 2021, respectively.
17. Claims, Lawsuits and Other Contingencies
Acquisition of Jardine Lloyd Thompson Group plc
On April 1, 2019, the Company completed its previously announced acquisition of all of the outstanding shares of JLT. Upon the consummation of
the acquisition of JLT, the Company assumed the legal liabilities and became responsible for JLT’s litigation and regulatory exposures as of April 1,
2019.
Nature of Contingencies
The Company and its subsidiaries are subject to a significant number of claims, lawsuits and proceedings in the course of our business. Such
claims and lawsuits consist principally of alleged errors and omissions in connection with the performance of professional services, including the
placement of insurance, the provision of actuarial services for corporate and public sector clients, the provision of investment advice and investment
management services to pension plans, the provision of advice relating to pension buy-out transactions and the provision of consulting services
relating to the drafting and interpretation of trust deeds and other documentation governing pension plans. These claims often seek damages,
including punitive and treble damages, in amounts that could be significant. In establishing liabilities for errors and omissions claims in accordance
with FASB guidance on Contingencies - Loss Contingencies, the Company uses case level reviews by inside and outside counsel, and internal
actuarial analysis by Oliver Wyman, a subsidiary of the Company, and other methods to estimate potential losses. A liability is established when a
loss is both probable and reasonably estimable. The liability is reviewed quarterly and adjusted as developments warrant. In many cases, the
Company has not recorded a liability, other than for legal fees to defend the claim, because we are unable, at the present time, to make a
determination that a loss is both probable and reasonably estimable. To the extent that expected losses exceed our deductible in any policy year,
the Company also records an asset for the amount that we expect to recover under any available third-party insurance programs. The Company
has varying levels of third-party insurance coverage, with policy limits and coverage terms varying significantly by policy year.
Our activities are regulated under the laws of the United States and its various states, United Kingdom, the European Union and its member states,
and the many other jurisdictions in which the Company operates. The Company also receives subpoenas in the ordinary course of business, and,
from time to time, requests for information in connection with government investigations.
Current Matters
Risk and Insurance Services Segment
• In January 2019, the Company received a notice that the Administrative Council for Economic Defense anti-trust agency in Brazil had
commenced an administrative proceeding against a number of insurance brokers, including both Marsh and JLT, and insurers “to
investigate an alleged sharing of sensitive commercial and competitive confidential information" in the aviation insurance and reinsurance
sector.
• In 2017, JLT identified payments to a third-party introducer that had been directed to unapproved bank accounts. These payments related
to reinsurance placements made on behalf of an Ecuadorian state-owned insurer between 2014 and 2017. In early 2018, JLT voluntarily
reported this matter to law enforcement authorities. In February and March 2020, money laundering charges were filed in the United
States against a former employee of JLT, the principals of the third-party introducer and a former official of the state-owned insurer. These
individuals, including the former JLT employee, have since pleaded guilty to criminal charges. In March 2022, the U.S. Department of
Justice (DOJ) issued a declination letter, declining to pursue any charges against any JLT entity and seeking disgorgement of $29 million
in alleged
28
-- 28 of 139 --
gross profits on this account. As previously disclosed, the Company recorded a charge for this amount in the fourth quarter 2021. In
addition, in March 2022, the Colombian Superintendecia de Sociedades (SS) concluded its investigation of this matter and notified JLT of
its intention to seek $2 million in civil penalties. We are cooperating with ongoing investigations by the U.K. authorities related to this
matter.
• From 2014, Marsh Ltd. was engaged by Greensill Capital (UK) Limited as its insurance broker. Marsh Ltd. placed a number of trade credit
insurance policies for Greensill. On March 1, 2021, Greensill filed an action against certain of its trade credit insurers in Australia seeking a
mandatory injunction compelling these insurers to renew coverage under expiring policies. Later that day, the Australian court denied
Greensill’s application. Since then, a number of Greensill entities have filed for, or been subject to, insolvency proceedings, and several
litigations and investigations have been commenced in the U.K., Australia, Germany, Switzerland and the U.S.
Consulting Segment
• In 2014, the FCA conducted an industry-wide review of the suitability of financial advice provided to individuals by a number of companies,
including JLT, relating to enhanced transfer value ("ETV") defined benefit pension transfers. In January 2015, the FCA notified JLT that it
was commissioning a Skilled Person review of ETV pension transfer advice given by JLT and a business acquired by JLT in 2012.
Following the Skilled Person review which took place between 2015 and 2018, JLT engaged a compliance consulting firm to conduct an
analysis of approximately 14,000 individual files to assess the suitability of the advice provided and, where appropriate, the amount of
redress to be paid. In February 2019, prior to the completion of its acquisition by the Company, JLT recorded a gross liability of £59 million
(or $77 million). This preliminary estimate by JLT, reflected projected redress amounts based on the limited number of files examined as
part of the Skilled person review and report. Thereafter, the FCA expanded the scope of the review. As of December 31, 2020, the updated
redress liability, including the projected costs of completing the review, increased to £155 million (or $210 million) resulting from the
expansion in the scope of the review, and the significant progress made in completing the individual suitability reviews. Payments of
redress and expenses during 2021 and the first quarter of 2022, together with a reduction of the actuarial estimates of future redress
payments, reduced the recorded liability to £10 million (or $13 million) as of March 31, 2022. The suitability review is substantially complete
and we expect to finalize the remaining redress calculations and to make substantially all redress payments by the end of the second
quarter 2022. This gross liability has been, and we anticipate will continue to be, partially offset by a contractual indemnity obligation and
insurance recoveries from third-party E&O insurers.
At this time, we are unable to predict the likely timing, outcome or ultimate impact of the foregoing matters. Adverse determinations in one or more
of these matters could have a material impact on the Company's consolidated results of operations, financial condition or cash flows in a future
period.
Other Contingencies-Guarantees
In connection with its acquisition of U.K.-based Sedgwick Group in 1998, the Company acquired several insurance underwriting businesses that
were already in run-off, including River Thames Insurance Company Limited ("River Thames"), which the Company sold in 2001. Sedgwick
guaranteed payment of claims on certain policies underwritten through the Institute of London Underwriters (the "ILU") by River Thames. The
policies covered by this guarantee are partly reinsured by a related party of River Thames. Payment of claims under the reinsurance agreement is
collateralized by funds withheld by River Thames from the reinsurer. To the extent River Thames or the reinsurer is unable to meet its obligations
under those policies, a claimant may seek to recover from the Company under the guarantee.
From 1980 to 1983, the Company owned indirectly the English & American Insurance Company ("E&A"), which was a member of the ILU. The ILU
required the Company to guarantee a portion of E&A's obligations. After E&A became insolvent in 1993, the ILU agreed to discharge the guarantee
in exchange for the Company's agreement to post an evergreen letter of credit that is available to pay claims by policyholders on certain E&A
policies issued through the ILU and incepting between July 3, 1980 and October 6, 1983. Certain claims have been paid under the letter of credit
and the Company anticipates that additional claimants may seek to recover against the letter of credit.
* * * *
The pending proceedings described above and other matters not explicitly described in this Note 17 on Claims, Lawsuits and Other Contingencies
may expose the Company or its subsidiaries to liability for significant monetary damages, fines, penalties or other forms of relief. Where a loss is
both probable and reasonably estimable, the Company establishes liabilities in accordance with FASB guidance on Contingencies - Loss
Contingencies.
29
-- 29 of 139 --
Except as described above, the Company is not able at this time to provide a reasonable estimate of the range of possible loss attributable to these
matters or the impact they may have on the Company's consolidated results of operations, financial position or cash flows. This is primarily because
these matters are still developing and involve complex issues subject to inherent uncertainty. Adverse determinations in one or more of these
matters could have a material impact on the Company's consolidated results of operations, financial condition or cash flows in a future period.
18. Segment Information
The Company is organized based on the types of services provided. Under this structure, the Company’s segments are:
• Risk and Insurance Services, comprising insurance services (Marsh) and reinsurance services (Guy Carpenter); and
• Consulting, comprising Mercer and Oliver Wyman Group.
The accounting policies of the segments are the same as those used for the consolidated financial statements described in Note 1, Summary of
Significant Accounting Policies, in the Company’s 2021 Form 10-K. Segment performance is evaluated based on segment operating income, which
includes directly related expenses, and charges or credits related to integration and restructuring but not the Company’s corporate-level expenses.
Revenues are attributed to geographic areas on the basis of where the services are performed.
Selected information about the Company’s operating segments for the three month period ended March 31, 2022 and 2021 is as follows:
Three Months Ended
March 31,
(In millions) Revenue
Operating Income
(Loss)
2022–
Risk and Insurance Services $ 3,549 $ 1,121
Consulting 2,010 392
Total Operating Segments 5,559 1,513
Corporate/Eliminations (10) (68)
Total Consolidated $ 5,549 $ 1,445
2021–
Risk and Insurance Services $ 3,225 $ 1,060
Consulting 1,873 361
Total Operating Segments 5,098 1,421
Corporate/Eliminations (15) (63)
Total Consolidated $ 5,083 $ 1,358
Includes interest income on fiduciary funds of $4 million and $5 million in 2022 and 2021. Revenue for 2022 also includes the loss on deconsolidation of the
Russian businesses of $27 million.
Includes inter-segment revenue of $10 million and $15 million in 2022 and 2021. Revenue for 2022 also includes the loss on deconsolidation of the Russian
businesses of $12 million.
(a)
(b)
(a)
(b)
(a)
(b)
30
-- 30 of 139 --
Details of operating segment revenue for the three month periods ended March 31, 2022 and 2021 are as follows:
Three Months Ended
March 31,
(In millions) 2022 2021
Risk and Insurance Services
Marsh $ 2,549 $ 2,329
Guy Carpenter 1,000 896
Total Risk and Insurance Services 3,549 3,225
Consulting
Mercer 1,343 1,288
Oliver Wyman Group 667 585
Total Consulting 2,010 1,873
Total Operating Segments 5,559 5,098
Corporate Eliminations (10) (15)
Total $ 5,549 $ 5,083
19. New Accounting Guidance
New Accounting Pronouncement Adopted Effective January 1, 2022:
In October, 2021, the FASB issued new guidance for measuring contract assets and contract liabilities acquired in a business combination. In
accordance with the new guidance, contract assets and contract liabilities should be measured in accordance with the guidance for revenue from
contracts with customers as opposed to the guidance for business combinations. The guidance must be applied on a prospective basis, and is
effective for fiscal years beginning after December 15, 2022, including interim periods therein. Early adoption is permitted. The Company elected to
adopt this new standard effective January 1, 2022. Adoption of this guidance did not have a material impact on the Company's financial position or
results of operations.
New Accounting Pronouncements Adopted Effective January 1, 2021:
In January 2020, the FASB issued guidance that addresses accounting for the transition into and out of the equity method and measuring certain
purchased options and forward contracts to acquire investments. The standard takes effect for public business entities for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2020. The adoption of this standard did not have a material impact on the
Company’s financial position or its results of operations.
In December 2019, the FASB issued guidance related to the accounting for income taxes. The standard removes specific exceptions in the current
rules and eliminates the need for an organization to analyze whether the following apply in a given period: (a) exception to the incremental
approach for intraperiod tax allocation; (b) exceptions to accounting for basis differences when there are ownership changes in foreign investments
and (c) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. The standard also is designed to
improve financial statement preparers’ application of income tax-related guidance and simplify GAAP for (a) franchise taxes that are partially based
on income; (b) transactions with a government that result in a step-up in the tax basis of goodwill; (c) separate financial statements of legal entities
that are not subject to tax and (d) enacted changes in tax laws in interim periods. The standard takes effect for public business entities for fiscal
years, and interim periods within those fiscal years, beginning after December 15, 2020. The adoption of this standard did not have a material
impact on the Company’s financial position or its results of operations.
31
-- 31 of 139 --
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
General
Marsh & McLennan Companies, Inc. and its consolidated subsidiaries (the "Company") is a global professional services firm offering clients advice
in the areas of risk, strategy and people. The Company’s 83,000 colleagues advise clients in over 130 countries. With annual revenue of
approximately $20 billion, the Company helps clients navigate an increasingly dynamic and complex environment through four market-leading
businesses. Marsh provides data-driven risk advisory services and insurance solutions to commercial and consumer clients. Guy Carpenter
develops advanced risk, reinsurance and capital strategies that help clients grow profitably and identify and capitalize on emerging opportunities.
Mercer delivers advice and solutions that help organizations create a dynamic world of work, shape retirement and investment outcomes, and
unlock health and well being for a changing workforce. Oliver Wyman Group serves as a critical strategic, economic and brand advisor to private
sector and governmental clients.
The Company conducts business through two segments:
• Risk and Insurance Services includes risk management activities (risk advice, risk transfer and risk control and mitigation solutions) as
well as insurance and reinsurance broking and services. The Company conducts business in this segment through Marsh and Guy
Carpenter.
• Consulting includes health, wealth and career consulting services and products, and specialized management, economic and brand
consulting services. The Company conducts business in this segment through Mercer and Oliver Wyman Group.
The results of operations in the Management Discussion & Analysis ("MD&A") includes an overview of the Company's consolidated three months
ended March 31, 2022 results compared to the corresponding quarter in 2021, and should be read in conjunction with the consolidated financial
statements and notes. This section also includes a discussion of the key drivers impacting the Company's financial results of operations both on a
consolidated basis and by reportable segments.
We describe the primary sources of revenue and categories of expense for each segment in the discussion of segment financial results. A
reconciliation of segment operating income to total operating income is included in Note 18, Segment Information, in the notes to the consolidated
financial statements included in Part I, Item 1 of this report.
For information on the three months ended March 31, 2021 results and similar comparisons, see "Item 2. Management's Discussion and Analysis
of Financial Condition and Results of Operations" of our Form 10-Q for the quarter ended March 31, 2021.
This MD&A contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. See "Information
Concerning Forward-Looking Statements" at the outset of this report.
Financial Highlights
• Consolidated revenue for the three months ended March 31, 2022 was $5.5 billion, an increase of 9% or 10% on an underlying basis.
• Consolidated operating income increased $87 million, or 6% to $1.4 billion for the three months ended March 31, 2022 compared to the
corresponding quarter in the prior year. Net income attributable to the Company was $1.1 billion. Earnings per share increased 10% to
$2.10.
• Risk and Insurance Services revenue for the three months ended March 31, 2022 was $3.5 billion, an increase of 10%, or 11% on an
underlying basis. Operating income was $1.1 billion for the three months ended March 31, 2022, compared to the corresponding quarter in
the prior year.
• Consulting revenue for the three months ended March 31, 2022 was $2.0 billion, an increase of 7%, or 10% on an underlying basis.
Operating income was $392 million, compared with $361 million for the three months ended March 31, 2021.
• Results for the three months ended March 31, 2022 include a loss of $52 million on the deconsolidation of the Company's Russian
businesses and other related charges. On March 10, 2022, the Company also announced it would exit its businesses in Russia and
transfer ownership of its Russian entities to local management who will operate independently in the Russian market.
• In the first quarter of 2022 the Company repurchased 3.2 million shares of stock for $500 million.
For additional details, refer to the Consolidated Results of Operations and Liquidity and Capital Resources sections in this MD&A.
32
-- 32 of 139 --
Acquisitions and dispositions impacting the Risk and Insurance Services and Consulting segments are discussed in Note 8, Acquisitions and
Dispositions, in the notes to the consolidated financial statements.
Deconsolidation of Russia
On February 24, 2022, Russian forces launched a military invasion of Ukraine. In response, the United States, the European Union, United
Kingdom and other governments have imposed significant economic sanctions on Russia, and Russia has responded with counter-sanctions. The
war in Ukraine has disrupted international commerce and the global economy.
On March 10, 2022, the Company announced it would exit its businesses in Russia and transfer ownership of its Russian businesses to local
management who will operate independently in the Russian market.
In the first quarter of 2022, the Company concluded that it does not meet the accounting criteria for control over its wholly-owned Russian
businesses due to the evolving trade and economic sanctions against Russia and related Russian counter-sanctions. These sanctions include
restrictions on payments to and from Russian companies and reduced currency access through official exchange markets that have significantly
impacted the Company's ability to effectively manage and operate its Russian businesses. For the three months ended March 31, 2022, the
Company recorded a loss of $52 million on the deconsolidation of the Russian businesses and other related charges. Refer to Note 8, Acquisitions
and Dispositions, in the notes to the consolidated financial statements for additional information on the deconsolidation of the Russian businesses.
The Company continues to monitor the ongoing situation and its potential impact on our business, financial condition, results of operations and
cash flows.
Business Update Related To COVID-19
For over two years, the COVID-19 pandemic has impacted businesses globally including in every geography in which the Company operates. Our
businesses have remained resilient throughout the pandemic and demand for our advice and services remains strong.
The Company had strong revenue growth for the first three months of 2022. However, uncertainty remains in the economic outlook, and the
ultimate extent of the impact of COVID-19 to the Company will depend on future developments that it is unable to predict, including new "waves" of
infection from emerging variants of the virus and potential renewed restrictions and mandates by various governments or agencies.
Factors that could adversely affect the Company’s financial statements related to the financial and operational impact of COVID-19 are outlined in
“Item 1A - Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2021.
33
-- 33 of 139 --
Consolidated Results of Operations
Three Months Ended
March 31,
(In millions, except per share data) 2022 2021
Revenue $ 5,549 $ 5,083
Expense:
Compensation and benefits 3,100 2,807
Other operating expenses 1,004 918
Operating expenses 4,104 3,725
Operating income 1,445 1,358
Income before income taxes 1,424 1,322
Net income before non-controlling interests 1,086 998
Net income attributable to the Company $ 1,071 $ 983
Net income per share attributable to the Company:
- Basic $ 2.13 $ 1.93
- Diluted $ 2.10 $ 1.91
Average number of shares outstanding:
- Basic 503 509
- Diluted 509 514
Shares outstanding at March 31, 502 509
Consolidated operating income increased $87 million, or 6% to $1.4 billion for the three months ended March 31, 2022 compared to the
corresponding prior year quarter, reflecting a 9% increase in revenue and 10% increase in expenses. Revenue growth was driven by increases in
the Risk and Insurance Services and Consulting segments of 10% and 7%, respectively, reflecting the continued strong demand for our advice and
services and the improvement in global economic conditions compared to the corresponding quarter in the prior year. The increase in expenses is
primarily due to increased headcount and higher incentive compensation.
Diluted earnings per share increased 10% to $2.10 for the three months ended March 31, 2022 compared to $1.91 for the three months ended
March 31, 2021. The increase is primarily the result of higher operating income for the three months ended March 31, 2022, compared to the
corresponding quarter in the prior year. Results for the three months ended March 31, 2022 also included a charge of approximately $52 million for
the deconsolidation of the Company's Russian businesses and other related charges in Marsh and Oliver Wyman.
The following table summarizes restructuring and other items discussed in more detail below:
Three Months Ended
March 31,
(In millions) 2022 2021
Restructuring $ 30 $ 34
Changes in contingent consideration 10 —
JLT acquisition related costs and other 13 12
JLT legacy E&O provision (10) —
Legal claims 30 —
Deconsolidation of Russian businesses and other related charges 52 —
Other — 1
Impact on income before taxes $ 125 $ 47
In the three months ended March 31, 2022 and 2021, the Company's results of operations and earnings per share were impacted by the following
items:
• Restructuring: Includes costs related to the Company's global information technology and HR functions, JLT integrations costs, Marsh
(RIS) operational excellence and adjustments to restructuring liabilities for future rent under non-cancellable leases.
34
-- 34 of 139 --
• Changes in contingent consideration: Primarily includes the change in fair value of contingent consideration related to acquisitions and
dispositions as measured each quarter.
• JLT acquisition-related costs and other: Includes retention costs and legal charges related to the acquisition of JLT.
• JLT legacy E&O provision: In the first quarter of 2022, the Company recorded $10 million of recoveries under indemnities for a legacy JLT
Errors and Omissions ("E&O") matter related to the suitability of advice provided to individuals for defined benefit pension transfers in the
U.K. See Note 17, Claims, Lawsuits and Other Contingencies, in the notes to the consolidated financial statements in this report for
additional detail.
• Legal claims: The Company recorded settlement charges and legal costs related to strategic recruiting.
• Deconsolidation of Russia entities and other related charges: The loss on deconsolidation is included in revenue and excluded from
the underlying revenue calculations.
Consolidated Revenue and Expense
Revenue – Components of Change
The Company conducts business in 130 countries. As a result, foreign exchange rate movements may impact period-to-period comparisons of
revenue. Similarly, certain other items such as the revenue impact of acquisitions and dispositions, including transfers among businesses, may
impact period-to-period comparisons of revenue. Underlying revenue measures the change in revenue from one period to the next by isolating
these impacts.
The impact of foreign currency exchange fluctuations, acquisitions and dispositions, including transfers among businesses, on the Company’s
operating revenues by segment are as follows:
Three Months Ended
March 31, % Change
GAAP
Revenue
Components of Revenue Change*
Currency
Impact
Acquisitions/
Dispositions/ Other
Impact
Underlying
Revenue (In millions, except percentages) 2022 2021
Risk and Insurance Services
Marsh $ 2,546 $ 2,325 10 % (2)% 1 % 11 %
Guy Carpenter 999 895 12 % (1)% 2 % 11 %
Subtotal 3,545 3,220 10 % (2)% 1 % 11 %
Fiduciary interest income 4 5
Total Risk and Insurance Services 3,549 3,225 10 % (2)% 1 % 11 %
Consulting
Mercer 1,343 1,288 4 % (2)% — 6 %
Oliver Wyman Group 667 585 14 % (2)% (1)% 17 %
Total Consulting 2,010 1,873 7 % (2)% — 10 %
Corporate Eliminations (10) (15)
Total Revenue $ 5,549 $ 5,083 9 % (2)% 1 % 10 %
* Components of revenue change may not add due to rounding.
35
-- 35 of 139 --
Three Months Ended
March 31, % Change
GAAP
Revenue
Components of Revenue Change*
Currency
Impact
Acquisitions/
Dispositions/ Other
Impact Underlying
Revenue (In millions, except percentages) 2022 2021
Marsh:
EMEA $ 842 $ 837 1 % (4)% (4)% 9 %
Asia Pacific 321 274 17 % (4)% 5 % 17 %
Latin America 104 90 15 % (1)% — 16 %
Total International 1,267 1,201 6 % (4)% (2)% 11 %
U.S./Canada 1,279 1,124 14 % — 4 % 10 %
Total Marsh $ 2,546 $ 2,325 10 % (2)% 1 % 11 %
Mercer:
Wealth $ 617 $ 623 (1)% (3)% — 2 %
Health 524 487 8 % (2)% 1 % 9 %
Career 202 178 13 % (3)% — 16 %
Total Mercer $ 1,343 $ 1,288 4 % (2)% — 6 %
* Components of revenue change may not add due to rounding.
Consolidated Revenue
Consolidated revenue increased $466 million, or 9% to $5.5 billion for the three months ended March 31, 2022 compared to $5.1 billion for the
three months ended March 31, 2021. Consolidated revenue increased 10% on an underlying basis and 1% from acquisitions, partly offset by a
decrease of 2% from the impact of foreign currency translation. On an underlying basis, revenue increased 11% and 10% for the three months
ended March 31, 2022 in Risk and Insurance Services and Consulting segments, respectively. Underlying revenue growth in the Risk and
Insurance Services and Consulting segments was driven by the continued strong demand for our advice and services.
Consolidated Operating Expenses
Consolidated operating expenses increased $379 million, or 10% to $4.1 billion for the three months ended March 31, 2022 compared to $3.7
billion for the three months ended March 31, 2021, reflecting increases of 11% on an underlying basis and 2% from acquisitions, partly offset by a
decrease of 2% from the impact of foreign currency translation. On an underlying basis, expenses increased 12% and 9% for the three months
ended March 31, 2022 in Risk and Insurance Services and Consulting, respectively. The increase in underlying expenses is primarily due to
increased headcount and higher incentive compensation.
Risk and Insurance Services
In the Risk and Insurance Services segment, the Company’s subsidiaries and other affiliated entities act as brokers, agents or consultants for
insureds, insurance underwriters and other brokers in the areas of risk management, insurance broking and insurance program management
services, primarily under the name of Marsh, and engage in reinsurance broking, catastrophe and financial modeling services and related advisory
functions, primarily under the name of Guy Carpenter.
The results of operations for the Risk and Insurance Services segment are presented below:
For the Three Months Ended March 31, Three Months
(In millions, except percentages) 2022 2021
Revenue $ 3,549 $ 3,225
Compensation and benefits 1,801 1,610
Other operating expenses 627 555
Operating expenses 2,428 2,165
Operating income $ 1,121 $ 1,060
Operating income margin 31.6% 32.9%
36
-- 36 of 139 --
Revenue
Revenue in the Risk and Insurance Services segment increased $324 million, or 10% to $3.5 billion for the three months ended March 31, 2022
compared to $3.2 billion for the three months ended March 31, 2021. Revenue grew 11% on an underlying basis and 1% from the impact of
acquisitions, partly offset by a decrease of 2% related to the impact of foreign currency translation. The increase in underlying revenue was
primarily due to strong growth in new business, solid retention, and benefits from pricing in the marketplace.
At Marsh, revenue increased $221 million, or 10% to $2.5 billion for the three months ended March 31, 2022 compared to $2.3 billion for the three
months ended March 31, 2021. This reflects an increase of 11% on an underlying basis and 1% from the impact of acquisitions, partly offset by a
decrease of 2% from the impact of foreign currency translation. On an underlying basis, the U.S. and Canada rose 10%. Results for the three
months ended March 31, 2022 also included a charge of approximately $27 million at Marsh related to the loss on deconsolidation of the
Company's Russian businesses. Total International operations produced underlying revenue growth of 11%, reflecting growth of 17% in Asia
Pacific, 9% in EMEA and 16% in Latin America.
At Guy Carpenter, revenue increased $104 million, or 12% to $999 million for the three months ended March 31, 2022 compared to $895 million for
the three months ended March 31, 2021. On an underlying basis, revenue increased 11%.
The Risk and Insurance Services segment completed one acquisition during the first three months ended March 31, 2022. Information regarding
this acquisition is included in Note 8, Acquisitions and Dispositions, in the notes to the consolidated financial statements.
Operating Expenses
Expenses in the Risk and Insurance Services segment increased $263 million, or 12% to $2.4 billion for the three months ended March 31, 2022
compared to $2.2 billion for the three months ended March 31, 2021. This reflects an increase of 12% on an underlying basis and 2% from the
impact of acquisitions, partly offset by a decrease of 2% from the impact of foreign currency translation. The increase in underlying expenses is
primarily due to increased headcount and higher incentive compensation.
Consulting
The Company conducts business in its Consulting segment through Mercer and Oliver Wyman Group. Mercer delivers advice and solutions that
help organizations create a dynamic world of work, shape retirement and investment outcomes, and unlock health and well being for a changing
workforce. Oliver Wyman serves as critical strategic, economic and brand advisor to private sector and governmental clients.
The results of operations for the Consulting segment are presented below:
For the Three Months Ended March 31, Three Months
(In millions, except percentages) 2022 2021
Revenue $ 2,010 $ 1,873
Compensation and benefits 1,164 1,074
Other operating expenses 454 438
Operating expenses 1,618 1,512
Operating income $ 392 $ 361
Operating income margin 19.5% 19.3%
Revenue
Consulting revenue increased $137 million, or 7% to $2.0 billion for the three months ended March 31, 2022, compared to $1.9 billion for the three
months ended March 31, 2021. This reflects an increase of 10% on an underlying basis partly offset by a decrease of 2% from the impact of foreign
currency translation.
Mercer's revenue increased $55 million, or 4% to $1.3 billion for the three months ended March 31, 2022 compared to the corresponding quarter in
the prior year. This reflects an increase of 6% on an underlying basis, partly offset by a decrease of 2% from the impact of foreign currency
translation. On an underlying basis, revenue for Career, Health and Wealth increased 16%, 9% and 2%, respectively, as compared to the
corresponding quarter in the prior year. The increase in underlying revenue at Mercer for the three months ended March 31, 2022 was due to
higher investment management fees from growth in assets under management and increased demand and retention for Health and Career
products and services.
37
-- 37 of 139 --
Oliver Wyman's revenue increased $82 million, or 14% to $667 million for the three months ended March 31, 2022 compared to $585 million for the
three months ended March 31, 2021, reflecting an increase of 17% on an underlying basis partly offset by decreases of 1% from dispositions, and
2% from the impact of foreign currency translation. Results for the three months ended March 31, 2022 also included a charge of approximately
$12 million at Oliver Wyman related to the loss on deconsolidation of the Company's Russian businesses. The increase in underlying revenue at
Oliver Wyman for the three months ended March 31, 2022 primarily reflects the impact of increased demand for project-based services across all
industries.
The Consulting segment completed two acquisitions during the first three months ended March 31, 2022. Information regarding the acquisitions is
included in Note 8, Acquisitions and Dispositions, in the notes to the consolidated financial statements.
Operating Expenses
Consulting expenses increased $106 million, or 7% to $1.6 billion for the three months ended March 31, 2022 compared to $1.5 billion for the first
three months ended March 31, 2021. This reflects an increase of 9% on an underlying basis partly offset by a 2% decrease from the impact of
foreign currency translation. The increase in underlying expenses in the Consulting segment for the three months ended March 31, 2022 is
primarily due to increased headcount and incentive compensation.
Corporate and Other
Corporate expenses were $68 million for the three months ended March 31, 2022 compared to $63 million for the three months ended March 31,
2021. Expenses increased 7% on an underlying basis primarily due to increased headcount and incentive compensation.
Interest
Interest expense was $110 million for the three months ended March 31, 2022 compared to $118 million for the for the three months ended March
31, 2021. Interest expense decreased $8 million due to lower average debt levels in 2022 compared with the corresponding quarter in the prior
year.
Investment Income
The caption "Investment income" in the consolidated statements of income comprises realized and unrealized gains and losses from investments. It
includes, when applicable, other than temporary declines in the value of securities, mark-to-market increases or decreases in equity investments
with readily determinable fair values and equity method gains or losses on its investments in private equity funds. The Company's investments may
include direct investments in insurance, consulting or other strategically linked companies and investments in private equity funds.
The Company recorded net investment income of $26 million for the three months ended March 31, 2022 compared to net investment income of
$11 million for the same period in the prior year. The increase in 2022 is primarily driven by higher mark-to-market gains in the Company's private
equity investments and its investment in Alexander Forbes.
Income and Other Taxes
The Company's effective tax rate in the first quarter of 2022 was 23.7% compared with 24.5% in the first quarter of 2021.
The tax rates in both periods reflect the impact of discrete tax matters such as excess tax benefits related to share-based compensation, enacted
tax legislation, changes in uncertain tax positions, deferred tax adjustments and non-taxable adjustments to contingent acquisition consideration.
The excess tax benefit related to share-based payments is the most significant discrete item, reducing the effective tax rate by 1.8% and 1.1% in
the first quarters of 2022 and 2021, respectively. The rate in the first quarter of 2022 also reflects tax benefits from planning implemented in the
period that postponed the utilization of current-year losses in the U.K. to a future year when the tax rate will be 25%.
The effective tax rate may vary significantly from period to period. The effective tax rate is sensitive to the geographic mix and repatriation of the
Company's earnings, which may result in higher or lower effective tax rates. Thus, a shift in the mix of profits among jurisdictions, or changes in the
Company's repatriation strategy to access offshore cash, can affect the effective tax rate.
38
-- 38 of 139 --
In addition, losses in certain jurisdictions cannot be offset by earnings from other operations, and may require valuation allowances that affect the
rate in a particular period, depending on estimates of the value of associated deferred tax assets which can be realized. A valuation allowance was
recorded to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The effective tax rate is also
sensitive to changes in unrecognized tax benefits, including the impact of settled tax audits and expired statutes of limitations.
Changes in tax laws, rulings, policies or related legal and regulatory interpretations occur frequently and may have a significant favorable or
adverse impact on our effective tax rate.
As a U.S. domiciled parent holding company, the Company is the issuer of essentially all of the external indebtedness and incurs the related
interest expense in the U.S. The Company’s interest expense deductions are not currently limited. Further, most senior executive and oversight
functions are conducted in the U.S. and the associated costs are incurred primarily in the U.S. Some of these expenses may not be deductible in
the U.S., which may impact the effective tax rate.
The quasi-territorial U.S. tax regime provides an opportunity for the Company to repatriate foreign earnings more tax efficiently and there is less
incentive for permanent reinvestment of these earnings. However, permanent reinvestment continues to be a component of the Company’s global
capital strategy. The Company continues to evaluate its global investment and repatriation strategy in light of its capital requirements, considering
the treatment of future earnings under the quasi-territorial tax regime.
The Company has established liabilities for uncertain tax positions in relation to potential assessments in the jurisdictions in which it operates. The
Company believes the resolution of tax matters will not have a material effect on the consolidated financial position of the Company, although a
resolution of tax matters could have a material impact on the Company's net income or cash flows and on its effective tax rate in a particular future
period. It is reasonably possible that the total amount of unrecognized tax benefits will decrease between zero and approximately $49 million within
the next twelve months due to settlement of audits and expiration of statutes of limitation.
The Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law on March 27, 2020. The CARES Act provided over
$2 trillion in economic relief to individuals, governmental agencies and companies, to deal with the public health and economic impacts of COVID-
19. Pursuant to the CARES Act, the Company deferred payroll taxes due from March 27, 2020 through December 31, 2020 and paid 50% in 2021
and will pay the remaining 50% in 2022.
Liquidity and Capital Resources
The Company is organized as a legal entity separate and distinct from its operating subsidiaries. As the Company does not have significant
operations of its own, the Company is dependent upon dividends and other payments from its operating subsidiaries to pay principal and interest on
its outstanding debt obligations, pay dividends to stockholders, repurchase its shares and pay corporate expenses. The Company can also provide
financial support to its operating subsidiaries for acquisitions, investments and certain parts of their business that require liquidity, such as the
capital markets business of Guy Carpenter. Other sources of liquidity include borrowing facilities discussed in financing cash flows.
The Company derives a significant portion of its revenue and operating profit from operating subsidiaries located outside of the U.S. Funds from
those operating subsidiaries are regularly repatriated to the U.S. out of annual earnings. At March 31, 2022, the Company had approximately $736
million of cash and cash equivalents in its foreign operations, which includes $281 million of operating funds required to be maintained for
regulatory requirements or as collateral under certain captive insurance arrangements. The Company expects to continue its practice of repatriating
available funds from its non-U.S. operating subsidiaries out of current annual earnings. Where appropriate, a portion of the current year earnings
will continue to be permanently reinvested.
During the first three months of 2022, the Company recorded foreign currency translation adjustments which decreased net equity by $169 million.
Continued strengthening of the U.S. dollar against foreign currencies would further decrease the translated U.S. dollar value of the Company’s net
investments in its non-U.S. subsidiaries, as well as the translated U.S. dollar value of cash repatriations from those subsidiaries.
Cash on our consolidated balance sheets includes funds available for general corporate purposes. Funds held on behalf of clients in a fiduciary
capacity are segregated and shown separately in the consolidated balance sheets as an offset to fiduciary liabilities. Fiduciary funds cannot be
used for general corporate purposes, and should not be considered as a source of liquidity for the Company.
39
-- 39 of 139 --
Operating Cash Flows
The Company used $702 million of cash from operations for the three months ended March 31, 2022 compared to $408 million used by operations
in the first three months of 2021. These amounts reflect the net income of the Company during those periods, excluding gains or losses from
investments, adjusted for non-cash charges and changes in working capital which relate primarily to the timing of payments of accrued liabilities or
receipts of assets and pension plan contributions. The Company paid $39 million and $54 million related to its restructuring activities for the three
months ended March 31, 2022 and 2021, respectively.
Pension Related Items
Contributions
The Company's policy for funding its tax-qualified defined benefit plans is to contribute amounts at least sufficient to meet the funding requirements
set forth in accordance with applicable law. During the first three months of 2022, the Company contributed $60 million to its non-U.S. defined
benefit pension plans and $8 million to its U.S. defined benefit pension plans. In the first three months of 2021, the Company contributed $17 million
to its non-U.S. defined benefit pension plans and $12 million to its U.S. defined benefit pension plans.
In the U.S., contributions to the tax-qualified defined benefit plans are based on ERISA guidelines and the Company generally expects to maintain
a funded status of 80% or more of the liability determined in accordance with the ERISA guidelines. During the first three months of 2022, the
Company made $8 million of contributions to its non-qualified plans and expects to fund approximately an additional $23 million over the remainder
of 2022. The Company is not required to make any contributions to its U.S. qualified plan in 2022.
Outside the U.S., the Company has a large number of non-U.S. defined benefit pension plans, the largest of which are in the U.K., which comprise
approximately 81% of non-U.S. plan assets at December 31, 2021. Contribution rates for non-U.S. plans are generally based on local funding
practices and statutory requirements, which may differ significantly from measurements under U.S. GAAP.
The Company contributed $58 million to its U.K. plans (including the JLT section) for the first three months of 2022. The Company contributions to
its U.K. plans (including the JLT section) for the remainder of 2022 are expected to be approximately $66 million.
In the U.K., the assumptions used to determine pension contributions are the result of legally-prescribed negotiations between the Company and
the plans' trustee that typically occur every three years in conjunction with the actuarial valuation of the plans. Currently, this results in a lower
funded status compared to U.S. GAAP and may result in contributions irrespective of the U.S. GAAP funded status.
During 2021, the JLT Pension Scheme was merged into the MMC U.K. Pension Fund with a new segregated JLT section created. The Company
made deficit contributions of $55 million to the JLT section in the first quarter of 2022 and is expected to make $57 million of contributions in the
remainder of 2022. The funding level of the JLT section will be reassessed during 2022 to determine contributions in 2023 and onwards.
For the Marsh McLennan U.K. Pension Fund, excluding the JLT section, an agreement was reached with the trustee in the fourth quarter of 2019
based on the surplus funding position at December 31, 2018. In accordance with the agreement, no deficit funding is required until 2023. The
funding level will be re-assessed during 2022 as part of the December 31, 2021 actuarial valuation to determine if contributions are required in
2023. As part of a long term strategy which depends on having greater influence over asset allocation and overall investment decisions, in
November 2019, the Company renewed its agreement to support annual deficit contributions by the U.K. operating companies under certain
circumstances, up to £450 million over a seven-year period.
The Company expects to fund an additional $87 million to its non-U.S. defined benefit plans over the remainder of 2022, comprising approximately
$21 million to plans outside of the U.K. and $66 million to the U.K. plans.
Financing Cash Flows
Net cash provided by financing activities was $855 million for the three months ended March 31, 2022, compared with $261 million used by
financing activities for the same period in 2021.
Credit Facilities
On April 2, 2021, the Company entered into an amended and restated multi-currency unsecured $2.8 billion five-year revolving credit facility ("New
Facility"). The interest rate on the New Facility is based on LIBOR plus a fixed margin which varies with the Company’s credit ratings. The New
Facility expires in April 2026 and requires the Company to maintain certain coverage and leverage ratios which are tested quarterly. The New
Facility includes provisions for determining a LIBOR successor rate in the event LIBOR reference rates are no longer available or in certain other
circumstances which are determined to make using an alternative rate desirable.
40
-- 40 of 139 --
As of March 31, 2022, the Company had no borrowings under this facility. In connection with the New Facility, the Company terminated its previous
multicurrency unsecured $1.8 billion five-year revolving credit facility and its unsecured $1.0 billion 364-day unsecured revolving credit facility.
The Company also maintains other credit facilities, guarantees and letters of credit with various banks, aggregating $483 million at March 31, 2022
and $508 million at December 31, 2021. There were no outstanding borrowings under these facilities at March 31, 2022 and December 31, 2021.
Debt
On April 9, 2021, the Company increased its short-term commercial paper financing program to $2.0 billion from $1.5 billion. The Company had
$825 million of commercial paper outstanding at March 31, 2022 at an effective interest rate of 0.91%.
In December 2021, the Company issued $400 million of 2.375% senior notes due 2031 and $350 million of 2.90% senior notes due 2051. The
Company used the net proceeds from these issuances for general corporate purposes, and repaid $500 million of 2.75% senior notes with an
original maturity date of January 2022 in December 2021.
On April 15, 2021, the Company repaid $500 million of senior notes maturing in July 2021.
The Company's senior debt is currently rated A- by Standard & Poor's ("S&P") and Baa1 by Moody's. The Company's short-term debt is currently
rated A-2 by S&P and P-2 by Moody's. The Company carries a Stable outlook with both S&P and Moody's.
Share Repurchases
On March 23, 2022, the Board of Directors of the Company authorized an additional $5 billion in share repurchases. This is in addition to the
Company's existing share repurchase program, which had approximately $1.3 billion of remaining authorization as of December 31, 2021. During
the first three months of 2022, the Company repurchased 3.2 million shares of its common stock for $500 million. As of March 31, 2022, the
Company remained authorized to repurchase up to approximately $5.8 billion in shares of its common stock. There is no time limit on the
authorization.
During the first three months of 2021, the Company repurchased 1 million shares of its common stock for total consideration of approximately $119
million, of which $112 million was paid during the first quarter of 2021.
Dividends
The Company paid dividends on its common shares of $272 million ($0.535 per share) during the first three months of 2022, as compared with
$237 million ($0.465 per share) during the first three months of 2021.
Contingent Payments Related to Acquisitions
The classification of contingent consideration in the consolidated statements of cash flows is dependent upon whether the receipt, payment, or
adjustment was part of the initial liability established on the acquisition date (financing) or an adjustment to the acquisition date liability (operating).
The following amounts are included in the consolidated statements of cash flows as operating and financing activities:
For the Three Months Ended March 31,
(In millions) 2022 2021
Operating:
Contingent consideration payments $ — $ (1)
Acquisition/disposition related net charges for adjustments 10 —
Adjustments and payments related to contingent consideration $ 10 $ (1)
Financing:
Contingent purchase consideration $ (4) $ (10)
Deferred purchase consideration related to prior years' acquisitions (12) (27)
Payments of deferred and contingent consideration for acquisitions $ (16) $ (37)
Receipt of contingent consideration related to prior years' dispositions $ 3 $ 5
41
-- 41 of 139 --
Derivatives
Net Investment Hedge
The Company has investments in various subsidiaries with Euro functional currencies. As a result, the Company is exposed to the risk of
fluctuations between the Euro and U.S. dollar exchange rates. As part of its risk management program to fund the JLT acquisition, the Company
issued €1.1 billion Senior Notes, and designated the debt instruments as a net investment hedge of its Euro denominated subsidiaries. The hedge
is re-assessed each quarter to confirm that the designated equity balance at the beginning of each period continues to equal or exceed 80% of the
outstanding balance of the Euro debt instrument and that all the critical terms of the hedging instrument and the hedged net investment continue to
match. If the hedge is highly effective, the change in the debt balance related to foreign exchange fluctuations will be recorded in foreign currency
translation gains (losses) in the consolidated balance sheets. The U.S. dollar value of the Euro notes decreased by $29 million through March 31,
2022 related to the change in foreign exchange rates. The Company concluded that the hedge was highly effective and recorded a decrease to
accumulated other comprehensive loss for the three months ended March 31, 2022.
Fiduciary Liabilities
Since cash and cash equivalents held in a fiduciary capacity are not available for corporate use, they are shown in the consolidated balance sheets
as an offset to fiduciary liabilities. Financing cash flows reflect an increase of $926 million and $190 million for the three months ended March 31,
2022 and 2021, respectively, related to the increase in fiduciary liabilities.
Investing Cash Flows
Net cash used for investing activities amounted to $159 million in the first three months of 2022, compared with $67 million used for investing
activities for the same period in 2021.
The Company paid $24 million, net of cash and cash equivalents for acquisitions it made during the first three months of 2022. The Company made
no acquisitions in the first three months of 2021.
During the first three months of 2022 and 2021, the Company sold its Mercer retirement plan administration and call center operations in Brazil, for
cash proceeds of approximately $4 million. There were no dispositions during the first three months of 2021.
The Company's additions to fixed assets and capitalized software, which amounted to $122 million in the first three months of 2022 and $69 million
in the first three months of 2021, primarily related to computer equipment purchases, the refurbishing and modernizing of office facilities, and
software development costs.
The Company has commitments for potential future investments of approximately $44 million in six private equity funds that invest primarily in
financial services companies. On April 1, 2022, the Company committed to invest $100 million in a private equity fund.
Commitments and Obligations
The following sets forth the Company’s future contractual obligations by the types identified in the table as of March 31, 2022:
(In millions) Payment due by Period
Contractual Obligations Total
Within
1 Year 1-3 Years 4-5 Years
After
5 Years
Commercial paper $ 825 $ 825 $ — $ — $ —
Current portion of long-term debt 366 366 — — —
Long-term debt 10,618 — 2,386 1,248 6,984
Interest on long-term debt 5,049 411 736 594 3,308
Net operating leases 2,433 384 650 526 873
Service agreements 274 169 77 23 5
Other long-term obligations 613 202 393 16 2
Total $ 20,178 $ 2,357 $ 4,242 $ 2,407 $ 11,172
The above table does not include the liability for unrecognized tax benefits of $94 million as the Company is unable to reasonably predict the timing
of settlement of these liabilities, other than approximately $35 million that may become payable within one year. The table also excludes the
provisional estimate of remaining transitional tax payments related to the Tax Cuts and Jobs Act ("the TCJA") of $62 million.
42
-- 42 of 139 --
Management’s Discussion of Critical Accounting Policies and Estimates
The Company’s discussion of critical accounting policies and estimates that place the most significant demands on management’s judgment and
requires management to make significant estimates about matters that are inherently uncertain are discussed in the MD&A in the 2021 Form 10-K.
New Accounting Guidance
Note 19, New Accounting Guidance, in the notes to the consolidated financial statements in this report contains a discussion of recently issued
accounting guidance and their impact or potential future impact on the Company’s financial results, if determinable.
43
-- 43 of 139 --
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Market Risk and Credit Risk
Certain of the Company’s revenues, expenses, assets and liabilities are exposed to the impact of interest rate changes and fluctuations in foreign
currency exchange rates and equity markets.
Interest Rate Risk and Credit Risk
Interest income generated from the Company's cash, cash equivalents, and cash and cash equivalents held in a fiduciary capacity will vary with the
general level of interest rates.
The Company had the following investments subject to variable interest rates:
(In millions) March 31, 2022
Cash and cash equivalents $ 772
Cash and cash equivalents held in a fiduciary capacity $ 10,461
Based on the above balances, if short-term interest rates increased or decreased by 10%, or 2 basis points, over the course of the year, annual
interest income, including interest earned on cash and cash equivalents held in a fiduciary capacity, would increase or decrease by approximately
$1.5 million.
Changes in interest rates can also affect the discount rate and assumed rate of return on plan assets, two of the assumptions among several others
used to measure net periodic pension expense. The assumptions used to measure plan assets and liabilities are typically assessed at the end of
each year, and determine the expense for the subsequent year. Assumptions used to determine net periodic expense for 2022 are discussed in
Note 13, Retirement Benefits, in the notes to the consolidated financial statements included in our most recently filed Annual Report on Form 10-K.
For a discussion on pension expense sensitivity to changes in these rates, see the "Management’s Discussion and Analysis of Financial Condition
and Results of Operations - Management’s Discussion of Critical Accounting Policies and Estimates - Retirement Benefits" section of our most
recently filed Annual Report on Form 10-K.
In addition to interest rate risk, our cash investments and fiduciary cash investments are subject to potential loss of value due to counter-party credit
risk. To minimize this risk, the Company invests pursuant to a Board approved investment policy. The policy mandates the preservation of principal
and liquidity and requires broad diversification with counter-party limits assigned based primarily on credit rating and type of investment. The
Company carefully monitors its cash, cash equivalents, and cash and cash equivalents held in a fiduciary capacity, and will further restrict the
portfolio as appropriate to market conditions. The majority of cash, cash equivalents and cash and cash equivalents held in a fiduciary capacity are
invested in short-term bank deposits and liquid money market funds.
Foreign Currency Risk
The translated values of revenue and expense from the Company’s international operations are subject to fluctuations due to changes in currency
exchange rates. The non-U.S. based revenue that is exposed to foreign exchange fluctuations is approximately 53% of total revenue. We
periodically use forward contracts and options to limit foreign currency exchange rate exposure on net income and cash flows for specific, clearly
defined transactions arising in the ordinary course of business. Although the Company has significant revenue generated in foreign locations which
is subject to foreign exchange rate fluctuations, in most cases both the foreign currency revenue and expenses are in the functional currency of the
foreign location. As such, under normal circumstances, the U.S. dollar translation of both the revenues and expenses, as well as the potentially
offsetting movements of various currencies against the U.S. dollar, generally tends to mitigate the impact on net operating income of foreign
currency risk. However, there have been periods where the impact was not mitigated due to external market factors, and external macroeconomic
events may result in greater foreign exchange rate fluctuations in the future. If foreign exchange rates of major currencies (Euro, Sterling, Australian
dollar and Canadian dollar) moved 10% in the same direction against the U.S. dollar that held constant over the course of the year, the Company
estimates that full year net operating income would increase or decrease by approximately $62 million. The Company has exposure to
approximately 80 foreign currencies overall. In Continental Europe, the largest amount of revenue from renewals for the Risk and Insurance
Services segment occurs in the first quarter.
If exchange rates at March 31, 2022 hold constant for the rest of 2022, the Company estimates the year-over-year impact from conversion of
foreign currency earnings will decrease full year net operating income by approximately $34 million.
44
-- 44 of 139 --
Equity Price Risk
The Company holds investments in both public and private companies as well as private equity funds, including investments of approximately $82
million that are valued using readily determinable fair values and approximately $39 million of investments without readily determinable fair values.
The Company also has investments of approximately $224 million that are accounted for using the equity method. The investments are subject to
risk of decline in market value, which, if determined to be other than temporary for assets without readily determinable fair values, could result in
realized impairment losses. The Company periodically reviews the carrying value of such investments to determine if any valuation adjustments are
appropriate under the applicable accounting pronouncements.
At March 31, 2022, the Company owns approximately 14% of the common stock of Alexander Forbes ("AF"), a South African company listed on the
Johannesburg Stock Exchange. The investment in AF is accounted at fair value, with unrealized gains and losses recorded as investment income
(loss) in the consolidated statements of income. The fair value of this investment at March 31, 2022 was approximately $64 million.
Other
A number of lawsuits and regulatory proceedings are pending. See Note 17, Claims, Lawsuits and Other Contingencies, in the notes to the
consolidated financial statements included in this report.
Item 4. Controls & Procedures.
a. Evaluation of Disclosure Controls and Procedures
Based on their evaluation, as of the end of the period covered by this report, the Company’s Chief Executive Officer and Chief Financial Officer
have concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange
Act of 1934) are effective.
b. Changes in Internal Control
There were no other changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by
Rules 13a-15(d) or 15d-15(d) under the Securities Exchange Act of 1934 that occurred during the Company’s last fiscal quarter that have materially
affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
45
-- 45 of 139 --
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
The Company and its subsidiaries are also party to a variety of other legal, administrative, regulatory and government proceedings, claims and
inquiries arising in the normal course of business. Additional information regarding certain legal proceedings and related matters as set forth in Note
17, Claims, Lawsuits and Other Contingencies, in the notes to the consolidated financial statements provided in Part I of this report is incorporated
herein by reference.
Item 1A. Risk Factors.
The Company and its subsidiaries face a number of risks and uncertainties. In addition to the other information in this report and our other filings
with the SEC, readers should consider carefully the risk factors discussed in "Part I, Item 1A. Risk Factors" in our Annual Report on Form 10-K for
the year ended December 31, 2021.
If any of the risks described in our Annual Report on Form 10-K or such other risks actually occur, our business, results of operations or financial
condition could be materially adversely affected.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Issuer Repurchases of Equity Securities
On March 23, 2022, the Board of Directors of the Company authorized an additional $5 billion in share repurchases. This is in addition to the
Company's existing share repurchase program, which had approximately $1.3 billion of remaining authorization as of December 31, 2021. The
Company repurchased approximately 3.2 million shares of its common stock for $500 million during the first quarter of 2022. As of March 31, 2022,
the Company remained authorized to repurchase up to approximately $5.8 billion in shares of its common stock. There is no time limit on the
authorization.
Period
(a)
Total
Number of
Shares (or
Units)
Purchased
(b)
Average
Price
Paid per
Share
(or Unit)
(c)
Total Number of
Shares (or Units)
Purchased as Part
of Publicly
Announced Plans
or Programs
(d)
Maximum
Number (or
Approximate
Dollar Value) of
Shares (or
Units) that May
Yet Be
Purchased
Under the Plans
or Programs
January 1-31, 2022 640,408 $ 162.3958 640,408 $ 1,159,976,641
February 1-28, 2022 1,411,026 $ 152.8169 1,411,026 $ 944,348,006
March 1-31, 2022 1,166,128 $ 154.6613 1,166,128 $ 5,763,993,137
Total 3,217,562 $ 155.3919 3,217,562 $ 5,763,993,137
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosure.
Not Applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.
See the Exhibit Index immediately following the signature page of this report, which is incorporated herein by reference.
46
-- 46 of 139 --
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Date: April 21, 2022 /s/ Mark C. McGivney
Mark C. McGivney
Chief Financial Officer
Date: April 21, 2022 /s/ Stacy M. Mills
Stacy M. Mills
Vice President & Controller
(Chief Accounting Officer)
47
-- 47 of 139 --
EXHIBIT INDEX
Exhibit No. Exhibit Name
10.1 Letter Agreement, effective as of January 1, 2022, between Marsh & McLennan Companies, Inc. and Peter C.
Hearn
10.2 Letter Agreement, effective as of April 1, 2022, between Marsh & McLennan Companies, Inc. and Martine
Ferland
10.3 Form of Deferred Stock Unit Award, with grant dates from March 1, 2022 through February 1, 2023, under the
Marsh & McLennan Companies, Inc. 2020 Incentive and Stock Award Plan – Cliff Vesting
10.4 Form of Deferred Stock Unit Award, with grant dates from March 1, 2022 through February 1, 2023, under the
Marsh & McLennan Companies, Inc. 2020 Incentive and Stock Award Plan – Ratable Vesting
10.5 Form of Restricted Stock Unit Award, dated as of February 23, 2022, under the Marsh & McLennan Companies,
Inc. 2020 Incentive and Stock Award Plan
10.6 Form of Performance Stock Unit Award, dated as of February 23, 2022, under the Marsh & McLennan
Companies, Inc. 2020 Incentive and Stock Award Plan
10.7 Form of Stock Option Award, dated as of February 23, 2022, under the Marsh & McLennan Companies, Inc.
2020 Incentive and Stock Award Plan
31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32.1 Section 1350 Certifications
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its
XBRL tags are embedded within the Inline XBRL document.
101.SCH XBRL Taxonomy Extension Schema
101.CAL XBRL Taxonomy Extension Calculation Linkbase
101.DEF XBRL Taxonomy Extension Definition Linkbase
101.LAB XBRL Taxonomy Extension Label Linkbase
101.PRE XBRL Taxonomy Extension Presentation Linkbase
48
-- 48 of 139 --
Daniel S. Glaser
President and Chief Executive Officer
Marsh McLennan
1166 Avenue of the Americas
New York, NY 10036
T +1 212 345 5000
www.mmc.com
Subject: Terms of Employment
Dear Peter,
This letter agreement sets forth the terms of your continued employment as Vice Chair of Marsh & McLennan Companies, Inc.
(“Marsh McLennan”, and together with its subsidiaries and affiliates, the “Company”). This position currently reports to the President
and Chief Executive Officer (the “Chief Executive Officer”) of Marsh McLennan. Your principal work location will be in Philadelphia, PA.
1. Effective Date, Duties and Responsibilities
The terms of this letter agreement are effective as of January 1, 2022. Effective as of December 31, 2021, you will cease to be
President and Chief Executive Officer of Guy Carpenter & Company LLC and a member of the Marsh McLennan Executive
Committee. Effective as of January 1, 2022, your position will be Vice Chair of Marsh McLennan. This is a full-time position.
You will continue to devote all of your attention and time during working hours to the affairs and business of Guy Carpenter and the
Company and use your best efforts to perform such duties and responsibilities as shall be reasonably assigned to you by the Chief
Executive Officer and are consistent with your position including those described in Exhibit A.
In addition, you agree to serve, without additional compensation, as an officer and director for any member of the Affiliated Group.
For purposes of this letter agreement, the term “Affiliated Group” means Marsh McLennan and any corporation, partnership, joint
venture, limited liability company, or other entity in which Marsh McLennan has a 10% or greater direct or indirect interest. You
may serve on the boards or committees set forth on Exhibit A and, with the prior written consent of Marsh McLennan, one
additional public company board.
2. Compensation and Benefits
Your compensation and benefits are as set forth below and in Exhibit A.
a. Annual Base Salary: You will receive an annual base salary of the amount set forth on Exhibit A, payable in installments in
accordance with the Company’s payroll procedures in effect from time to time. Your base salary includes compensation for all
time worked, as well as appropriate consideration for sick days, personal days, and other time off.
b. Annual Bonus: For the 2022 performance year, you are eligible for an annual bonus on the terms set forth here and on Exhibit
A. Bonus awards are discretionary and are paid in cash. Except as provided in this paragraph, to qualify for an annual bonus
for the 2022 performance year, you must comply with the Company’s standard terms and conditions for the receipt of a bonus
payment other than being employed on the bonus payment date. The annual bonus shall be paid no later than March 15 of
the year following the year for which such bonus is earned.
-- 49 of 139 --
Page 2
December 1, 2021
Peter Hearn
In the event of your Permanent Disability (as defined below) or death, the Company shall pay you (or your estate in the case of
death) a prorated target annual bonus for the year in which your termination occurs based on the portion of the year elapsed
as of the date of your termination. Any such bonus amount shall be paid within 30 days of your death. In the event of your
Permanent Disability, your prorated annual bonus payment is conditioned upon, and subject to, your execution and delivery to
the Company within 30 days of the date of such event a valid confidential waiver and release of claims agreement (including
restrictive covenants) in a form satisfactory to the Company (the “Release”) and such Release has become irrevocable as
provided therein (the “Release Effective Date”). Payment of any such annual bonus amount shall then be paid within 30 days
following the Release Effective Date, but in no event later than March 15 of the year following the year for which such bonus is
earned.
As used in this letter agreement, “Permanent Disability” will be deemed to occur when it is determined (by Marsh McLennan’s
disability carrier for the primary long-term disability plan or program applicable to you because of your employment with the
Company) that you are unable to engage in any substantial gainful activity by reason of any medically determinable physical or
mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than
12 months.
c. Long-Term Incentive Compensation: You are eligible to receive an award under Marsh McLennan’s long-term incentive
program in February 2022. Long-term incentive awards are discretionary and are governed by terms and conditions approved
by the Compensation Committee of the Marsh McLennan Board of Directors (“Compensation Committee”) as set forth in the
award agreement and in Marsh McLennan’s 2020 Incentive and Stock Award Plan (or other plan under which the long-term
incentive award is granted). In accordance with Company practice, you may be required to enter into a “Restrictive Covenants
Agreement” in connection with long-term incentive awards.
d. Benefit Programs: You and your eligible family members will continue to have the opportunity to participate in the employee
benefit plans, policies and programs provided by Marsh McLennan, on such terms and conditions as are generally provided to
similarly situated employees of the Company. These plans may include retirement, savings, medical, life, disability, and other
insurance programs as well as an array of work/life effectiveness policies and programs. Please be aware that nothing in this
letter agreement shall limit Marsh McLennan’s ability to change, modify, cancel or amend any such policies or plans. In
addition, you will be entitled to the benefits, if any, set forth on Exhibit A and you will continue to be eligible to participate in the
Marsh McLennan Executive Financial Services Program, as in effect from time to time. See the following section regarding
entitlement to severance benefits.
3. Termination of Employment
a. Your employment with the Company is expected to terminate no later than December 31, 2022.
b. Effective as of January 1, 2022, you will no longer participate in the Marsh & McLennan Companies, Inc. Senior Executive
Severance Pay Plan or any other Company severance pay plan. In consideration of the payments and other benefits
hereunder, when your employment with the Company terminates for any reason and at any time, you will not be eligible for any
severance payments or benefits under any severance plan or arrangement sponsored by the Company.
-- 50 of 139 --
Page 3
December 1, 2021
Peter Hearn
c. Upon the termination of your employment for any reason, you shall immediately resign, as of your date of termination, from all
positions that you then hold with any member of the Affiliated Group. You hereby agree to execute any and all documentation
to effectuate such resignations upon request by the Company, but you shall be treated for all purposes as having so resigned
upon your date of termination, regardless of when or whether you execute any such documentation.
d. During the term of this letter agreement, and, subject to any other business obligations that you may have, following your date
of termination, you agree to assist the Affiliated Group in the investigation and/or defense of any claims or potential claims that
may be made or threatened to be made against any member of the Affiliated Group, including any of their officers or directors
(a “Proceeding”), and will assist the Affiliated Group in connection with any claims that may be made by any member of the
Affiliated Group in any Proceeding. You agree, unless precluded by law, to promptly inform Marsh McLennan if you are asked
to participate in any Proceeding or to assist in any investigation of any member of the Affiliated Group. In addition, you agree to
provide such services as are reasonably requested by the Company to assist any successor to you in the transition of duties
and responsibilities to such successor. Following the receipt of reasonable documentation, the Company agrees to reimburse
you for all of your reasonable out-of-pocket expenses associated with such assistance. Your request for any reimbursement,
including reasonable documentation, must be submitted as soon as practicable and otherwise consistent with Company policy.
In any event, your request for a taxable reimbursement, including reasonable documentation, must be submitted by the
October 31st of the year following the year in which the expense is incurred. The Company will generally reimburse such
expenses within 60 days of the date they are submitted, but in no event will they be reimbursed later than the December 31st
of the year following the year in which the expense is incurred.
4. Restrictive Covenants
You are subject to existing restrictions with respect to confidentiality, noncompetition and nonsolicitation under confidentiality,
noncompetition, nonsolicitation, or other agreements, including the Non-competition and Non-solicitation Agreement dated as of
April 12, 2016 (“The April 2016 Agreement”). Such restrictions shall remain in full force and effect and, by your execution of this
letter agreement, you hereby reaffirm and ratify such restrictions; provided that, the non-competition restrictions contained in
Section 3 of the April 2016 Agreement shall expire no later than January 1, 2023.
5. Code of Conduct & Other Mandatory Training
As a condition of your continued employment by Marsh McLennan as Vice Chair, you must read, understand and abide by all
applicable Marsh McLennan compliance policies found on Marsh McLennan’s compliance website (integrity.mmc.com), as
updated from time to time, including but not
-- 51 of 139 --
Page 4
December 1, 2021
Peter Hearn
limited to the Marsh McLennan Code of Conduct, The Greater Good. You must complete any required online compliance training
for your position within 30 days after it becomes available. In addition, you understand that you must complete any and all
additional training that the Company determines is appropriate for your position during the course of your employment.
6. Credentialing
The Company supports continuing professional education. If you hold a professional license or certification, you acknowledge that
you understand the obligations and the specific code of professional ethics associated with this license or certificate and agree to
perform your duties in accordance with these standards. In addition, you acknowledge your responsibility to maintain any job-
related licenses or certificates in accordance with the requirements issued by the applicable regulatory body or bodies. The
Company agrees to reimburse you for the fees you incur during your employment with the Company in maintaining such licenses
or certificates applicable to your position. You must submit your fees within 60 days after the date they are incurred. The Company
will generally reimburse such fees within 60 days of the date they are submitted, but in no event will they be reimbursed later than
December 31st of the year following the year in which the fee was incurred.
7. Waiver and Release
The terms of this letter agreement, and all amounts payable by the Company including any bonus award for the 2021 performance
year, are contingent upon:
a. your execution and delivery to the Company of the Waiver and Release Agreement attached as Exhibit B within the time
period described in the penultimate paragraph thereof following
(i) your execution of this letter agreement and
(ii) your termination of employment and
b. each such Waiver and Release Agreement becoming irrevocable as provided therein.
8. Miscellaneous
a. Notices. Notices given pursuant to this letter agreement shall be in writing and shall be deemed received when personally
delivered, or on the date of written confirmation of receipt by (i) overnight carrier, (ii) telecopy, (iii) registered or certified mail,
return receipt requested, postage prepaid, or (iv) such other method of delivery as provides a written confirmation of delivery.
Notice to the Company shall be directed to:
General Counsel
Marsh McLennan
1166 Avenue of the Americas
New York, NY 10036
Notices to or with respect to you will be directed to you, or in the event of your death, your executors, personal representatives
or distributees, at your home address as set forth in the records of the Company.
-- 52 of 139 --
Page 5
December 1, 2021
Peter Hearn
b. Assignment of this Agreement. This letter agreement is personal to you and shall not be assignable by you without the prior
written consent of Marsh McLennan. This letter agreement shall inure to the benefit of and be binding upon the Company and
its respective successors and assigns. Marsh McLennan may assign this letter agreement, without your consent, to any
member of the Affiliated Group or to any other respective successor (whether directly or indirectly, by agreement, purchase,
merger, consolidation, operation of law or otherwise) to all, substantially all or a substantial portion of the business and/or
assets of the Company, as applicable. If and to the extent that this letter agreement is so assigned, references to the
“Company” throughout this letter agreement shall mean the Company as hereinbefore defined and any successor to, or
assignee of, its business and/or assets as applicable.
c. Merger of Terms. Except regarding an annual bonus for the 2021 performance year, this letter agreement supersedes all prior
discussions and agreements between you and the Company or any member of the Affiliated Group with respect to the subject
matters covered herein, including without limitation the Letter Agreements dated May 1, 2015, September 20, 2017 and April
16, 2019. For the avoidance of doubt, compensation that was paid or awarded to you prior to the effective date of this letter
agreement will continue to be governed by the terms pursuant to which such compensation was paid or awarded.
d. Indemnification. The Company shall indemnify you to the extent permitted by its bylaws, as in effect from time to time, with
respect to the work you have performed for, or at the request of, the Company or any member of the Affiliated Group (as such
term is defined in Section 1 above) during the term of this letter agreement.
e. Governing Law; Amendments. This letter agreement shall be governed by and construed in accordance with the laws of the
State of New York, without reference to principles of conflict of laws. This letter agreement may not be amended or modified
other than by a written agreement executed by you and an authorized employee of Marsh McLennan.
f. Choice of Forum. The Company and you each hereby irrevocably and unconditionally submits to the exclusive jurisdiction of
any New York state court or federal court of the United States of America sitting in the State of New York, and any appellate
court thereof, in any action or proceeding arising out of or relating to this letter agreement or for recognition or enforcement of
any judgment relating thereto, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in
respect of any such action or proceeding may be heard and determined in any such New York state court or, to the extent
permitted by law, in such federal court. The Company and you agree that a final judgment in any such action or proceeding
shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.
g. Severability; Captions. In the event that any provision of this letter agreement is determined to be invalid or unenforceable, in
whole or in part, the remaining provisions of this letter agreement will be unaffected thereby and shall remain in full force and
effect to the fullest extent permitted by law. The captions in this letter agreement are not part of the provisions of this letter
agreement and will have no force or effect.
h. Section 409A. The provisions of this Section 8(h) will only apply if and to the extent required to avoid the imposition of taxes,
interest and penalties on you under Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”).
Section 409A applies to nonqualified deferred compensation which exists if an individual has a “legally binding right” to
compensation that is or may be payable in a later year. In furtherance of the objective of this Section 8(h), to the
-- 53 of 139 --
Page 6
December 1, 2021
Peter Hearn
extent that any regulations or other guidance issued under Section 409A would result in your being subject to payment of
taxes, interest or penalties under Section 409A, you and the Company agree to use our best efforts to amend this letter
agreement and any other plan, award, arrangement or agreement between you and the Company in order to avoid or limit the
imposition of any such taxes, interest or penalties, while maintaining to the maximum extent practicable the original intent of
the applicable provisions. This Section 8(h) does not guarantee that you will not be subject to taxes, interest or penalties under
Section 409A with respect to compensation or benefits described or referenced in this letter agreement or any other plan,
award, arrangement or agreement between you and the Company.
Furthermore, and notwithstanding any contrary provision in this letter agreement or any other plan, award, arrangement or
agreement between you and the Company, to the extent necessary to avoid the imposition of taxes, interest and penalties on
you under Section 409A, if at the time of the termination of your employment you are a “specified employee” (as defined in
Section 409A), you will not be entitled to any payments upon termination of employment until the first day of the seventh month
after the termination of employment and any such payments to which you would otherwise be entitled during the first six
months following your termination of employment will be accumulated and paid without interest on the first day of the seventh
month after the termination of employment.
Furthermore, and notwithstanding any contrary provision in this letter agreement or in any other plan, award, arrangement or
agreement between you and the Company that: (i) provides for the payment of nonqualified deferred compensation that is
subject to Section 409A; and (ii) conditions payment or commencement of payment on one or more employment-related
actions, such as the execution and effectiveness of a release of claims or a restrictive covenant (each an “Employment-
Related Action”) (any such plan, award, arrangement or agreement is a “Relevant Plan”):
1) if the Relevant Plan does not specify a period or provides for a period of more than 90 days for the completion of an
Employment-Related Action, then the period for completion of the Employment-Related Action will be the period
specified by the Company, which shall be no longer than 90 days following the event otherwise triggering the right to
payment; and
2) if the period for the completion of an Employment-Related Action includes the January 1 next following the event
otherwise triggering the right to payment, then the payment shall be made or commence following the completion of the
Employment-Related Action, but in no event earlier than that January 1.
i. Withholding Requirements. All amounts paid or provided to you under this letter agreement shall be subject to any applicable
income, payroll or other tax withholding requirements.
Please acknowledge your agreement with the terms of this letter agreement by signing and dating this and the enclosed copies of the
letter agreement and Waiver and Release Agreement and returning one copy of each to me.
Sincerely,
-- 54 of 139 --
Page 7
December 1, 2021
Peter Hearn
/s/ Daniel S. Glaser
Daniel S. Glaser
President and Chief Executive Officer
Marsh McLennan
Accepted and Agreed:
/s/ Peter C. Hearn________________
(Signature)
April 18, 2022______________________________
(Date)
-- 55 of 139 --
Page 8
December 1, 2021
Peter Hearn
Exhibit A
Board or Committee Memberships St. Mark’s School
Annual Base Salary $800,000, effective January 1, 2022.
Annual Target Bonus Opportunity Bonus awards are discretionary. Target bonus of $1,500,000 for the 2022 performance year
(awarded in 2023). Actual bonus awards will be based on performance over the applicable
fiscal year.
Key Responsibilities • Expected to work full-time, focusing on three areas:
◦ Clients & Sales
• Advise Senior Relationship Officers on client account management and sales
• Provide guidance on RFPs to client teams
• Act as coach on sales, including leadership on sales training
◦ Recruiting
• Assist with strategic hiring
◦ CEO Transition
• Be available to advise the new Guy Carpenter CEO as requested
• Other duties as requested by the Marsh McLennan Chief Executive Officer
Other Benefits • The Company will pay for travel and expenses in accordance with its travel and expense
policies in effect from time to time.
-- 56 of 139 --
Exhibit B to December 1, 2021 Employment Letter
Waiver and Release Agreement
I, Peter Hearn, in consideration of the terms and conditions in the Terms of Employment Letter dated December 1, 2021 (the “Letter”)
which I acknowledge are sufficient consideration to support this Waiver and Release Agreement (“Agreement”), agree to accept the
Letter in full resolution and satisfaction of, and hereby irrevocably and unconditionally release and forever discharge Marsh &
McLennan Companies, Inc. (the “Company”) and its past and present, direct and indirect parents, subsidiaries, affiliates, divisions,
predecessors, successors, assigns and representatives, and all of its or their respective past and present benefit and severance
plans, plan administrators, insurers, agents, shareholders, officers, directors, employees, attorneys and representatives, whether
acting as agents or in individual capacities (collectively, the “Releasees”) with respect to any and all agreements, promises, rights,
liabilities, claims and demands of any kind whatsoever, at law or in equity, whether known or unknown, asserted or unasserted, fixed
or contingent, apparent or concealed, that I, my heirs, executors, administrators, successors or assigns ever had, now have or
hereafter can, shall or may have for, upon, or by reason of any matter, cause or thing whatsoever existing, accruing, arising or
occurring at any time on or prior to the date I execute this Agreement, including, without limitation,
(i) any and all rights and claims arising out of or relating to my employment, compensation and benefits with the Company, and
any change in position or status with the Company or any of its affiliates;
(ii) any and all rights or claims under any prior agreements between me and the Company or any of the Releasees (except as
set forth in the Letter), including, without limitation, the Letter Agreements dated May 1, 2015, September 20, 2017 and April 16, 2019
between me and the Company.
(iii) fraud, whistleblower, public policy, defamation, disparagement and other personal injury and tort claims; and
(iv) claims under any federal, state or municipal employee benefit, wage payment, discrimination or fair employment practices
law, statute or regulation (e.g., claims based on race, color, sex, religion, age, national origin, disability, sexual orientation, or veteran,
marital or citizenship status) law, and claims for costs, expenses and attorneys’ fees with respect thereto, including, without limitation,
any and all rights and claims under Title VII of the Civil Rights Act of 1964, the Civil Rights Acts of 1866 and 1991, the Age
Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, the Americans with Disabilities Act the
Uniformed Services Employment and Reemployment Rights Act, the Equal Pay Act, the Genetic Information Non-Discrimination Act,
the National Labor Relations Act, the
-- 57 of 139 --
WAIVER AND RELEASE AGREEMENT
Page 2
Pregnancy Discrimination Act, the Immigration Reform and Control Act, the Employee Retirement Income Security Act of 1974,
Sections 503 and 504 of the Rehabilitation Act of 1973, the Occupational Safety and Health Act, the Worker Adjustment Retraining
and Notification Act, the Sarbanes-Oxley Act, and the Family and Medical Leave Act, as such laws have been or may be amended.
I acknowledge that I have not raised and do not have any claims of discrimination, harassment or retaliation, including but not limited
to claims of sexual harassment, against any of the Releasees.
Nothing in this Agreement releases or diminishes any obligations under the Letter, which shall continue in full force and effect in
accordance with its terms. Nothing in this Agreement releases or diminishes any vested monies or other vested benefits to which I
may be entitled from, under, or pursuant to any incentive, savings, stock, retirement or compensation plan of the Company or the
Releasees, or my right, if any, to obtain contribution and/or indemnification, as permitted by applicable law and Company by-laws. In
addition, this Agreement does not release any claims that I cannot lawfully release, and does not limit my ability to, without notice, (i)
file a charge and/or complaint, testify, assist, comply with a subpoena from, or participate in any manner in an investigation, hearing or
proceeding; respond to any inquiry; or otherwise communicate, including providing documents or other information, with any criminal
or civil law enforcement agency, the Equal Employment Opportunity Commission, the National Labor Relations Board, the
Occupational Safety and Health Administration, the Securities and Exchange Commission, and/or any other federal, state, or local
governmental or administrative agency or commission (individually, “Government Agency” or collectively, the “Government Agencies”);
(ii) speak with my attorney, or (iii) exercise my rights under Section 7 of the National Labor Relations Act to engage in protected or
concerted activity with other employees. In addition, this Agreement does not limit my right to receive any award, monetary payment,
and/or financial incentive from any Government Agency (and not the Company) for information provided to said Government Agency.
Further, this Agreement is not intended to and does not affect any rights or claims I may have arising after the date that I execute this
Agreement.
This Agreement shall inure to the benefit of and shall be binding upon and enforceable by each and all of the Releasees.
I acknowledge that: before signing this Agreement, I was given a period of twenty-one (21) days in which to review and consider it; I
have, in fact, carefully reviewed this Agreement; and that I am entering into the Agreement voluntarily and of my own free will. Further,
I am advised to consult with an attorney before signing this Agreement. I acknowledge that, to the extent I wished to do so, I have
consulted with
-- 58 of 139 --
WAIVER AND RELEASE AGREEMENT
Page 3
an attorney. I represent, warrant and agree that, if I choose to execute this Agreement before the end of the 21-day period, I do so
with the understanding that I am choosing not to exercise my right to take the full 21-day period to consider this Agreement, that such
early execution was not induced by fraud, misrepresentation or a threat to withdraw or alter the Agreement prior to the expiration of
the 21-day period, that such early execution was completely knowing and voluntary, and that I had reasonable and ample time in
which to review this Agreement with the advice of counsel.
I agree that, for a period of seven (7) days after I sign this Agreement, I have the right to revoke it by providing written notice to the
General Counsel of Marsh & McLennan Companies, Inc., 1166 Avenue of the Americas, 44 Floor, New York, New York 10036. For
this revocation to be effective, written notice must be received by the General Counsel no later than the close of business on the
eighth (8 ) day after I sign this Agreement. Notwithstanding anything contained herein to the contrary, this Agreement will not become
fully effective and enforceable until after the expiration of the seven-day revocation period.
Accepted and Agreed:
/s/ Peter C. Hearn April 18, 2022
Peter C. Hearn (Date)
th
th
-- 59 of 139 --
John Q. Doyle
Group President and Chief Operating Officer
Marsh McLennan
1166 Avenue of the Americas
New York, NY 10036
www.mmc.com
Subject: Terms of Employment
Dear Martine,
This second amendment to the Letter Agreement, dated January 16, 2019, between you and Marsh & McLennan Companies, Inc.
(“Marsh McLennan”) as subsequently amended on February 22, 2021 (the “Letter Agreement”), revises the terms and conditions of
your employment by Mercer Consulting Group, Inc. (“Mercer”) as its President and Chief Executive Officer. The Letter Agreement will
continue to govern your employment except as specified below:
1. Exhibit A to the Letter Agreement shall be deleted and replaced in its entirety with the attached Exhibit A.
The terms of this amendment are effective as of April 1, 2022. Please acknowledge your agreement with the terms of the Letter
Agreement, as further amended by this second amendment, by signing and dating this and the enclosed copy and returning one to
me.
Sincerely,
/s/ John Q. Doyle
John Q. Doyle
Group President and Chief Operating Officer
Marsh McLennan
Accepted and Agreed:
/s/ Martine Ferland
(Signature)
March 21, 2022
(Date)
-- 60 of 139 --
Page 2
February 23, 2022
Martine Ferland
Exhibit A
Board or Committee Memberships Board of Trustees for the New York Academy of Medicine
Annual Base Salary $1,000,000 effective as of April 1, 2022
Annual Target Bonus Opportunity Bonus awards are discretionary. Target bonus of $1,900,000 commencing with the 2021
performance year (awarded in February 2022). Actual bonus may range from 0% - 200% of
target, based on achievement of individual performance objectives, Mercer’s performance
and/or Marsh McLennan’s performance as Marsh McLennan may establish from time to time.
Annual Target Long-Term Incentive
Opportunity
Long-term incentive awards are discretionary. Target award value of $2,300,000, commencing
with the award made in 2021.
-- 61 of 139 --
MARSH & McLENNAN COMPANIES, INC.
2020 INCENTIVE AND STOCK AWARD PLAN
TERMS AND CONDITIONS
OF
DEFERRED STOCK UNIT AWARDS
WITH GRANT DATES FROM MARCH 1, 2022 THROUGH FEBRUARY 1, 2023
-- 62 of 139 --
TABLE OF CONTENTS
Page
I. BACKGROUND 1
II. AWARDS 1
III. EMPLOYMENT EVENTS 3
IV. CHANGE IN CONTROL PROVISIONS 6
V. DEFINITIONS 7
VI. ADDITIONAL PROVISIONS 8
VII. QUESTIONS AND ADDITIONAL INFORMATION 10
-- 63 of 139 --
I. BACKGROUND
An award (“Award”) has been granted to you under the Marsh & McLennan Companies, Inc. 2020 Incentive
and Stock Award Plan (the “Plan”), subject to your acceptance as described in Section II.A.1. The Award type,
the number of shares of Marsh & McLennan Companies, Inc. (“Marsh McLennan”) common stock covered by
the Award, instructions on how to accept or decline the Award and the deadline for accepting the Award will be
provided to you by Executive Compensation and/or the stock plan service provider of the Company (as defined
in Section V.). The Award is also subject to the terms and conditions set forth herein (the “Terms and
Conditions”) and to additional terms and conditions as set forth in the country-specific notices (the “Country-
Specific Notices”). The Prospectus dated [DATE] also describes important information about the Plan. The
Terms and Conditions, the Country-Specific Notices, and the Plan will be referred to herein as the “Award
Documentation”. As used herein, “Common Stock” means common stock of Marsh McLennan.
Capitalized terms in these Terms and Conditions are defined in Section V.
II. AWARDS
A. General.
1. Award Acceptance. The grant of this Award is contingent upon your acceptance, by the date and
in the manner specified by Executive Compensation and/or the Company’s stock plan service
provider, of these Terms and Conditions, the Country-Specific Notices and Restrictive Covenants
Agreement as described in Section II.A.3. If you decline the Award or if you do not accept the Award
and any applicable documents described in the preceding sentence by the deadline date and in the
manner specified, then the Award will be cancelled as of the grant date of the Award.
2. Rights of Award Holders. Unless and until the vesting conditions of the Award have been
satisfied and cash or shares of Common Stock, as applicable, have been delivered to you in
accordance with the Award Documentation, you have only the rights of a general unsecured creditor
of Marsh McLennan. Unless and until shares of Common Stock have been delivered to you, you have
none of the rights of ownership to such shares (e.g., units cannot be used as payment for stock
option exercises; units may not be transferred or assigned; units have no voting rights).
3. Restrictive Covenants Agreement. As described in Section II.A.1., a Restrictive Covenants
Agreement (“Restrictive Covenants Agreement”) in a form determined by Marsh McLennan must be
in place in order to accept the Award and you must execute or reaffirm, as determined by Marsh
McLennan, in its sole discretion, the Restrictive Covenants Agreement in order for the Award to vest
pursuant to certain employment events as described in Section III. Failure to timely execute the
Restrictive Covenants Agreement by the date specified by the Company or failure to timely execute
or reaffirm and comply with the Restrictive Covenants Agreement as described in Section III.F.1. or
2., as applicable, will result in cancellation or forfeiture of any rights, title and interest in and to the
Award, without any liability to the Company.
B. Stock Units.
1. General. A deferred stock unit (“Stock Unit”) represents an unfunded and unsecured promise to
deliver (or cause to be delivered) to you, subject to the terms of the Award Documentation, one
share of Common Stock after vesting.
1
-- 64 of 139 --
2. Vesting. Subject to your continued employment, 100% of the Stock Units will vest on the 15th of
the month in which the third anniversary of the grant date of the Award occurs. The date on which a
Stock Unit is scheduled to vest pursuant to this Section II.B.2. is the “Scheduled Vesting Date.” In
the event of your termination of employment or the occurrence of your Permanent Disability (as
defined in Section V.) prior to the Scheduled Vesting Date, your right to any Stock Units that are
unvested immediately prior to your termination of employment or occurrence of your Permanent
Disability, as applicable, will be determined in accordance with Section III. below. For the avoidance
of doubt, the date of your termination of employment for purposes of determining vesting under this
Section II.B.2. will be determined in accordance with Section III.E.
3. Dividend Equivalents. For each outstanding Stock Unit covered by the Award, an amount equal
to the dividend payment (if any) made in respect of one share of Common Stock (a “Dividend
Equivalent”) will accrue in U.S. dollars on each dividend record date that occurs on or after the grant
date of the Award while the Award is outstanding, with no interest paid on such amounts. Accrued
Dividend Equivalents will vest when the Stock Units in respect of which such Dividend Equivalents
were accrued vest. No further Dividend Equivalents will accrue on Stock Units that do not vest or are
cancelled or forfeited. If a pro-rata amount of the outstanding unvested Stock Unit award is eligible
to vest upon a termination of employment as described in Section III.C., the pro-rata calculation (as
described in Section III.G.) will be applied to the Dividend Equivalents that have accrued on the
Award as of the date of termination. Accrued Dividend Equivalents will not be paid, and no further
Dividend Equivalents will accrue, on Stock Units that do not vest or are cancelled or forfeited as per
a termination of employment event described in Section III.D.
4. Delivery.
a. Shares of Common Stock deliverable in respect of the Stock Units covered by the Award shall be
delivered to you as soon as practicable after vesting, and in no event later than 60 days after
vesting, except as otherwise provided in Section VI.B.
b. The value of vested Dividend Equivalents will be delivered to you in cash as soon as practicable
after vesting and in no event later than 60 days after vesting.
c. The delivery of shares of Common Stock and/or cash or other property that may be deliverable
under these Terms and Conditions, is conditioned on the satisfaction or withholding of any
applicable tax obligations, as described in Section II.C.
d. Any shares of Common Stock and/or cash or other property that may be deliverable following
your death shall be delivered to the person or persons to whom your rights pass by will or the law
of descent and distribution, and such delivery shall completely discharge Marsh McLennan and
any of its subsidiaries’ or affiliates’ obligations under the Award.
e. Notwithstanding the foregoing, additional delivery rules for certain Award recipients subject to
U.S. federal income tax (whether or not the recipient is a U.S. citizen or employed in the U.S.)
are reflected in Section III.H.
C. Satisfaction of Tax Obligations.
1. Personal Tax Advisor. Neither the Company nor any Company employee is authorized to provide
personal tax advice to you. It is recommended that you consult with your personal tax advisor for
more
2
-- 65 of 139 --
detailed information regarding the tax treatment of the Award, especially before making any
decisions that rely on that tax treatment.
2. U.S. Employees. Applicable employment taxes are required by law to be withheld when a Stock
Unit or Dividend Equivalent vests. Applicable income taxes are required by law to be withheld when
shares of Common Stock in respect of Stock Units or cash in respect of Dividend Equivalents are
delivered to you. A sufficient number of whole shares of Common Stock, cash or other property, as
applicable, will be retained by Marsh McLennan to satisfy the tax withholding obligation.
3. Non-U.S. Employees.
a. Stock Units and Dividend Equivalents. In most countries, the value of a Stock Unit or
Dividend Equivalent is generally not taxable on the grant date. If the value of the Stock Unit or
Dividend Equivalent is not taxable on the grant date, it will, in most countries, be taxed at a later
time, for example, upon delivery of a share of Common Stock in respect of the Stock Unit that
vests, and/or the subsequent sale of the share of Common Stock received in connection with the
vesting of the Stock Unit or upon delivery of cash in respect of a Dividend Equivalent.
b. Withholding. Marsh McLennan and/or your employer shall have the power and the right to
deduct and withhold from the Award and other compensation or to require you to remit to Marsh
McLennan and/or to your employer, an amount sufficient to satisfy any Tax-Related Items (as
defined in Section V.) that Marsh McLennan expects to be payable under the laws of any country,
state, province, city or other jurisdiction. If applicable, Marsh McLennan and/or your employer
will, to the extent permissible under applicable law or otherwise agreed between you and Marsh
McLennan and/or your employer, retain and sell a sufficient number of whole shares of Common
Stock distributable in respect of the Award for purposes of satisfying applicable obligations with
respect to Tax-Related Items.
III. EMPLOYMENT EVENTS
A. Death. In the event your employment is terminated because of your death, all of the unvested Stock
Units that are outstanding as of the date of your death will fully vest and will be distributed as described
in Section II.B.4.
B. Permanent Disability. Upon the occurrence of your Permanent Disability, the unvested Stock Units will
fully vest and will be distributed as described in Section II.B.4., provided that you satisfy the conditions
to vesting described in Section III.F.1.
C. Termination by the Company Other Than for Cause.
1. General. Except as otherwise provided in Section IV., in the event the Company, in its sole
discretion, determines that your employment is terminated by the Company other than for Cause (as
defined in Section V.), the unvested Stock Units will vest at such termination of employment on a
pro-rata basis as described in Section III.G. and will be distributed as described in Section II.B.4.,
provided that you satisfy the conditions to vesting described in Section III.F.2.
2. Important Notes.
a. Sale of Business Unit. For purposes of this Award, in the event of a sale or similar transaction
involving the business unit for which you work (“Employing Company”) as a result of which the
Employing Company ceases to be a subsidiary or affiliate of Marsh
3
-- 66 of 139 --
McLennan, your employment will be deemed terminated by the Company other than for Cause,
even if your employment with the Employing Company continues after the sale or similar
transaction.
b. Constructive Discharge. The Award will not vest, whether on a pro-rata or full basis, upon a
constructive discharge, including if any court or regulatory agency retroactively concludes or
interprets events to have constituted a constructive discharge.
D. All Other Terminations. For all other terminations of employment not described in Sections III.A.
through C. or Section IV. (including, but not limited to, a termination by the Company for Cause or a
resignation by you of your employment with the Company), any rights, title and interest in and to any
remaining unvested portion of the Award shall be cancelled as of the date your employment is treated
as having terminated as described in Section III.E.
E. Date of Termination of Employment.
1. If Section III.E.2 does not apply to you, then for purposes of determining vesting under Section
II.B.2. and the number of unvested Stock Units that vest on a pro-rata basis as described in Section
III.G., your employment will be treated as having terminated on your last day of employment with
the Company.
2. If you are obligated (whether by law or contract) to provide the Company advance notice of your
intention to terminate your employment then, in the event you terminate your employment or
service relationship pursuant to Section III.D (regardless of the reason for such termination and
whether or not later found to be invalid or in breach of employment laws in the jurisdiction where
you are employed or the terms of your employment agreement, if any), for purposes of determining
vesting under Section II.B.2. and the pro rata calculation described in Section III.G., your
employment will be treated as having terminated on your last day of active service with the
Company, as determined by the Company in its sole discretion.
You shall be deemed to have ceased active service with the Company when you are no longer
required by the Company to provide regular services to the Company even if you remain legally
employed by the Company, such as may occur if the Company were to place you on “garden leave”,
a terminal leave of absence or any similar period mandated under employment laws in the
jurisdiction where you are employed or the terms of your employment agreement, if any (in each
case as determined by the Company in its sole discretion).
F. Conditions to Vesting of Award Prior to the Scheduled Vesting Date.
1. Restrictive Covenants Agreement. In the event of the occurrence of your Permanent Disability
as described in Section III.B., you will be required to execute or reaffirm, as determined by Marsh
McLennan in its sole discretion, and return to Marsh McLennan (or an agent appointed by Marsh
McLennan) a Restrictive Covenants Agreement. Failure to (a) execute or reaffirm such an agreement
by the date specified by the Company, which shall be in no event later than 60 days following the
occurrence of your Permanent Disability as described in Section III.B., or (b) comply with the
Restrictive Covenants Agreement, will result in the cancellation or forfeiture of any rights, title and
interest in and to the Award without any liability to the Company.
2. Waiver and Release and Restrictive Covenants Agreement. In the event of your termination
of employment by the Company other than for Cause as described in Section III.C., you will be
required to (i) execute or reaffirm, as determined by Marsh McLennan in its sole
4
-- 67 of 139 --
discretion, and return to Marsh McLennan (or an agent appointed by Marsh McLennan) a Restrictive
Covenants Agreement and (ii) execute and not revoke a waiver and release agreement, if provided
to you by the Company at the time of your termination of employment. Failure to meet these
requirements by the date specified by the Company, which shall be in no event later than 60 days
following your termination of employment, or failure to comply with the waiver and release
agreement or the Restrictive Covenants Agreement, as applicable, will result in the cancellation or
forfeiture of any rights, title and interest in and to the Award without any liability to the Company.
G. Determination of Pro-Rata Vesting upon Termination of Employment.
The number of Stock Units and accrued Dividend Equivalents that vest on a pro-rata basis upon your
termination of employment will be determined using the following formula:
where
A = the number of Stock Units/accrued Dividend Equivalents covered by the Award;
B = the number of days in the period beginning on the grant date of the Award and ending on the
date of your termination of employment, as determined in accordance with Section III.E.;
C = the number of days in the period beginning on the grant date of the Award and ending on the
Scheduled Vesting Date; and
D = the number of Stock Units/accrued Dividend Equivalents that have previously vested, as
determined in accordance with Section III.E.
H. Section 409A of the Code for Award Recipients Subject to U.S. Federal Income Tax (whether or
not the recipient is a U.S. citizen or employed in the U.S.).
1. For Award recipients subject to U.S. federal income tax, notwithstanding any other provision
herein, the Award may be subject to additional restrictions to ensure compliance with (or continued
exemption from) the requirements of Section 409A of the Code (as defined in Section V.). The
Compensation Committee of the Board of Directors of Marsh McLennan (the “Committee”) intends to
administer the Award in accordance with Section 409A of the Code and reserves the right to make
changes in the terms or operations of the Award (including changes that may have retroactive
effect) deemed necessary or desirable to comply with Section 409A of the Code. This means, for
example, that the timing of distributions may be different from those described in the Award
Documentation that do not reflect Section 409A of the Code. If the Award is not in compliance with
Section 409A of the Code, you may be subject to immediate taxation of all unpaid awards under the
Plan that are subject to Section 409A of the Code at your regular federal income tax rate, plus a
20% additional tax, plus interest at the underpayment rate plus 1%, as well as any state and local
taxes, penalties, additional taxes and interest, if applicable, imposed under any state tax law similar
to Section 409A of the Code.
2. Notwithstanding any other provision herein, if any portion of the Award is determined to be
nonqualified deferred compensation subject to Section 409A of the Code, any references to
“termination of employment,” or “when you are no longer employed” in these Terms and Conditions
shall have the following meaning:
5
-- 68 of 139 --
Your “termination of employment” (or similar terms) shall occur when you have incurred a
“separation from service” within the meaning of Section 409A of the Code and as further defined
herein. Specifically, you will have incurred a “separation from service” when the level of services you
provide to the Company in any capacity, including as an employee, director, independent contractor
or consultant, does not exceed 20% of the average level of services that you provided to the
Company in the preceding 36 months (or shorter period of service if, for example, your total service
with the Company is less than 36 months), all as determined in accordance with Section 409A of the
Code. In determining whether a “separation from service” has occurred, any period of up to six
months during which you are on a bona fide leave of absence or up to 29 months during which you
are absent from work due to a disability for which you are receiving Marsh McLennan long-term
disability benefits will be ignored.
3. Notwithstanding any other provision herein, if at the time of your termination of employment you
are a “specified employee” (as defined in Section 409A of the Code) no portion of the Award that is
determined to be nonqualified deferred compensation subject to Section 409A of the Code can be
distributed prior to the first day of the seventh month after your termination of employment and any
such distributions to which you would otherwise be entitled during the first six months following your
termination of employment will be accumulated and paid without interest on the first day of the
seventh month after your termination of employment, except to the extent that earlier distribution
would not result in your incurring interest or additional tax under Section 409A of the Code.
4. Nothing in this Section III.H. is intended to nor does it guarantee that the Award will not be subject
to “additional tax” or other adverse tax consequences under Section 409A of the Code or any similar
state tax law. In no event will the Company be liable for all or any portion of any taxes, penalties,
interest or other expenses that may be incurred on account of non-compliance with Section 409A of
the Code.
IV. CHANGE IN CONTROL PROVISIONS
A. Upon the occurrence of a “Change in Control”, as defined in the Plan, the Award will continue to vest in
accordance with the vesting schedule specified in Section II.B.2. and subject to earlier vesting or
forfeiture pursuant to Section III., provided that the Award will become fully vested at your termination
of employment by the Company other than for Cause, or by you for Good Reason (as defined in Section
V.), during the 24-month period following such Change in Control and will be distributed as described in
Section II.B.4., provided that you satisfy the conditions to vesting described in Section IV.B.
Notwithstanding the foregoing, if the Award is not assumed, converted or replaced in connection with a
Change in Control on an equivalent basis, the Award will fully vest immediately prior to the Change in
Control and will be distributed as described in Section II.B.4.
B. As a condition to vesting of any unvested portion of the Award, in the event of your termination of
employment by the Company other than for Cause or by you for Good Reason during the 24-month
period following such Change in Control, you will be required to execute and not revoke a waiver and
release agreement, if provided by the Company at the time of your termination of employment. Failure
to meet these requirements by the date specified by the Company, which shall be in no event later than
60 days following your termination of employment, or failure to comply with the waiver and release
agreement, if applicable, will result in the
6
-- 69 of 139 --
cancellation or forfeiture of any rights, title and interest in and to the Award.
V. DEFINITIONS
As used in these Terms and Conditions:
A. “Cause” shall mean:
1. willful failure to substantially perform the duties consistent with your position which is not
remedied within 30 days after receipt of written notice from the Company specifying such failure;
2. willful violation of any written Company policies including, but not limited to, The Marsh McLennan
Code of Conduct, The Greater Good;
3. commission at any time of any act or omission that results in a conviction, plea of no contest, plea
of nolo contendere, or imposition of unadjudicated probation for any felony or crime involving moral
turpitude;
4. unlawful use (including being under the influence) or possession of illegal drugs;
5. any gross negligence or willful misconduct resulting in a material loss to the Company, or material
damage to the reputation of the Company; or
6. any violation of any statutory or common law duty of loyalty to the Company, including the
commission at any time of any act of fraud, embezzlement, or material breach of fiduciary duty
against the Company.
B. “Change in Control” shall have the meaning set forth in the Plan.
C. “Company” shall mean Marsh McLennan or any of its subsidiaries or affiliates.
D. “Good Reason” shall mean any one of the following events without your written consent:
1. material reduction in your base salary;
2. material reduction in your annual incentive opportunity (including a material adverse change in the
method of calculating your annual incentive);
3. material diminution of your duties, responsibilities or authority; or
4. relocation of more than 50 miles from your principal place of employment immediately prior to the
Change in Control;
provided that you provide Marsh McLennan with written notice of your intent to terminate your
employment for Good Reason within 60 days of your becoming aware of any circumstances set forth
above (with such notice indicating the specific termination provision above on which you are relying
and describing in reasonable detail the facts and circumstances claimed to provide a basis for
termination of your employment under the indicated provision) and that you provide Marsh
McLennan with at least 30 days following receipt of such notice to remedy such circumstances.
E. “Permanent Disability” will be deemed to occur when it is determined (by Marsh McLennan’s disability
carrier for the primary long-term disability plan or program applicable to you because of your
employment with the Company) that you are unable to engage in any substantial gainful activity by
reason of any medically determinable physical or mental impairment that can be expected to result in
death or can be expected to last for a continuous period of not less than 12 months.
7
-- 70 of 139 --
F. “Section 409A of the Code” shall mean Section 409A of the U.S. Internal Revenue Code of 1986, as
amended, and the regulations and guidance thereunder (regarding nonqualified deferred
compensation).
G. “Tax-Related Items” shall have the meaning ascribed to such term in the Plan.
VI. ADDITIONAL PROVISIONS
A. Additional Provisions—General
1. Administrative Rules. The Award shall be subject to such additional administrative regulations as
the Committee may, from time to time, adopt. All decisions of the Committee upon any questions
arising under the Award Documentation shall be conclusive and binding. The Committee may
delegate to any other individual or entity the authority to perform any or all of the functions of the
Committee under the Award, and references to the Committee shall be deemed to include any such
delegate.
2. Amendment. The Committee may, in its sole discretion, amend the terms of the Award, including,
without limitation, to impose additional requirements on the Award and on any shares of Common
Stock with respect to the Award; provided, however, that if the Committee concludes, in its sole
discretion, that such amendment is likely to materially impair your rights with respect to the Award,
such amendment shall not be implemented with respect to the Award without your consent, except
to the extent that any such action is made to cause the Award to comply with applicable law,
currency controls, stock market or exchange rules and regulations, or accounting or tax rules and
regulations, or is otherwise made in accordance with Section VI.A.4.
3. Limitations. Payment of the Award is not secured by trust, insurance contract or other funding
medium, and you do not have any interest in any fund or specific asset of Marsh McLennan by
reason of the Award. Your right to payment of the Award is the same as the right of an unsecured
general creditor of Marsh McLennan.
4. Cancellation or Clawback of Awards.
a. Marsh McLennan may, to the extent permitted or required by any applicable law, stock
exchange rules, currency controls, or the Company Incentive Compensation Clawback Policy or
any other applicable Company policy or arrangement in effect prior to the vesting of any
unvested portion of the Award, or as specified in the Award Documentation, cancel, reduce or
require reimbursement of the Award in the event of fraud, financial restatements, or other events
as may be determined by the Committee.
b. If you fail to repay any amount due pursuant to this Section VI.A.4., the Company may bring an
action in court to recover the amount due. You acknowledge that, by accepting the Award, you
agree to pay all costs, expenses and attorney’s fees incurred by the Company in any proceeding
for the collection of amounts due pursuant to this Section VI.A.4., provided that the Company
prevails in whole or in part in any such proceeding. The Company may also, to the extent
permitted by applicable law, reduce any amounts owed to you by the Company in an amount up
to the full amount of the repayment due.
5. Governing Law; Choice of Forum. The Award and the Award Documentation applicable to the
Award are governed by, and subject to the laws of the state of Delaware, without regard to the
conflict of law provisions, as set forth in Section 10.K of the Plan. For purposes
8
-- 71 of 139 --
of any action, lawsuit, or other proceedings arising out of or relating to this Award, including without
limitation, to enforce the Award Documentation, the Company and you each hereby irrevocably and
unconditionally submits to the exclusive jurisdiction of any New York state court or federal court of
the United States of America sitting in the State of New York, and any appellate court thereof. The
Company and you agree that a final judgment in any such action or proceeding shall be conclusive
and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided
by law.
6. Severability; Captions. In the event that any provision of this Award is determined to be invalid
or unenforceable, in whole or in part, the remaining provisions of this Award will be unaffected
thereby and will remain in full force and effect to the fullest extent permitted by law. The captions of
this Award are not part of the provisions of this Award and will have no force or effect.
7. Electronic Delivery and Acceptance. Marsh McLennan may, in its sole discretion, decide to
deliver any documents related to the Award and/or your current or future participation in the Plan by
electronic means. You hereby consent to receive such documents by electronic delivery and agree to
participate in the Plan through an on-line or electronic system established and maintained by Marsh
McLennan or an agent appointed by Marsh McLennan.
8. Waiver. You acknowledge that neither a waiver by Marsh McLennan of your breach of any
provision of the Award Documentation nor a prior waiver by Marsh McLennan of a breach of any
provision of the Award Documentation by any other participant of the Plan shall operate or be
construed as a waiver of any other provision of the Award Documentation, or of any subsequent
breach by you.
9. Eligibility for Award. In order to be granted an Award, you must satisfy the eligibility criteria for
grantees set forth in the Plan as of the grant date.
B. Additional Provisions—Outside of the United States
1. Changes to Delivery. In the event that Marsh McLennan considers that due to legal, regulatory or
tax issues the normal delivery of an Award (as described in these Terms and Conditions) to a
participant outside the United States would not be appropriate, then Marsh McLennan may, in its sole
discretion, determine how and when the value of the Award will be delivered. Without limitation, this
may include making any payments due under the Award in cash instead of shares of Common Stock
or in shares of Common Stock instead of cash, in an amount equivalent to the value of the Award on
the date of vesting after payment of applicable Tax-Related Items and fees. If the value of an Award
is to be delivered in cash instead of shares of Common Stock, Marsh McLennan may sell any shares
of Common Stock distributable in respect of the Award on your behalf and use the proceeds (after
payment of applicable Tax-Related Items and fees) to satisfy the Award.
2. Amendment and Modification. The Committee may modify the terms of any Award under the
Plan granted to you in any manner deemed by the Committee to be necessary or appropriate in
order for such Award to conform to laws, regulations, and customs of the country (other than the
United States) in which you are then resident or primarily employed or were resident or primarily
employed at the time of grant or during the term of the Award, or so that the value and other
benefits of the Award to you, as affected by non-U.S. tax laws and other restrictions applicable as a
result of your residence or employment outside of the United States, shall be comparable to the
9
-- 72 of 139 --
value of such an Award to an individual who is resident or primarily employed in the United States.
VII. QUESTIONS AND ADDITIONAL INFORMATION
Please retain this document in your permanent records. If you have any questions regarding the Award
Documentation or if you would like an account statement detailing the number of shares of Common Stock
covered by the Award and the vesting date(s) of the Award, or any other information, please contact:
Executive Compensation
Marsh & McLennan Companies, Inc.
1166 Avenue of the Americas
New York, NY 10036-2774
United States of America
Telephone Number: +1 212 345-9722
Facsimile Number: +1 212 948-8481
Email: mmc.compensation@mmc.com
10
-- 73 of 139 --
IN WITNESS WHEREOF, Marsh McLennan has caused these Terms & Conditions to be duly executed by the
facsimile signature of its Senior Vice President, Chief People Officer as of the day and year first above written. By
consenting to these Terms and Conditions, you agree to the following: (i) you have carefully read, fully
understand and agree to all of the terms and conditions described herein and in the Award Documentation; and
(ii) you understand and agree that these Terms & Conditions and the Award Documentation constitute the entire
understanding between you and Marsh McLennan regarding the Award, and that any prior agreements,
commitments or negotiations concerning the Award are replaced and superseded. The grant of the Award is
contingent upon your acceptance of these Terms and Conditions, Country-Specific Notices and Restrictive
Covenants Agreement (if applicable) by the date and in the manner specified in materials provided to you by
Executive Compensation and/or the Company’s stock plan service provider. If you decline the Award or you do not
accept the Award and any applicable documents described in the preceding sentence by the date and in the
manner specified, the Award will be cancelled as of the grant date of the Award.
/s/Carmen Fernandez
Carmen Fernandez
SVP, Chief People Officer
11
-- 74 of 139 --
-- 75 of 139 --
MARSH & McLENNAN COMPANIES, INC.
2020 INCENTIVE AND STOCK AWARD PLAN
TERMS AND CONDITIONS
OF
DEFERRED STOCK UNIT AWARDS
WITH GRANT DATES FROM MARCH 1, 2022 THROUGH FEBRUARY 1, 2023
-- 76 of 139 --
-- 77 of 139 --
TABLE OF CONTENTS
Page
I. BACKGROUND 1
II. AWARDS 1
III. EMPLOYMENT EVENTS 3
IV. CHANGE IN CONTROL PROVISIONS 6
V. DEFINITIONS 7
VI. ADDITIONAL PROVISIONS 8
VII. QUESTIONS AND ADDITIONAL INFORMATION 10
-- 78 of 139 --
I. BACKGROUND
An award (“Award”) has been granted to you under the Marsh & McLennan Companies, Inc. 2020 Incentive
and Stock Award Plan (the “Plan”), subject to your acceptance as described in Section II.A.1. The Award type,
the number of shares of Marsh & McLennan Companies, Inc. (“Marsh McLennan”) common stock covered by
the Award, instructions on how to accept or decline the Award and the deadline for accepting the Award will be
provided to you by Executive Compensation and/or the stock plan service provider of the Company (as defined
in Section V.). The Award is also subject to the terms and conditions set forth herein (the “Terms and
Conditions”) and to additional terms and conditions as set forth in the country-specific notices (the “Country-
Specific Notices”). The Prospectus dated [DATE] also describes important information about the Plan. The
Terms and Conditions, the Country-Specific Notices, and the Plan will be referred to herein as the “Award
Documentation”. As used herein, “Common Stock” means common stock of Marsh McLennan.
Capitalized terms in these Terms and Conditions are defined in Section V.
II. AWARDS
A. General.
1. Award Acceptance. The grant of this Award is contingent upon your acceptance, by the date and
in the manner specified by Executive Compensation and/or the Company’s stock plan service
provider, of these Terms and Conditions, the Country-Specific Notices and Restrictive Covenants
Agreement as described in Section II.A.3. If you decline the Award or if you do not accept the Award
and any applicable documents described in the preceding sentence by the deadline date and in the
manner specified, then the Award will be cancelled as of the grant date of the Award.
2. Rights of Award Holders. Unless and until the vesting conditions of the Award have been
satisfied and cash or shares of Common Stock, as applicable, have been delivered to you in
accordance with the Award Documentation, you have only the rights of a general unsecured creditor
of Marsh McLennan. Unless and until shares of Common Stock have been delivered to you, you have
none of the rights of ownership to such shares (e.g., units cannot be used as payment for stock
option exercises; units may not be transferred or assigned; units have no voting rights).
3. Restrictive Covenants Agreement. As described in Section II.A.1., a Restrictive Covenants
Agreement (“Restrictive Covenants Agreement”) in a form determined by Marsh McLennan must be
in place in order to accept the Award and you must execute or reaffirm, as determined by Marsh
McLennan, in its sole discretion, the Restrictive Covenants Agreement in order for the Award to vest
pursuant to certain employment events as described in Section III. Failure to timely execute the
Restrictive Covenants Agreement by the date specified by the Company or failure to timely execute
or reaffirm and comply with the Restrictive Covenants Agreement as described in Section III.F.1. or
2., as applicable, will result in cancellation or forfeiture of any rights, title and interest in and to the
Award, without any liability to the Company.
B. Stock Units.
1. General. A deferred stock unit (“Stock Unit”) represents an unfunded and unsecured promise to
deliver (or cause to be delivered) to you, subject to the terms of the Award Documentation, one
share of Common Stock after vesting.
1
-- 79 of 139 --
2. Vesting. Subject to your continued employment, 33-1/3% of the Stock Units will vest on the 15th
of the month in which each of the first, second and third anniversaries of the grant date of the Award
occurs. Each date on which a Stock Unit is scheduled to vest pursuant to this Section II.B.2. is a
“Scheduled Vesting Date.” In the event of your termination of employment or the occurrence of your
Permanent Disability (as defined in Section V.) prior to a Scheduled Vesting Date, your right to any
Stock Units that are unvested immediately prior to your termination of employment or occurrence of
your Permanent Disability, as applicable, will be determined in accordance with Section III. below.
For the avoidance of doubt, the date of your termination of employment for purposes of determining
vesting under this Section II.B.2. will be determined in accordance with Section III.E.
3. Dividend Equivalents. For each outstanding Stock Unit covered by the Award, an amount equal
to the dividend payment (if any) made in respect of one share of Common Stock (a “Dividend
Equivalent”) will accrue in U.S. dollars on each dividend record date that occurs on or after the grant
date of the Award while the Award is outstanding, with no interest paid on such amounts. Accrued
Dividend Equivalents will vest when the Stock Units in respect of which such Dividend Equivalents
were accrued vest. No further Dividend Equivalents will accrue on Stock Units that do not vest or are
cancelled or forfeited. If a pro-rata amount of the outstanding unvested Stock Unit award is eligible
to vest upon a termination of employment as described in Section III.C., the pro-rata calculation (as
described in Section III.G.) will be applied to the Dividend Equivalents that have accrued on the
Award as of the date of termination. Accrued Dividend Equivalents will not be paid, and no further
Dividend Equivalents will accrue, on Stock Units that do not vest or are cancelled or forfeited as per
a termination of employment event described in Section III.D.
4. Delivery.
a. Shares of Common Stock deliverable in respect of the Stock Units covered by the Award shall be
delivered to you as soon as practicable after vesting, and in no event later than 60 days after
vesting, except as otherwise provided in Section VI.B.
b. The value of vested Dividend Equivalents will be delivered to you in cash as soon as practicable
after vesting and in no event later than 60 days after vesting.
c. The delivery of shares of Common Stock and/or cash or other property that may be deliverable
under these Terms and Conditions, is conditioned on the satisfaction or withholding of any
applicable tax obligations, as described in Section II.C.
d. Any shares of Common Stock and/or cash or other property that may be deliverable
following your death shall be delivered to the person or persons to whom your rights pass by
will or the law of descent and distribution, and such delivery shall completely discharge Marsh
McLennan and any of its subsidiaries’ or affiliates’ obligations under the Award.
e. Notwithstanding the foregoing, additional delivery rules for certain Award recipients subject to
U.S. federal income tax (whether or not the recipient is a U.S. citizen or employed in the U.S.)
are reflected in Section III.H.
C. Satisfaction of Tax Obligations.
1. Personal Tax Advisor. Neither the Company nor any Company employee is authorized to provide
personal tax advice to you. It is recommended that you consult with your personal tax advisor for
more
2
-- 80 of 139 --
detailed information regarding the tax treatment of the Award, especially before making any
decisions that rely on that tax treatment.
2. U.S. Employees. Applicable employment taxes are required by law to be withheld when a Stock
Unit or Dividend Equivalent vests. Applicable income taxes are required by law to be withheld when
shares of Common Stock in respect of Stock Units or cash in respect of Dividend Equivalents are
delivered to you. A sufficient number of whole shares of Common Stock, cash or other property, as
applicable, will be retained by Marsh McLennan to satisfy the tax withholding obligation.
3. Non-U.S. Employees.
a. Stock Units and Dividend Equivalents. In most countries, the value of a Stock Unit or
Dividend Equivalent is generally not taxable on the grant date. If the value of the Stock Unit or
Dividend Equivalent is not taxable on the grant date, it will, in most countries, be taxed at a later
time, for example, upon delivery of a share of Common Stock in respect of the Stock Unit that
vests, and/or the subsequent sale of the share of Common Stock received in connection with the
vesting of the Stock Unit or upon delivery of cash in respect of a Dividend Equivalent.
b. Withholding. Marsh McLennan and/or your employer shall have the power and the right to
deduct and withhold from the Award and other compensation or to require you to remit to Marsh
McLennan and/or to your employer, an amount sufficient to satisfy any Tax-Related Items (as
defined in Section V.) that Marsh McLennan expects to be payable under the laws of any country,
state, province, city or other jurisdiction. If applicable, Marsh McLennan and/or your employer
will, to the extent permissible under applicable law or otherwise agreed between you and Marsh
McLennan and/or your employer, retain and sell a sufficient number of whole shares of Common
Stock distributable in respect of the Award for purposes of satisfying applicable obligations with
respect to Tax-Related Items.
III. EMPLOYMENT EVENTS
A. Death. In the event your employment is terminated because of your death, all of the unvested Stock
Units that are outstanding as of the date of your death will fully vest and will be distributed as described
in Section II.B.4.
B. Permanent Disability. Upon the occurrence of your Permanent Disability, the unvested Stock Units will
fully vest and will be distributed as described in Section II.B.4., provided that you satisfy the conditions
to vesting described in Section III.F.1.
C. Termination by the Company Other Than for Cause.
1. General. Except as otherwise provided in Section IV., in the event the Company, in its sole
discretion, determines that your employment is terminated by the Company other than for Cause (as
defined in Section V.), the unvested Stock Units will vest at such termination of employment on a
pro-rata basis as described in Section III.G. and will be distributed as described in Section II.B.4.,
provided that you satisfy the conditions to vesting described in Section III.F.2.
2. Important Notes.
a. Sale of Business Unit. For purposes of this Award, in the event of a sale or similar transaction
involving the business unit for which you work (“Employing Company”) as a result of which the
Employing Company ceases to be a subsidiary or affiliate of Marsh
3
-- 81 of 139 --
McLennan, your employment will be deemed terminated by the Company other than for Cause,
even if your employment with the Employing Company continues after the sale or similar
transaction.
b. Constructive Discharge. The Award will not vest, whether on a pro-rata or full basis, upon a
constructive discharge, including if any court or regulatory agency retroactively concludes or
interprets events to have constituted a constructive discharge.
D. All Other Terminations. For all other terminations of employment not described in Sections III.A.
through C. or Section IV. (including, but not limited to, a termination by the Company for Cause or a
resignation by you of your employment with the Company), any rights, title and interest in and to any
remaining unvested portion of the Award shall be cancelled as of the date your employment is treated
as having terminated as described in Section III.E.
E. Date of Termination of Employment.
1. If Section III.E.2 does not apply to you, then for purposes of determining vesting under Section
II.B.2. and the number of unvested Stock Units that vest on a pro-rata basis as described in Section
III.G., your employment will be treated as having terminated on your last day of employment with
the Company.
2. If you are obligated (whether by law or contract) to provide the Company advance notice of your
intention to terminate your employment then, in the event you terminate your employment or
service relationship pursuant to Section III.D (regardless of the reason for such termination and
whether or not later found to be invalid or in breach of employment laws in the jurisdiction where
you are employed or the terms of your employment agreement, if any), for purposes of determining
vesting under Section II.B.2. and the pro rata calculation described in Section III.G., your
employment will be treated as having terminated on your last day of active service with the
Company, as determined by the Company in its sole discretion.
You shall be deemed to have ceased active service with the Company when you are no longer
required by the Company to provide regular services to the Company even if you remain legally
employed by the Company, such as may occur if the Company were to place you on “garden leave”,
a terminal leave of absence or any similar period mandated under employment laws in the
jurisdiction where you are employed or the terms of your employment agreement, if any (in each
case as determined by the Company in its sole discretion).
F. Conditions to Vesting of Award Prior to a Scheduled Vesting Date.
1. Restrictive Covenants Agreement. In the event of the occurrence of your Permanent Disability
as described in Section III.B., you will be required to execute or reaffirm, as determined by Marsh
McLennan in its sole discretion, and return to Marsh McLennan (or an agent appointed by Marsh
McLennan) a Restrictive Covenants Agreement. Failure to (a) execute or reaffirm such an agreement
by the date specified by the Company, which shall be in no event later than 60 days following the
occurrence of your Permanent Disability as described in Section III.B., or (b) comply with the
Restrictive Covenants Agreement, will result in the cancellation or forfeiture of any rights, title and
interest in and to the Award without any liability to the Company.
2. Waiver and Release and Restrictive Covenants Agreement. In the event of your termination
of employment by the Company other than for Cause as described in Section III.C., you will be
required to (i)
4
-- 82 of 139 --
execute or reaffirm, as determined by Marsh McLennan in its sole discretion, and return to Marsh
McLennan (or an agent appointed by Marsh McLennan) a Restrictive Covenants Agreement and (ii)
execute and not revoke a waiver and release agreement, if provided to you by the Company at the
time of your termination of employment. Failure to meet these requirements by the date specified by
the Company, which shall be in no event later than 60 days following your termination of
employment, or failure to comply with the waiver and release agreement or the Restrictive
Covenants Agreement, as applicable, will result in the cancellation or forfeiture of any rights, title
and interest in and to the Award without any liability to the Company.
G. Determination of Pro-Rata Vesting upon Termination of Employment.
The number of Stock Units and accrued Dividend Equivalents that vest on a pro-rata basis upon your
termination of employment will be determined using the following formula:
where
A = the number of Stock Units/accrued Dividend Equivalents covered by the Award;
B = the number of days in the period beginning on the grant date of the Award and ending on the
date of your termination of employment, as determined in accordance with Section III.E.;
C = the number of days in the period beginning on the grant date of the Award and ending on the last
Scheduled Vesting Date; and
D = the number of Stock Units/accrued Dividend Equivalents that have previously vested, as
determined in accordance with Section III.E.
H. Section 409A of the Code for Award Recipients Subject to U.S. Federal Income Tax (whether or
not the recipient is a U.S. citizen or employed in the U.S.).
1. For Award recipients subject to U.S. federal income tax, notwithstanding any other provision
herein, the Award may be subject to additional restrictions to ensure compliance with (or continued
exemption from) the requirements of Section 409A of the Code (as defined in Section V.). The
Compensation Committee of the Board of Directors of Marsh McLennan (the “Committee”) intends to
administer the Award in accordance with Section 409A of the Code and reserves the right to make
changes in the terms or operations of the Award (including changes that may have retroactive
effect) deemed necessary or desirable to comply with Section 409A of the Code. This means, for
example, that the timing of distributions may be different from those described in the Award
Documentation that do not reflect Section 409A of the Code. If the Award is not in compliance with
Section 409A of the Code, you may be subject to immediate taxation of all unpaid awards under the
Plan that are subject to Section 409A of the Code at your regular federal income tax rate, plus a
20% additional tax, plus interest at the underpayment rate plus 1%, as well as any state and local
taxes, penalties, additional taxes and interest, if applicable, imposed under any state tax law similar
to Section 409A of the Code.
2. Notwithstanding any other provision herein, if any portion of the Award is determined to be
nonqualified deferred compensation subject to Section 409A of the Code, any references to
“termination of
5
-- 83 of 139 --
employment,” or “when you are no longer employed” in these Terms and Conditions shall have the
following meaning:
Your “termination of employment” (or similar terms) shall occur when you have incurred a
“separation from service” within the meaning of Section 409A of the Code and as further defined
herein. Specifically, you will have incurred a “separation from service” when the level of services
you provide to the Company in any capacity, including as an employee, director, independent
contractor or consultant, does not exceed 20% of the average level of services that you provided
to the Company in the preceding 36 months (or shorter period of service if, for example, your
total service with the Company is less than 36 months), all as determined in accordance with
Section 409A of the Code. In determining whether a “separation from service” has occurred, any
period of up to six months during which you are on a bona fide leave of absence or up to 29
months during which you are absent from work due to a disability for which you are receiving
Marsh McLennan long-term disability benefits will be ignored.
3. Notwithstanding any other provision herein, if at the time of your termination of employment you
are a “specified employee” (as defined in Section 409A of the Code) no portion of the Award that is
determined to be nonqualified deferred compensation subject to Section 409A of the Code can be
distributed prior to the first day of the seventh month after your termination of employment and any
such distributions to which you would otherwise be entitled during the first six months following your
termination of employment will be accumulated and paid without interest on the first day of the
seventh month after your termination of employment, except to the extent that earlier distribution would
not result in your incurring interest or additional tax under Section 409A of the Code.
4. Nothing in this Section III.H. is intended to nor does it guarantee that the Award will not be subject
to “additional tax” or other adverse tax consequences under Section 409A of the Code or any similar
state tax law. In no event will the Company be liable for all or any portion of any taxes, penalties,
interest or other expenses that may be incurred on account of non-compliance with Section 409A of
the Code.
IV. CHANGE IN CONTROL PROVISIONS
A. Upon the occurrence of a “Change in Control”, as defined in the Plan, the Award will continue to vest in
accordance with the vesting schedule specified in Section II.B.2. and subject to earlier vesting or
forfeiture pursuant to Section III., provided that the Award will become fully vested at your termination
of employment by the Company other than for Cause, or by you for Good Reason (as defined in Section
V.), during the 24-month period following such Change in Control and will be distributed as described in
Section II.B.4., provided that you satisfy the conditions to vesting described in Section IV.B.
Notwithstanding the foregoing, if the Award is not assumed, converted or replaced in connection with a
Change in Control on an equivalent basis, the Award will fully vest immediately prior to the Change in
Control and will be distributed as described in Section II.B.4.
B. As a condition to vesting of any unvested portion of the Award, in the event of your termination of
employment by the Company other than for Cause or by you for Good Reason during the 24-month
period following such Change in Control, you will be required to execute and not revoke a waiver and
release agreement, if provided by the Company at the time of your termination of employment. Failure
to meet these requirements by the date specified by the Company, which shall be in no event later than
6
-- 84 of 139 --
60 days following your termination of employment, or failure to comply with the waiver and release
agreement, if applicable, will result in the cancellation or forfeiture of any rights, title and interest in and
to the Award.
V. DEFINITIONS
As used in these Terms and Conditions:
A. “Cause” shall mean:
1. willful failure to substantially perform the duties consistent with your position which is not
remedied within 30 days after receipt of written notice from the Company specifying such failure;
2. willful violation of any written Company policies including, but not limited to, The Marsh McLennan
Code of Conduct, The Greater Good;
3. commission at any time of any act or omission that results in a conviction, plea of no contest, plea
of nolo contendere, or imposition of unadjudicated probation for any felony or crime involving moral
turpitude;
4. unlawful use (including being under the influence) or possession of illegal drugs;
5. any gross negligence or willful misconduct resulting in a material loss to the Company, or material
damage to the reputation of the Company; or
6. any violation of any statutory or common law duty of loyalty to the Company, including the
commission at any time of any act of fraud, embezzlement, or material breach of fiduciary duty
against the Company.
B. “Change in Control” shall have the meaning set forth in the Plan.
C. “Company” shall mean Marsh McLennan or any of its subsidiaries or affiliates.
D. “Good Reason” shall mean any one of the following events without your written consent:
1. material reduction in your base salary;
2. material reduction in your annual incentive opportunity (including a material adverse change in the
method of calculating your annual incentive);
3. material diminution of your duties, responsibilities or authority; or
4. relocation of more than 50 miles from your principal place of employment immediately prior to the
Change in Control;
provided that you provide Marsh McLennan with written notice of your intent to terminate your
employment for Good Reason within 60 days of your becoming aware of any circumstances set forth
above (with such notice indicating the specific termination provision above on which you are relying
and describing in reasonable detail the facts and circumstances claimed to provide a basis for
termination of your employment under the indicated provision) and that you provide Marsh
McLennan with at least 30 days following receipt of such notice to remedy such circumstances.
E. “Permanent Disability” will be deemed to occur when it is determined (by Marsh McLennan’s disability
carrier for the primary long-term disability plan or program applicable to you because of your
employment with the Company) that you are unable to engage in any substantial gainful activity by
reason of any medically determinable physical or
7
-- 85 of 139 --
mental impairment that can be expected to result in death or can be expected to last for a continuous
period of not less than 12 months.
F. “Section 409A of the Code” shall mean Section 409A of the U.S. Internal Revenue Code of 1986, as
amended, and the regulations and guidance thereunder (regarding nonqualified deferred
compensation).
G. “Tax-Related Items” shall have the meaning ascribed to such term in the Plan.
VI. ADDITIONAL PROVISIONS
A. Additional Provisions—General
1. Administrative Rules. The Award shall be subject to such additional administrative regulations
as the Committee may, from time to time, adopt. All decisions of the Committee upon any
questions arising under the Award Documentation shall be conclusive and binding. The
Committee may delegate to any other individual or entity the authority to perform any or all of
the functions of the Committee under the Award, and references to the Committee shall be
deemed to include any such delegate.
2. Amendment. The Committee may, in its sole discretion, amend the terms of the Award,
including, without limitation, to impose additional requirements on the Award and on any shares
of Common Stock with respect to the Award; provided, however, that if the Committee concludes,
in its sole discretion, that such amendment is likely to materially impair your rights with respect
to the Award, such amendment shall not be implemented with respect to the Award without your
consent, except to the extent that any such action is made to cause the Award to comply with
applicable law, currency controls, stock market or exchange rules and regulations, or accounting
or tax rules and regulations, or is otherwise made in accordance with Section VI.A.4.
3. Limitations. Payment of the Award is not secured by trust, insurance contract or other funding
medium, and you do not have any interest in any fund or specific asset of Marsh McLennan by
reason of the Award. Your right to payment of the Award is the same as the right of an unsecured
general creditor of Marsh McLennan.
4. Cancellation or Clawback of Awards.
a. Marsh McLennan may, to the extent permitted or required by any applicable law, stock
exchange rules, currency controls, or the Company Incentive Compensation Clawback Policy or
any other applicable Company policy or arrangement in effect prior to the vesting of any
unvested portion of the Award, or as specified in the Award Documentation, cancel, reduce or
require reimbursement of the Award in the event of fraud, financial restatements, or other events
as may be determined by the Committee.
b. If you fail to repay any amount due pursuant to this Section VI.A.4., the Company may bring an
action in court to recover the amount due. You acknowledge that, by accepting the Award, you
agree to pay all costs, expenses and attorney’s fees incurred by the Company in any proceeding
for the collection of amounts due pursuant to this Section VI.A.4., provided that the Company
prevails in whole or in part in any such proceeding. The Company may also, to the extent
permitted by applicable law, reduce any
8
-- 86 of 139 --
amounts owed to you by the Company in an amount up to the full amount of the repayment due.
5. Governing Law; Choice of Forum. The Award and the Award Documentation applicable to the
Award are governed by, and subject to the laws of the state of Delaware, without regard to the
conflict of law provisions, as set forth in Section 10.K of the Plan. For purposes of any action,
lawsuit, or other proceedings arising out of or relating to this Award, including without limitation, to
enforce the Award Documentation, the Company and you each hereby irrevocably and
unconditionally submits to the exclusive jurisdiction of any New York state court or federal court of
the United States of America sitting in the State of New York, and any appellate court thereof. The
Company and you agree that a final judgment in any such action or proceeding shall be conclusive
and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided
by law.
6. Severability; Captions. In the event that any provision of this Award is determined to be invalid
or unenforceable, in whole or in part, the remaining provisions of this Award will be unaffected
thereby and will remain in full force and effect to the fullest extent permitted by law. The captions of
this Award are not part of the provisions of this Award and will have no force or effect.
7. Electronic Delivery and Acceptance. Marsh McLennan may, in its sole discretion, decide to
deliver any documents related to the Award and/or your current or future participation in the Plan by
electronic means. You hereby consent to receive such documents by electronic delivery and agree to
participate in the Plan through an on-line or electronic system established and maintained by Marsh
McLennan or an agent appointed by Marsh McLennan.
8. Waiver. You acknowledge that neither a waiver by Marsh McLennan of your breach of any
provision of the Award Documentation nor a prior waiver by Marsh McLennan of a breach of any
provision of the Award Documentation by any other participant of the Plan shall operate or be
construed as a waiver of any other provision of the Award Documentation, or of any subsequent
breach by you.
9. Eligibility for Award. In order to be granted an Award, you must satisfy the eligibility criteria for
grantees set forth in the Plan as of the grant date.
B. Additional Provisions—Outside of the United States
1. Changes to Delivery. In the event that Marsh McLennan considers that due to legal, regulatory or
tax issues the normal delivery of an Award (as described in these Terms and Conditions) to a
participant outside the United States would not be appropriate, then Marsh McLennan may, in its sole
discretion, determine how and when the value of the Award will be delivered. Without limitation, this
may include making any payments due under the Award in cash instead of shares of Common Stock
or in shares of Common Stock instead of cash, in an amount equivalent to the value of the Award on
the date of vesting after payment of applicable Tax-Related Items and fees. If the value of an Award
is to be delivered in cash instead of shares of Common Stock, Marsh McLennan may sell any shares
of Common Stock distributable in respect of the Award on your behalf and use the proceeds (after
payment of applicable Tax-Related Items and fees) to satisfy the Award.
2. Amendment and Modification. The Committee may modify the terms of any Award under the
Plan granted to you in any manner deemed by the Committee to be necessary or appropriate in
order for such Award to conform to laws, regulations, and customs of the
9
-- 87 of 139 --
country (other than the United States) in which you are then resident or primarily employed or were
resident or primarily employed at the time of grant or during the term of the Award, or so that the
value and other benefits of the Award to you, as affected by non-U.S. tax laws and other restrictions
applicable as a result of your residence or employment outside of the United States, shall be
comparable to the value of such an Award to an individual who is resident or primarily employed in
the United States.
VII. QUESTIONS AND ADDITIONAL INFORMATION
Please retain this document in your permanent records. If you have any questions regarding the Award
Documentation or if you would like an account statement detailing the number of shares of Common Stock
covered by the Award and the vesting date(s) of the Award, or any other information, please contact:
Executive Compensation
Marsh & McLennan Companies, Inc.
1166 Avenue of the Americas
New York, NY 10036-2774
United States of America
Telephone Number: +1 212 345-9722
Facsimile Number: +1 212 948-8481
Email: mmc.compensation@mmc.com
10
-- 88 of 139 --
IN WITNESS WHEREOF, Marsh McLennan has caused these Terms & Conditions to be duly executed by the
facsimile signature of its Senior Vice President, Chief People Officer as of the day and year first above written. By
consenting to these Terms and Conditions, you agree to the following: (i) you have carefully read, fully
understand and agree to all of the terms and conditions described herein and in the Award Documentation; and
(ii) you understand and agree that these Terms & Conditions and the Award Documentation constitute the entire
understanding between you and Marsh McLennan regarding the Award, and that any prior agreements,
commitments or negotiations concerning the Award are replaced and superseded. The grant of the Award is
contingent upon your acceptance of these Terms and Conditions, Country-Specific Notices and Restrictive
Covenants Agreement (if applicable) by the date and in the manner specified in materials provided to you by
Executive Compensation and/or the Company’s stock plan service provider. If you decline the Award or you do not
accept the Award and any applicable documents described in the preceding sentence by the date and in the
manner specified, the Award will be cancelled as of the grant date of the Award.
/s/Carmen Fernandez
Carmen Fernandez
SVP, Chief People Officer
11
-- 89 of 139 --
-- 90 of 139 --
MARSH & McLENNAN COMPANIES, INC.
2020 INCENTIVE AND STOCK AWARD PLAN
TERMS AND CONDITIONS
OF
RESTRICTED STOCK UNIT AWARDS
GRANTED ON [DATE], 2022
-- 91 of 139 --
TABLE OF CONTENTS
Page
I. BACKGROUND 1
II. AWARDS 1
III. EMPLOYMENT EVENTS 3
IV. CHANGE IN CONTROL PROVISIONS 9
V. DEFINITIONS 10
VI. ADDITIONAL PROVISIONS 11
VII. QUESTIONS AND ADDITIONAL INFORMATION 13
-- 92 of 139 --
I. BACKGROUND
An award (“Award”) has been granted to you under the Marsh & McLennan Companies, Inc. 2020 Incentive
and Stock Award Plan (the “Plan”), subject to your acceptance as described in Section II.A.1. The Award type,
the number of shares of Marsh & McLennan Companies, Inc. (“Marsh McLennan”) common stock covered by
the Award, instructions on how to accept or decline the Award and the deadline for accepting the Award will be
provided to you by Executive Compensation and/or the stock plan service provider of the Company (as defined
in Section V.). The Award is also subject to the terms and conditions set forth herein (the “Terms and
Conditions”) and to additional terms and conditions as set forth in the country-specific notices (the “Country-
Specific Notices”). The Prospectus dated [DATE], also describes important information about the Plan. The
Terms and Conditions, the Country-Specific Notices and the Plan will be referred to herein as the “Award
Documentation”. As used herein, “Common Stock” means common stock of Marsh McLennan.
Capitalized terms in these Terms and Conditions are defined in Section V.
II. AWARDS
A. General.
1. Award Acceptance. The grant of this Award is contingent upon your acceptance, by the date and
in the manner specified by Executive Compensation and/or the Company’s stock plan service
provider, of these Terms and Conditions, the Country-Specific Notices and Restrictive Covenants
Agreement as described in Section II.A.3. If you decline the Award or if you do not accept the Award
and any applicable documents described in the preceding sentence by the deadline date and in the
manner specified, then the Award will be cancelled as of the grant date of the Award.
2. Rights of Award Holders. Unless and until the vesting conditions of the Award have been
satisfied and cash or shares of Common Stock, as applicable, have been delivered to you in
accordance with the Award Documentation, you have only the rights of a general unsecured creditor
of Marsh McLennan. Unless and until shares of Common Stock have been delivered to you, you have
none of the rights of ownership to such shares (e.g., units cannot be used as payment for stock
option exercises; units may not be transferred or assigned; units have no voting rights).
3. Restrictive Covenants Agreement. As described in Section II.A.1., a Restrictive Covenants
Agreement (“Restrictive Covenants Agreement”) in a form determined by Marsh McLennan must be
in place in order to accept the Award, you must execute or reaffirm, as determined by Marsh
McLennan in its sole discretion, the Restrictive Covenants Agreement in order for the Award to vest
pursuant to certain employment events as described in Section III., and you must further execute or
reaffirm, as determined by Marsh McLennan in its sole discretion, and be in compliance with the
Restrictive Covenants Agreement in order for the Award to become distributable to you whether or
not you are employed by the Company at that time. Failure to timely execute the Restrictive
Covenants Agreement by the date specified by the Company or failure to timely execute or reaffirm
and comply with the Restrictive Covenants Agreement as described in Section III.G.1. or 2., as
applicable, will result in cancellation or forfeiture of any rights, title and interest in and to the Award,
without any liability to the Company.
B. Stock Units.
1. General. A restricted stock unit (“Stock Unit”) represents an unfunded and unsecured promise to
deliver (or cause to be delivered)
1
-- 93 of 139 --
to you, subject to the terms of the Award Documentation, one share of Common Stock after vesting.
2. Vesting. Subject to your continued employment, 33-1/3% of the Stock Units will vest on [DATE]
of [YEAR], [YEAR] and [YEAR]. Each date on which a Stock Unit is scheduled to vest pursuant to this
Section II.B.2. is a “Scheduled Vesting Date.” In the event of your termination of employment, the
occurrence of your Permanent Disability (as defined in Section V.) or the occurrence of a Change in
Control (as defined in the Plan) prior to a Scheduled Vesting Date, your right to any Stock Units that
are unvested immediately prior to your termination of employment or occurrence of your Permanent
Disability, as applicable, will be determined in accordance with Section III. or Section IV., as
applicable. For the avoidance of doubt, the date of your termination of employment for purposes of
determining vesting under this Section II.B.2. will be determined in accordance with Section III.F.
3. Dividend Equivalents. For each outstanding Stock Unit covered by the Award, an amount equal
to the dividend payment (if any) made in respect of one share of Common Stock (a “Dividend
Equivalent”) will accrue in U.S. dollars on each dividend record date that occurs on or after the grant
date of the Award while the Award is outstanding, with no interest paid on such amounts. Accrued
Dividend Equivalents will vest when the Stock Units in respect of which such Dividend Equivalents
were accrued vest. No further Dividend Equivalents will accrue on Stock Units that do not vest or are
cancelled or forfeited. If a pro-rata amount of the outstanding unvested Stock Unit award is eligible
to vest upon a termination of employment event as described in Section III.C.1 and III.D.1, the pro-
rata calculation (as described in Section III.H) will be applied to the Dividend Equivalents that have
accrued on the Award as of the date of termination. Accrued Dividend Equivalents will not be paid,
and no further Dividend Equivalents will accrue, on Stock Units that do not vest or are cancelled or
forfeited as per a termination of employment event described in Section III.E.
4. Delivery.
a. Shares of Common Stock deliverable in respect of the Stock Units covered by the Award shall be
delivered to you as soon as practicable following the Scheduled Vesting Date, and in no event
later than 60 days following the Scheduled Vesting Date, except as otherwise provided in Sections
III., IV., and VI.B.
b. The value of vested Dividend Equivalents will be delivered to you in cash as soon as practicable
after delivery of the shares of Common Stock described in II.B.4.a above, and in no event later
than 60 days following the Scheduled Vesting Date, except as otherwise provided in Sections III.,
IV., and VI.B.
c. The delivery of shares of Common Stock and/or cash or other property that may be deliverable
under these Terms and Conditions, is conditioned on the satisfaction or withholding of any
applicable tax obligations, as described in Section II.C.
d. Any shares of Common Stock and/or cash or other property that may be deliverable following
your death shall be delivered to the person or persons to whom your rights pass by will or the law
of descent and distribution, and such delivery shall completely discharge Marsh McLennan and
any of its subsidiaries’ or affiliates’ obligations under the Award.
e. Notwithstanding the foregoing, additional delivery rules for certain Award recipients subject to
U.S. federal income tax (whether or not
2
-- 94 of 139 --
the recipient is a U.S. citizen or employed in the U.S.) are reflected in Section III.I.
C. Satisfaction of Tax Obligations.
1. Personal Tax Advisor. Neither the Company nor any Company employee is authorized to provide
personal tax advice to you. It is recommended that you consult with your personal tax advisor for
more detailed information regarding the tax treatment of the Award, especially before making any
decisions that rely on that tax treatment.
2. U.S. Employees. Applicable employment taxes are required by law to be withheld when a Stock
Unit or Dividend Equivalent vests. Applicable income taxes are required by law to be withheld when
shares of Common Stock in respect of Stock Units or cash in respect of Dividend Equivalents are
delivered to you. A sufficient number of whole shares of Common Stock, cash or other property, as
applicable, will be retained by Marsh McLennan to satisfy the tax withholding obligation.
3. Non-U.S. Employees.
a. Stock Units and Dividend Equivalents. In most countries, the value of a Stock Unit or
Dividend Equivalent is generally not taxable on the grant date. If the value of the Stock Unit or
Dividend Equivalent is not taxable on the grant date, it will, in most countries, be taxed at a later
time, for example, upon delivery of a share of Common Stock in respect of the Stock Unit that
vests, and/or the subsequent sale of the share of Common Stock received in connection with the
vesting of the Stock Unit or upon delivery of cash in respect of a Dividend Equivalent.
b. Withholding. Marsh McLennan and/or your employer shall have the power and the right to
deduct and withhold from the Award and other compensation or to require you to remit to Marsh
McLennan and/or to your employer, an amount sufficient to satisfy any Tax-Related Items (as
defined in Section V.) that Marsh McLennan expects to be payable under the laws of any country,
state, province, city or other jurisdiction. If applicable, Marsh McLennan and/or your employer
will, to the extent permissible under applicable law or otherwise agreed between you and Marsh
McLennan and/or your employer, retain and sell a sufficient number of whole shares of Common
Stock distributable in respect of the Award for purposes of satisfying applicable obligations with
respect to Tax-Related Items.
III. EMPLOYMENT EVENTS
A. Death. In the event your employment is terminated because of your death, all of the unvested Stock
Units that are outstanding as of the date of your death will fully vest and will be distributed within 60
days following such date.
B. Permanent Disability. Upon the occurrence of your Permanent Disability, all of the unvested Stock Units
that are outstanding as of the occurrence of your Permanent Disability will remain outstanding and will
be distributed as soon as practicable following the next Scheduled Vesting Date as described in Section
II.B.4.; provided that you have satisfied the conditions described in Section III.G.1.
For the avoidance of doubt, if the occurrence of your Permanent Disability occurs on a Scheduled Vesting
Date, distribution will occur as soon as practicable following such Scheduled Vesting Date as described
in Section II.B.4.
3
-- 95 of 139 --
C. Termination by You – Age and Service Treatment. If you have satisfied the Age and Service Criteria
for Pro-Rata Vesting (as defined in Section V.) or the Age and Service Criteria for Full Vesting (as
defined in Section V.) on or before the date you terminate your employment with the Company for any
reason other than death or the occurrence of your Permanent Disability, then:
1. If you have satisfied the Age and Service Criteria for Pro-Rata Vesting but not the Age and Service
Criteria for Full Vesting, upon such termination of employment, a pro-rata portion of the unvested
Stock Units that are outstanding as of such termination of employment will remain outstanding (as
described in Section III.H) and will be distributed as soon as practicable following the next Scheduled
Vesting Date as described in Section II.B.4.; provided that you have satisfied the conditions
described in Section III.G.1. The portion of the unvested Stock Units that does not remain
outstanding pursuant to this paragraph will be forfeited and cancelled.
2. If you have satisfied the Age and Service Criteria for Full Vesting, upon such termination of
employment, all of the unvested Stock Units that are outstanding as of such termination of
employment will remain outstanding and be distributed as soon as practicable following the next
Scheduled Vesting Date as described in Section II.B.4.; provided that you have satisfied the
conditions described in Section III.G.1.
For the avoidance of doubt, for purposes of each of Sections III.C.1. and 2., if your termination of
employment occurs on a Scheduled Vesting Date, distribution will occur as soon as practicable
following such Scheduled Vesting Date as described in Section II.B.4. For the further avoidance of
doubt, Section III.D. will govern the treatment of the Award in the event your employment is
terminated by the Company other than for Cause (as defined in Section V.).
For the avoidance of doubt, the date of your termination of employment for purposes of determining
whether you have satisfied either the Age and Service Criteria for Pro-Rata Vesting or the Age and
Service Criteria for Full Vesting under this Section III.C. will be determined in accordance with
Section III.F.
Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it has received an
opinion of counsel that there has been a legal judgment and/or legal development in the jurisdiction
where you are employed that would likely result in the favorable treatment applicable to the Stock Units
pursuant to this Section III.C. being deemed unlawful and/or discriminatory, then the Company will not
apply this favorable treatment upon your termination of employment, and the Stock Units will be
treated as set forth in the other subparagraphs of this Section III., as applicable.
D. Termination by the Company Other Than for Cause.
1. General. Except as otherwise provided in Sections III.D.2. and IV., in the event the Company, in
its sole discretion, determines that your employment is terminated by the Company other than for
Cause, a pro-rata portion of the unvested Stock Units that are outstanding as of such termination of
employment will remain outstanding (as described in Section III.H.) and will be distributed as soon
as practicable following the next Scheduled Vesting Date as described in Section II.B.4., provided
that you have satisfied the conditions described in Section III.G.2. The portion of the unvested Stock
Units that does not remain outstanding pursuant to this paragraph will be forfeited and cancelled.
For the avoidance of doubt, this Section III.D.1. shall apply regardless of whether you have satisfied
the Age and Service Criteria for Pro-Rata Vesting on or before your termination of employment by
the Company.
4
-- 96 of 139 --
2. Prior Satisfaction of Age and Service Criteria for Full Vesting. In the event the Company, in
its sole discretion, determines that your employment is terminated by the Company other than for
Cause, and on or before your termination of employment you satisfy the Age and Service Criteria for
Full Vesting, all of the unvested Stock Units that are outstanding as of such termination of
employment will remain outstanding and will be distributed as soon as practicable following the next
Scheduled Vesting Date as described in Section II.B.4.; provided that you have satisfied the
conditions described in Section III.G.2.
For the avoidance of doubt, if your termination of employment occurs on a Scheduled Vesting Date,
distribution will occur as soon as practicable following such Scheduled Vesting Date as described in
Section II.B.4.
3. Important Notes.
a. Sale of Business Unit. For purposes of this Award, in the event of a sale or similar transaction
involving the business unit for which you work (“Employing Company”) as a result of which the
Employing Company ceases to be a subsidiary or affiliate of Marsh McLennan, your employment
will be deemed terminated by the Company other than for Cause, even if your employment with
the Employing Company continues after the sale or similar transaction.
b. Constructive Discharge. The Award will not vest, whether on a pro-rata or full basis, upon a
constructive discharge, including if any court or regulatory agency retroactively concludes or
interprets events to have constituted a constructive discharge.
E. All Other Terminations. For all other terminations of employment not described in Sections III.A.
through D. or Section IV. (including, but not limited to, a termination by the Company for Cause or your
resignation without having satisfied the Age and Service Criteria for Pro-Rata Vesting or the Age and
Service Criteria for Full Vesting as described in Section III.C.), any rights, title and interest in and to
any remaining unvested portion of the Award shall be cancelled as of the date your employment is
treated as having terminated as described in Section III.F.
F. Date of Termination of Employment.
1. If Section III.F.2. does not apply to you, then for purposes of determining vesting under Section
II.B.2. and the number of unvested Stock Units that vest on a pro-rata basis as described in Section
III.H., your employment will be treated as having terminated on your last day of employment with
the Company.
2. If you are obligated (whether by law or contract) to provide the Company advance notice of your
intention to terminate your employment or service relationship then, in the event you terminate your
employment pursuant to Section III.C. or III.E. (regardless of the reason for such termination and
whether or not later found to be invalid or in breach of employment laws in the jurisdiction where
you are employed or the terms of your employment agreement, if any), for purposes of determining
vesting under Section II.B.2. and the pro-rata calculation described in Section III.H., your
employment will be treated as having terminated on your last day of active service with the
Company, as determined by the Company in its sole discretion.
You shall be deemed to have ceased active service with the Company when you are no longer
required by the Company to provide regular services to the Company even if you remain legally
employed by the Company, such as may occur if the Company were to place you on “garden leave”,
a terminal leave of absence or any similar period mandated under employment laws in the
jurisdiction where you are
5
-- 97 of 139 --
employed or the terms of your employment agreement, if any (in each case as determined by the
Company in its sole discretion.)
G. Conditions for All or a Portion of the Award to Remain Outstanding Following a Termination of
Employment
1. Restrictive Covenants Agreement. In the event of (i) the occurrence of your Permanent
Disability as described in Section III.B., or (ii) your termination of employment after satisfying the
Age and Service Criteria for Pro-Rata Vesting or the Age and Service Criteria for Full Vesting as
described in Section III.C., you will be required to execute or reaffirm, as determined by Marsh
McLennan in its sole discretion, and return to Marsh McLennan (or an agent appointed by Marsh
McLennan) a Restrictive Covenants Agreement. Failure to (a) execute or reaffirm such an agreement
by the date specified by the Company, which shall be in no event later than 60 days following the
occurrence of your Permanent Disability as described in Section III.B. or your termination of
employment as described in Section III.C., or (b) comply with the Restrictive Covenants Agreement
or to continue to be in compliance with the Restrictive Covenants Agreement as of the delivery date
(as described in Section II.B.4.) or, at the Company’s discretion, to reaffirm compliance prior to the
delivery date, will result in the cancellation or forfeiture of any rights, title and interest in and to the
Award without any liability to the Company.
2. Waiver and Release and Restrictive Covenants Agreement. In the event of your termination
of employment by the Company other than for Cause as described in Section III.D., you will be
required to (i) execute or reaffirm, as determined by Marsh McLennan in its sole discretion, and
return to Marsh McLennan (or an agent appointed by Marsh McLennan) a Restrictive Covenants
Agreement and (ii) execute and not revoke a waiver and release agreement, if provided to you by
the Company at the time of your termination of employment. Failure to meet these requirements by
the date specified by the Company, which shall be in no event later than 60 days following your
termination of employment, or failure to comply with the waiver and release agreement or the
Restrictive Covenants Agreement, as applicable, or continue to be in compliance with the applicable
agreement as of the delivery date (as described in Section II.B.4.) and, at the Company’s discretion,
to reaffirm compliance prior to the delivery date, will result in the cancellation or forfeiture of any
rights, title and interest in and to the Award without any liability to the Company.
H. Determination of Pro-Rata Calculation upon Termination of Employment.
The pro-rata portion of the unvested Stock Units and accrued Dividend Equivalents that are outstanding
as of a termination of employment that will become distributable under certain circumstances described
in Section III. will be determined using the following formula:
where
A = the number of Stock Units/accrued Dividend Equivalents covered by the Award;
B = the number of days in the period beginning on the grant date of the Award and ending on the
date of your termination of employment, as determined in accordance with Section III.F;
C = the number of days in the period beginning on the grant date of the Award and ending on the last
Scheduled Vesting Date; and
6
-- 98 of 139 --
D = the number of Stock Units/accrued Dividend Equivalents that have previously vested, as
determined in accordance with Section III.F.
I. Section 409A of the Code for Award Recipients Subject to U.S. Federal Income Tax (whether or
not the recipient is a U.S. citizen or employed in the U.S.).
1. For Award recipients subject to U.S. federal income tax, notwithstanding any other provision
herein, the Award may be subject to additional restrictions to ensure compliance with (or continued
exemption from) the requirements of Section 409A of the Code (as defined in Section V.). The
Compensation Committee of the Board of Directors of Marsh McLennan (the “Committee”) intends to
administer the Award in accordance with Section 409A of the Code and reserves the right to make
changes in the terms or operations of the Award (including changes that may have retroactive
effect) deemed necessary or desirable to comply with Section 409A of the Code. This means, for
example, that the timing of distributions may be different from those described in the Award
Documentation that do not reflect Section 409A of the Code. If the Award is not in compliance with
Section 409A of the Code, you may be subject to immediate taxation of all unpaid awards under the
Plan that are subject to Section 409A of the Code at your regular federal income tax rate, plus a
20% additional tax, plus interest at the underpayment rate plus 1%, as well as any state and local
taxes, penalties, additional taxes and interest, if applicable, imposed under any state tax law similar
to Section 409A of the Code.
2. Notwithstanding any other provision herein, if any portion of the Award is determined to be
nonqualified deferred compensation subject to Section 409A of the Code, any references to
“termination of employment,” or “when you are no longer employed” in these Terms and Conditions
shall have the following meaning:
Your “termination of employment” (or similar terms) shall occur when you have incurred a
“separation from service” within the meaning of Section 409A of the Code and as further defined
herein. Specifically, you will have incurred a “separation from service” when the level of services
you provide to the Company in any capacity, including as an employee, director, independent
contractor or consultant, does not exceed 20% of the average level of services that you provided
to the Company in the preceding 36 months (or shorter period of service if, for example, your
total service with the Company is less than 36 months), all as determined in accordance with
Section 409A of the Code. In determining whether a “separation from service” has occurred, any
period of up to six months during which you are on a bona fide leave of absence or up to 29
months during which you are absent from work due to a disability for which you are receiving
Marsh McLennan long-term disability benefits will be ignored.
3. Notwithstanding any other provision herein, if at the time of your termination of employment you
are a “specified employee” (as defined in Section 409A of the Code), no portion of the Award that is
determined to be nonqualified deferred compensation subject to Section 409A of the Code can be
distributed prior to the first day of the seventh month after your termination of employment and any
such distributions to which you would otherwise be entitled during the first six months following your
termination of employment will be accumulated and paid without interest on the first day of the
seventh month after your termination of employment, except to the extent that earlier distribution
would not result in your incurring interest or additional tax under Section 409A of the Code.
7
-- 99 of 139 --
4. Notwithstanding any other provision herein other than Section III.I.6., (and any Dividend
Equivalents payable with respect to the Stock Units)
a. If you have satisfied the Age and Service Criteria for Pro-Rata Vesting at any time prior to
[DATE] and you do not satisfy the Age and Service Criteria for Full Vesting at any time prior to
[DATE], then for each Scheduled Vesting Date following the date that you satisfy the Age and
Service Criteria for Pro-Rata Vesting, shares of Common Stock and/or cash pursuant to Section
II.B.4. will be delivered by March 15 of the year in which the Scheduled Vesting Date occurs.
b. If you first satisfy the Age and Service Criteria for Full Vesting in calendar year [YEAR], then
shares of Common Stock and/or cash pursuant to Section II.B.4. with respect to the [DATE]
Scheduled Vesting Date will be delivered by March 15, [YEAR].
c. If your employment is terminated on or after March 1 but on or before December 31 in any year
pursuant to Section III.B. (Permanent Disability), C.1. (Age and Service Pro-rata Vesting), or D.
(Termination Other Than for Cause), then shares of Common Stock and/or cash pursuant to
Section II.B.4. will be delivered by March 15 of the year following the year of such termination.
5. Notwithstanding any provision herein, for distributions of Stock Units or cash attributable to such
Stock Units that are subject to one or more Employment-Related Actions (as defined in Section V.)
where you have not satisfied, and would not satisfy, the Age and Service Criteria for Full Vesting
prior to [DATE]:
a. With respect to Stock Units, no later than March 15 of the year following the year in which the
substantial risk of forfeiture (as determined under Section 409A of the Code) (the “Substantial
Risk of Forfeiture”) lapses with respect to such Stock Units, shares of Common Stock underlying
such Stock Units shall be delivered to you (to the extent not previously delivered), subject to a
stop transfer order and subject to withholding of any applicable tax obligations, as described in
Section II.C. at the time of such delivery. Upon your timely satisfaction of all applicable
Employment-Related Actions, Marsh McLennan will remove or cause to be removed such stop
transfer order; and
b. With respect to a cash payment attributable to Stock Units, to the extent that such payment will
not be made by March 15 of the year following the year in which the Substantial Risk of
Forfeiture lapses with respect to such payment, such payment shall be placed in escrow or
contributed to a secular trust (in the sole discretion of Marsh McLennan) for your benefit on or
before such March 15 and subject to withholding of any applicable tax obligations, as described
in Section II.C. at the time of such placement or contribution. Upon your timely satisfaction of all
applicable Employment-Related Actions, Marsh McLennan shall cause such amounts to be
released from escrow or paid to you out of such trust.
In either case, if any Employment-Related Action is not timely satisfied, the shares of Common
Stock or the cash payment shall revert to Marsh McLennan with no further compensation due to
you.
6. Notwithstanding any provision herein, with respect to distributions of Stock Units or cash
attributable to such Stock Units (i) where you have satisfied or would satisfy the Age and Service
Criteria for Full Vesting prior to [DATE] and (ii) where such distributions are subject to one or more
Employment-Related Actions:
th
th
th
8
-- 100 of 139 --
a. With respect to Stock Units, no later than December 31 of the year in which Scheduled Vesting
Date occurs, shares of Common Stock underlying such Stock Units shall be delivered to you (to
the extent not previously delivered), subject to a stop transfer order and subject to withholding of
any applicable tax obligations, as described in Section II.C. at the time of such delivery. Upon
your timely satisfaction of all applicable Employment-Related Actions, Marsh McLennan will
remove or cause to be removed such stop transfer order; and
b. With respect to a cash payment attributable to Stock Units, to the extent any such payment will
not be made by December 31 of the year in which the Scheduled Vesting Date occurs, any
payment that relates to such Scheduled Vesting Date shall be placed in escrow or contributed to a
secular trust (in the sole discretion of Marsh McLennan) for your benefit on or before such
December 31 and subject to withholding of any applicable tax obligations, as described in
Section II.C. at the time of such placement or contribution. Upon your timely satisfaction of all
applicable Employment-Related Actions, Marsh McLennan shall cause such amounts to be
released from escrow or paid to you out of such trust.
In either case, if any Employment-Related Action is not timely satisfied, the shares of Common
Stock or the cash payment shall revert to Marsh McLennan with no further compensation due to
you.
7. Nothing in this Section III.I. is intended to nor does it guarantee that the Award will not be subject
to “additional tax” or other adverse tax consequences under Section 409A of the Code or any similar
state tax law. In no event will the Company be liable for all or any portion of any taxes, penalties,
interest or other expenses that may be incurred on account of non-compliance with Section 409A of
the Code.
IV. CHANGE IN CONTROL PROVISIONS
A. Upon the occurrence of a Change in Control, the Award will continue to vest in accordance with the
vesting schedule specified in Section II.B.2., subject to earlier vesting or forfeiture pursuant to Section
III.; provided that upon your termination of employment by the Company other than for Cause, or by
you for Good Reason (as defined in Section V.), during the 24-month period following such Change in
Control, all unvested Stock Units that are outstanding as of your termination of employment will remain
outstanding and will be distributed as soon as practicable following the next Scheduled Vesting Date as
described in Section II.B.4.; provided that you have satisfied the conditions described in Section IV.B.
Notwithstanding the foregoing, if the Stock Units are not assumed, converted or replaced in connection
with a Change in Control on an equivalent basis, the Stock Units (to the extent permitted in accordance
with the requirements of Treas. Reg. § 1.409A-3(j)(4)(ix)(B)) will fully vest immediately prior to the
Change in Control and will be distributed as soon as practicable following vesting and in no event later
than 60 days following vesting.
B. In the event of your termination of employment by the Company other than for Cause or by you for Good
Reason during the 24-month period following such Change in Control, you will be required to execute
and not revoke a waiver and release agreement, if provided by the Company at the time of your
termination of employment. Failure to meet these requirements by the date specified by the Company,
which shall be in no event later than 60 days following your termination of employment, or failure to
comply with the waiver and release agreement and be in compliance with the agreement, if applicable,
as of the delivery date as
st
st
st
9
-- 101 of 139 --
described in II.B.4., will result in the cancellation or forfeiture of any rights, title and interest in and to
the Award.
C. For the avoidance of doubt, in the event of your termination of employment by the Company other than
for Cause or by you for Good Reason during the 24-month period following such Change in Control and,
on or before the date of your termination of employment you satisfy the Age and Service Criteria for
Pro-Rata Vesting or the Age and Service Criteria for Full Vesting as described in Section III.C., any
unvested Stock Units covered by the Award will be treated as described in this Section IV.; provided
that you have satisfied the conditions described in Section IV.B.
V. DEFINITIONS
As used in these Terms and Conditions:
A. “Age and Service Criteria for Full Vesting” shall mean you are at least age 62 and have a minimum
of five years of service with the Company.
B. “Age and Service Criteria for Pro-Rata Vesting” shall mean you are at least age 55 but are not yet
age 62 and have a minimum of five years of service with the Company.
C. “Cause” shall mean:
1. willful failure to substantially perform the duties consistent with your position which is not
remedied within 30 days after receipt of written notice from the Company specifying such failure;
2. willful violation of any written Company policies, including but not limited to, The Marsh McLennan
Code of Conduct, The Greater Good;
3. commission at any time of any act or omission that results in a conviction, plea of no contest, plea
of nolo contendere, or imposition of unadjudicated probation for any felony or crime involving moral
turpitude;
4. unlawful use (including being under the influence) or possession of illegal drugs;
5. any gross negligence or willful misconduct resulting in a material loss to the Company, or material
damage to the reputation of the Company; or
6. any violation of any statutory or common law duty of loyalty to the Company, including the
commission at any time of any act of fraud, embezzlement, or material breach of fiduciary duty
against the Company.
D. “Change in Control” shall have the meaning set forth in the Plan.
E. “Company” shall mean Marsh McLennan or any of its subsidiaries or affiliates.
F. “Employment-Related Action” shall mean the execution and effectiveness of a release of claims and/or
a restrictive covenant.
G. “Good Reason” shall mean any one of the following events without your written consent:
1. material reduction in your base salary;
2. material reduction in your annual incentive opportunity (including a material adverse change in the
method of calculating your annual incentive);
3. material diminution of your duties, responsibilities or authority; or
10
-- 102 of 139 --
4. relocation of more than 50 miles from your principal place of employment immediately prior to the
Change in Control; provided that you provide Marsh McLennan with written notice of your intent to
terminate your employment for Good Reason within 60 days of your becoming aware of any
circumstances set forth above (with such notice indicating the specific termination provision above
on which you are relying and describing in reasonable detail the facts and circumstances claimed to
provide a basis for termination of your employment under the indicated provision) and that you
provide Marsh McLennan with at least 30 days following receipt of such notice to remedy such
circumstances.
H. “Permanent Disability” will be deemed to occur when it is determined (by Marsh McLennan’s disability
carrier for the primary long-term disability plan or program applicable to you because of your
employment with the Company) that you are unable to engage in any substantial gainful activity by
reason of any medically determinable physical or mental impairment that can be expected to result in
death or can be expected to last for a continuous period of not less than 12 months.
I. “Section 409A of the Code” shall mean Section 409A of the U.S. Internal Revenue Code of 1986, as
amended, and the regulations and guidance thereunder (regarding nonqualified deferred
compensation).
J. “Tax-Related Items” shall have the meaning ascribed to such term in the Plan.
VI. ADDITIONAL PROVISIONS
A. Additional Provisions—General
1. Administrative Rules. The Award shall be subject to such additional administrative regulations as
the Committee may, from time to time, adopt. All decisions of the Committee upon any questions
arising under the Award Documentation shall be conclusive and binding. The Committee may
delegate to any other individual or entity the authority to perform any or all of the functions of the
Committee under the Award, and references to the Committee shall be deemed to include any such
delegate.
2. Amendment. The Committee may, in its sole discretion, amend the terms of the Award, including,
without limitation, to impose additional requirements on the Award and on any shares of Common
Stock with respect to the Award; provided, however, that if the Committee concludes, in its sole
discretion, that such amendment is likely to materially impair your rights with respect to the Award,
such amendment shall not be implemented with respect to the Award without your consent, except
to the extent that any such action is made to cause the Award to comply with applicable law,
currency controls, stock market or exchange rules and regulations, or accounting or tax rules and
regulations, or is otherwise made in accordance with Section VI.A.4.
3. Limitations. Payment of the Award is not secured by trust, insurance contract or other funding
medium, and you do not have any interest in any fund or specific asset of Marsh McLennan by
reason of the Award. Your right to payment of the Award is the same as the right of an unsecured
general creditor of Marsh McLennan.
4. Cancellation or Clawback of Awards.
a. Marsh McLennan may, to the extent permitted or required by any applicable law, stock
exchange rules, currency controls, the Company Incentive Compensation Clawback Policy or any
other applicable Company policy or arrangement in effect prior to the vesting of any unvested
portion of the Award, or as specified in the
11
-- 103 of 139 --
Award Documentation, cancel, reduce or require reimbursement of the Award in the event of
fraud, financial restatements, or other events as may be determined by the Committee.
b. If you fail to repay any amount due pursuant to this Section VI.A.4., the Company may bring an
action in court to recover the amount due. You acknowledge that, by accepting the Award, you
agree to pay all costs, expenses and attorney’s fees incurred by the Company in any proceeding
for the collection of amounts due pursuant to this Section VI.A.4., provided that the Company
prevails in whole or in part in any such proceeding. The Company may also, to the extent
permitted by applicable law, reduce any amounts owed to you by the Company in an amount up
to the full amount of the repayment due.
5. Governing Law; Choice of Forum. The Award and the Award Documentation applicable to the
Award are governed by, and subject to the laws of the state of Delaware, without regard to the
conflict of law provisions, as set forth in Section 10.K of the Plan. For purposes of any action,
lawsuit, or other proceedings arising out of or relating to this Award, including without limitation, to
enforce the Award Documentation, the Company and you each hereby irrevocably and
unconditionally submits to the exclusive jurisdiction of any New York state court or federal court of
the United States of America sitting in the State of New York, and any appellate court thereof. The
Company and you agree that a final judgment in any such action or proceeding shall be conclusive
and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided
by law.
6. Severability; Captions. In the event that any provision of this Award is determined to be invalid
or unenforceable, in whole or in part, the remaining provisions of this Award will be unaffected
thereby and will remain in full force and effect to the fullest extent permitted by law. The captions of
this Award are not part of the provisions of this Award and will have no force or effect.
7. Electronic Delivery and Acceptance. Marsh McLennan may, in its sole discretion, decide to
deliver any documents related to the Award and/or your current or future participation in the Plan by
electronic means. You hereby consent to receive such documents by electronic delivery and agree to
participate in the Plan through an on-line or electronic system established and maintained by Marsh
McLennan or an agent appointed by Marsh McLennan.
8. Waiver. You acknowledge that neither a waiver by Marsh McLennan of your breach of any
provision of the Award Documentation nor a prior waiver by Marsh McLennan of a breach of any
provision of the Award Documentation by any other participant of the Plan shall operate or be
construed as a waiver of any other provision of the Award Documentation, or of any subsequent
breach by you.
9. Eligibility for Award. In order to be granted an Award, you must satisfy the eligibility criteria for
grantees set forth in the Plan as of the grant date.
B. Additional Provisions—Outside of the United States
1. Changes to Delivery. In the event that Marsh McLennan considers that due to legal, regulatory or
tax issues the normal delivery of an Award (as described in these Terms and Conditions) to a
participant outside the United States would not be appropriate, then Marsh McLennan may, in its sole
discretion, determine how and when the value of the Award will be delivered. Without limitation, this
may include making any payments due under the Award in cash instead of shares of Common Stock
or in shares of Common Stock instead of
12
-- 104 of 139 --
cash, in an amount equivalent to the value of the Award on the date of vesting after payment of
applicable Tax-Related Items and fees, or, delivering or paying out the Award as soon as practicable
following a termination of employment. If the value of an Award is to be delivered in cash instead of
shares of Common Stock, Marsh McLennan may sell any shares of Common Stock distributable in
respect of the Award on your behalf and use the proceeds (after payment of applicable Tax-Related
Items and fees) to satisfy the Award.
2. Amendment and Modification. The Committee may modify the terms of any Award under the
Plan granted to you in any manner deemed by the Committee to be necessary or appropriate in
order for such Award to conform to laws, regulations, and customs of the country (other than the
United States) in which you are then resident or primarily employed or were resident or primarily
employed at the time of grant or during the term of the Award, or so that the value and other
benefits of the Award to you, as affected by non-U.S. tax laws and other restrictions applicable as a
result of your residence or employment outside of the United States, shall be comparable to the
value of such an Award to an individual who is resident or primarily employed in the United States.
VII. QUESTIONS AND ADDITIONAL INFORMATION
Please retain this document in your permanent records. If you have any questions regarding the Award
Documentation or if you would like an account statement detailing the number of shares of Common Stock
covered by the Award and the vesting date(s) of the Award, or any other information, please contact:
Executive Compensation
Marsh & McLennan Companies, Inc.
1166 Avenue of the Americas
New York, NY 10036-2774
United States of America
Telephone Number: +1 212 345-9722
Facsimile Number: +1 212 948-8481
Email: mmc.compensation@mmc.com
13
-- 105 of 139 --
IN WITNESS WHEREOF, Marsh McLennan has caused these Terms & Conditions to be duly executed by the facsimile
signature of its Senior Vice President, Chief People Officer as of the day and year first above written. By consenting
to these Terms and Conditions, you agree to the following: (i) you have carefully read, fully understand and agree to
all of the terms and conditions described herein and in the Award Documentation; and (ii) you understand and agree
that these Terms & Conditions and the Award Documentation constitute the entire understanding between you and
Marsh McLennan regarding the Award, and that any prior agreements, commitments or negotiations concerning the
Award are replaced and superseded. The grant of the Award is contingent upon your acceptance of these Terms and
Conditions, Country-Specific Notices and Restrictive Covenants Agreement (if applicable) by the date and in the
manner specified in materials provided to you by Executive Compensation and/or the Company’s stock plan service
provider. If you decline the Award or you do not accept the Award and any applicable documents described in the
preceding sentence by the date and in the manner specified, the Award will be cancelled as of the grant date of the
Award.
/s/Carmen Fernandez
Carmen Fernandez
SVP, Chief People Officer
14
-- 106 of 139 --
MARSH & McLENNAN COMPANIES, INC.
2020 INCENTIVE AND STOCK AWARD PLAN
TERMS AND CONDITIONS
OF
PERFORMANCE STOCK UNIT AWARDS
GRANTED ON [DATE], 2022
-- 107 of 139 --
TABLE OF CONTENTS
Page
I. BACKGROUND 1
II. AWARDS 1
III. EMPLOYMENT EVENTS 4
IV. CHANGE IN CONTROL PROVISIONS 11
V. DEFINITIONS 10
VI. ADDITIONAL PROVISIONS 12
VII. QUESTIONS AND ADDITIONAL INFORMATION 14
-- 108 of 139 --
I. BACKGROUND
A Performance Stock Unit award (“Award”) has been granted to you under the Marsh & McLennan Companies,
Inc. 2020 Incentive and Stock Award Plan (the “Plan”), subject to your acceptance as described in Section
II.A.1. The number of shares of Marsh & McLennan Companies, Inc. (“Marsh McLennan”) common stock
covered by the Award, instructions on how to accept or decline the Award and the deadline for accepting the
Award will be provided to you by Executive Compensation and/or the stock plan service provider of the
Company (as defined in Section V.). The Award is also subject to the terms and conditions set forth herein (the
“Terms and Conditions”) and to additional terms and conditions as set forth in the country-specific notices (the
“Country-Specific Notices”). The Prospectus dated [DATE], also describes important information about the
Plan. The Terms and Conditions, the Country-Specific Notices and the Plan will be referred to herein as the
“Award Documentation”. As used herein, “Common Stock” means common stock of Marsh McLennan.
Capitalized terms in these Terms and Conditions are defined in Section V.
II. AWARDS
A. General.
1. Award Acceptance. The grant of this Award is contingent upon your acceptance, by the date and in
the manner specified by Executive Compensation and/or the Company’s stock plan service provider,
of these Terms and Conditions, the Country-Specific Notices and Restrictive Covenants Agreement as
described in Section II.A.3. If you decline the Award or if you do not accept the Award and any
applicable documents described in the preceding sentence by the deadline date and in the manner
specified, then the Award will be cancelled as of the grant date of the Award.
2. Rights of Award Holders. Unless and until the vesting conditions of the Award have been
satisfied and cash or shares of Common Stock, as applicable, have been delivered to you in
accordance with the Award Documentation, you have only the rights of a general unsecured creditor
of Marsh McLennan. Unless and until shares of Common Stock have been delivered to you, you have
none of the rights of ownership to such shares (e.g., units cannot be used as payment for stock
option exercises; units may not be transferred or assigned; units have no voting rights, etc.).
3. Restrictive Covenants Agreement. As described in Section II.A.1., a Restrictive Covenants
Agreement (“Restrictive Covenants Agreement”) in a form determined by Marsh McLennan must be
in place in order to accept the Award, you must execute or reaffirm, as determined by Marsh
McLennan in its sole discretion, the Restrictive Covenants Agreement in order for the Award to vest
pursuant to certain employment events as described in Section III., and you must further execute or
reaffirm, as determined by Marsh McLennan in its sole discretion, and be in compliance with the
Restrictive Covenants Agreement in order for the Award to become distributable to you whether or
not you are employed by the Company at that time. Failure to timely execute the Restrictive
Covenants Agreement by the date specified by the Company or failure to timely execute or reaffirm
and comply with the Restrictive Covenants Agreement as described in Section III.H.1. or 2., as
applicable, will result in cancellation or forfeiture of any rights, title and interest in and to the Award,
without any liability to the Company.
1
-- 109 of 139 --
B. Performance Stock Units.
1. General. A performance stock unit (“PSU”) represents an unfunded and unsecured promise to
deliver (or cause to be delivered) to you, subject to the terms of the Award Documentation, a
minimum of zero (0) and up to a maximum of two (2) shares of Common Stock after vesting,
depending on the achievement, as determined by the Compensation Committee of the Board of
Directors of Marsh McLennan (the “Committee”), of the Company earnings per share performance
factor (the “EPS Performance Factor”) and relative shareholder return modifier (“Relative TSR
Modifier”) performance objectives established by the Committee for the Performance Period (as
defined in Section V.). In the event of your termination of employment or occurrence of your
Permanent Disability (as defined in Section V.) prior to the PSU Scheduled Vesting Date (defined
below), the number of shares of Common Stock deliverable in respect of a PSU shall be determined
as provided in Sections III. and IV.
2. Vesting. Subject to your continued employment, the PSUs are scheduled to vest on [DATE] (the
“PSU Scheduled Vesting Date”). In the event of your termination of employment, the occurrence of
your Permanent Disability or the occurrence of a Change in Control (as defined in the Plan) prior to
the PSU Scheduled Vesting Date, your right to the PSUs will be determined in accordance with
Section III. or Section IV., as applicable. For the avoidance of doubt, the date of your termination of
employment for purposes of this Section II.B.2. will be determined in accordance with Section III.G.
3. Dividend Equivalents. A payment will be made that is equal to the dividend payment (if any) that
would have been made, on each dividend record date that occurs on or after the date of grant while
the PSUs are outstanding, in respect of the number of shares of Common Stock that is determined
under Section II.B.1 to be delivered in respect of vested PSUs (a “Dividend Equivalent”). Dividend
Equivalents will vest when the PSUs, in respect of which such Dividend Equivalents were calculated,
vest. Prior to the determination described in Section II.B.1, for each outstanding PSU, an amount
equal to the dividend payment (if any) made in respect of one share of Common Stock will accrue in
U.S. dollars on each dividend record date that occurs on or after the grant date of the Award while
the Award is outstanding, with no interest paid on such amounts. No further dividend equivalents will
accrue on PSUs that do not vest or are cancelled or forfeited. If a pro-rata amount of the outstanding
unvested PSUs is eligible to vest upon a termination of employment as described in Section III.C and
III.E, the pro-rata calculation applied to the outstanding PSUs described in Section III.I will be
applied to the dividend equivalents that have accrued on the Award as of the date of termination.
Accrued dividend equivalents will not be paid, and no further dividend equivalents will accrue, on
PSUs that do not vest or are cancelled or forfeited as described in Section III.F.
4. Delivery.
a. Shares of Common Stock deliverable, if any, in respect of the PSUs covered by the Award that
vest on the PSU Scheduled Vesting Date shall be delivered to you as soon as practicable following
the PSU Scheduled Vesting Date, and in no event later than 60 days following the PSU Scheduled
Vesting Date, except as otherwise provided in Sections III., IV., and VI.B.
b. The value of vested Dividend Equivalents that vest on the PSU Scheduled Vesting Date will be
delivered to you in cash as soon as practicable after delivery of the shares of Common Stock
described in II.B.4.a. above, and in no event later than 60 days following the
2
-- 110 of 139 --
PSU Scheduled Vesting Date, except as otherwise provided in Sections III., IV., and VI.B.
c. The delivery of shares of Common Stock and/or cash or other property that may be deliverable
under these Terms and Conditions, is conditioned on the satisfaction or withholding of any
applicable tax obligations, as described in Section II.C.
d. Any shares of Common Stock and/or cash or other property that may be deliverable following
your death shall be delivered to the person or persons to whom your rights pass by will or the law
of descent and distribution, and such delivery shall completely discharge the Company’s
obligations under the Award.
e. Notwithstanding the foregoing, additional delivery rules for certain Award recipients subject to
U.S. federal income tax (whether or not the recipient is a U.S. citizen or employed in the U.S.)
are reflected in Section III.J.
C. Satisfaction of Tax Obligations.
1. Personal Tax Advisor. Neither the Company nor any Company employee is authorized to provide
personal tax advice to you. It is recommended that you consult with your personal tax advisor for
more detailed information regarding the tax treatment of the Award, especially before making any
decisions that rely on that tax treatment.
2. U.S. Employees - Performance Stock Units and Dividend Equivalents. Applicable
employment taxes are required by law to be withheld when a PSU or Dividend Equivalent vests, or, if
later, when the number of shares of Common Stock deliverable in respect of a PSU (or the amount of
cash payable in respect of a Dividend Equivalent corresponding to a PSU) is determined. Applicable
income taxes are required by law to be withheld when shares of Common Stock in respect of PSUs or
cash in respect of Dividend Equivalents are delivered to you. A sufficient number of whole shares of
Common Stock, cash or other property, as applicable, will be retained by Marsh McLennan to satisfy
the tax withholding obligation.
3. Non-U.S. Employees.
a. Performance Stock Units and Dividend Equivalents. In most countries, the value of a PSU
or Dividend Equivalent is generally not taxable on the grant date. If the value of the PSU or
Dividend Equivalent is not taxable on the grant date, it will, in most countries, be taxed at a later
time, for example, upon delivery of a share of Common Stock in respect of the PSU that vests,
and/or the subsequent sale of the share of Common Stock received in connection with the vesting
of the PSU, or upon delivery of cash in respect of a Dividend Equivalent.
b. Withholding. Marsh McLennan and/or your employer shall have the power and the right to
deduct and withhold from the Award and other compensation or to require you to remit to Marsh
McLennan and/or to your employer, an amount sufficient to satisfy any Tax-Related Items (as
defined in Section V.) that Marsh McLennan expects to be payable under the laws of any country,
state, province, city or other jurisdiction. If applicable, Marsh McLennan and/or your employer
will, to the extent permissible under applicable law or otherwise agreed between you and Marsh
McLennan and/or your employer, retain and sell a sufficient number of whole shares of Common
Stock distributable in respect of the Award for purposes of satisfying applicable obligations with
respect to Tax-Related Items.
3
-- 111 of 139 --
III. EMPLOYMENT EVENTS
A. Death. In the event your employment is terminated because of your death, all of the unvested PSUs that
are outstanding as of the date of your death will fully vest and will be distributed within 60 days
following such date. The Performance Period will be deemed to have ended on December 31 of the year
immediately preceding the date of your death, and the number of shares of Common Stock distributable
in respect of the PSUs will be determined in accordance with Section II.B.1.; provided that, in the event
that your death occurs on or prior to December 31 of the year in which the PSUs are granted, you will
receive one (1) share of Common Stock in respect of each PSU.
B. Permanent Disability. Upon the occurrence of your Permanent Disability, all of the unvested PSUs that
are outstanding as of the occurrence of your Permanent Disability will remain outstanding until the PSU
Scheduled Vesting Date and will be distributed as soon as practicable following the PSU Scheduled
Vesting Date as described in Section II.B.4; provided that you have satisfied the conditions described in
Section III.H.1.; and provided further that the number of shares of Common Stock distributable in
respect of such PSUs will be determined in accordance with Section II.B.1.
C. Termination by You– Age and Service Pro-Rata Vesting. If you have satisfied the Age and Service
Criteria for Pro-Rata Vesting (as defined in Section V.) but do not satisfy the Age and Service Criteria for
Full Vesting (as defined in Section V.) on or before the date you terminate your employment with the
Company for any reason other than death or the occurrence of your Permanent Disability, then this
Section III.C. shall apply. For the avoidance of doubt, Section III.E. will govern the treatment of the
Award in the event your employment is terminated by the Company other than for Cause (as defined in
Section V.).
Upon such termination of employment, a pro-rata portion of the unvested PSUs that are outstanding as of
such termination of employment will remain outstanding (as described in Section III.I.) until the PSU
Scheduled Vesting Date and will be distributed as soon as practicable following the PSU Scheduled
Vesting Date as described in Section II.B.4; provided that you have satisfied the conditions described in
Section III.H.1., and provided further that the number of shares of Common Stock distributable in
respect of such PSUs will be determined in accordance with Section II.B.1. The portion of the unvested
PSUs that does not remain outstanding pursuant to this paragraph will be forfeited and cancelled.
For the avoidance of doubt, the date of your termination of employment for purposes of determining
whether you have satisfied the Age and Service Criteria for Pro-Rata Vesting under this Section III.C.
will be determined in accordance with Section III.G.
Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it has received an
opinion of counsel that there has been a legal judgment and/or legal development in the jurisdiction
where you are employed that would likely result in the favorable treatment applicable to the Stock Units
pursuant to this Section III.C. being deemed unlawful and/or discriminatory, then the Company will not
apply this favorable treatment upon your termination of employment, and the Stock Units will be
treated as set forth in the other subparagraphs of this Section III., as applicable.
D. Termination by You – Age and Service Full Vesting. If you have satisfied the Age and Service
Criteria for Full Vesting on or before the date
4
-- 112 of 139 --
you terminate your employment with the Company for any reason other than death or the occurrence of
your Permanent Disability, then this Section III.D. shall apply. For the avoidance of doubt, Section III.E.
will govern the treatment of the Award in the event your employment is terminated by the Company
other than for Cause.
Upon such termination of employment, all of the unvested PSUs that are outstanding as of such termination
of employment will remain outstanding until the PSU Scheduled Vesting Date and will be distributed as
soon as practicable following the PSU Scheduled Vesting Date as described in Section II.B.4; provided
that you have satisfied the conditions described in Section III.H.1., and provided further that the
number of shares of Common Stock distributable in respect of such PSUs will be determined in
accordance with Section II.B.1.
For the avoidance of doubt, the date of your termination of employment for purposes of determining
whether you have satisfied the Age and Service Criteria for Full Vesting under this Section III.D. will be
determined in accordance with Section III.G.
Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it has received an
opinion of counsel that there has been a legal judgment and/or legal development in the jurisdiction
where you are employed that would likely result in the favorable treatment applicable to the Stock Units
pursuant to this Section III.D. being deemed unlawful and/or discriminatory, then the Company will not
apply this favorable treatment upon your termination of employment, and the Stock Units will be
treated as set forth in the other subparagraphs of this Section III., as applicable.
E. Termination by the Company Other Than for Cause.
1. Treatment of Performance Stock Units.
a. General. Except as otherwise provided in Sections III.E.1.b. and IV., in the event the Company,
in its sole discretion, determines that your employment is terminated other than for Cause, a pro-
rata portion of the unvested PSUs that are outstanding as of such termination of employment will
remain outstanding (as described in Section III.I.) until the PSU Scheduled Vesting Date and will
be distributed as soon as practicable following the PSU Scheduled Vesting Date as described in
Section II.B.4; provided that you have satisfied the conditions described in Section III.H.2., and
provided further that the number of shares of Common Stock distributable in respect of such
PSUs will be determined in accordance with Section II.B.1. The portion of the unvested PSUs that
does not remain outstanding pursuant to this paragraph will be forfeited and cancelled. For the
avoidance of doubt, this Section III.E.1.a. shall apply regardless of whether you have satisfied
the Age and Service Criteria for Pro-Rata Vesting on or before your termination of employment by
the Company.
b. Termination by the Company Other Than for Cause After Satisfaction of Age and
Service Criteria for Full Vesting. In the event the Company, in its sole discretion, determines
that your employment is terminated other than for Cause, and on or before such time you satisfy
the Age and Service Criteria for Full Vesting, all unvested PSUs that are outstanding as of such
termination of employment will remain outstanding until the PSU Scheduled Vesting Date and will
be distributed as soon as practicable following the PSU Scheduled Vesting Date as described in
Section II.B.4; provided that you have satisfied the conditions described in Section III.H.2., and
provided further that the number of shares of
5
-- 113 of 139 --
Common Stock distributable in respect of such PSUs will be determined in accordance with
Section II.B.1.
2. Important Notes.
a. Sale of Business Unit. For purposes of this Award, in the event of a sale or similar transaction
involving the business unit for which you work (“Employing Company”) as a result of which the
Employing Company ceases to be a subsidiary or affiliate of Marsh McLennan, your employment
will be deemed terminated by the Company other than for Cause, even if your employment with
the Employing Company continues after the sale or similar transaction.
b. Constructive Discharge. The Award will not vest, whether on a pro-rata or full basis, upon a
constructive discharge, including if any court or regulatory agency retroactively concludes or
interprets events to have constituted a constructive discharge.
F. All Other Terminations. For all other terminations of employment not described in Sections III.A.
through E. or Section IV. (including, but not limited to, a termination by the Company for Cause, or your
resignation without having satisfied the Age and Service Criteria for Pro-Rata Vesting as described in
Section III.C., or the Age and Service Criteria for Full Vesting as described in Section III.D.), any rights,
title and interest in and to any remaining unvested portion of the Award shall be cancelled as of the
date your employment is treated as having terminated as described in Section III.G.
G. Date of Termination of Employment.
1. If Section III.G.2 does not apply to you, then for purposes of determining vesting under Section
II.B.2. and the number of unvested PSUs that vest on a pro-rata basis as described in Section III.I.,
your employment will be treated as having terminated on your last day of employment with the
Company.
2. If you are obligated (whether by law or contract) to provide the Company advance notice of your
intention to terminate your employment then, in the event you terminate your employment or
service relationship pursuant to Section III.C, III.D., or III.F. (and regardless of the reason for such
termination and whether or not later found to be invalid or in breach of employment laws in the
jurisdiction where you are employed or the terms of your employment agreement, if any), for
purposes of determining vesting under Section II.B.2. and the pro rata calculation described in
Section III.I., your employment will be treated as having terminated on your last day of active
service with the Company, as determined by the Company in its sole discretion.
You shall be deemed to have ceased active service with the Company when you are no longer
required by the Company to provide regular services to the Company even if you remain legally
employed by the Company, such as may occur if the Company were to place you on “garden leave”,
a terminal leave of absence or any similar period mandated under employment laws in the
jurisdiction where you are employed or the terms of your employment agreement, if any (in each
case as determined by the Company in its sole discretion).
H. Conditions for All or a Portion of an Award to Remain Outstanding Following a Termination of
Employment.
1. Restrictive Covenants Agreement. In the event of (i) the occurrence of your Permanent
Disability as described in Section III.B. or (ii) your termination of employment after satisfying the
Age and
6
-- 114 of 139 --
Service Criteria for Pro-Rata Vesting or the Age and Service Criteria for Full Vesting as described in
Sections III.C. and D., respectively, you will be required to execute or reaffirm, as determined by
Marsh McLennan in its sole discretion, and return to Marsh McLennan (or an agent appointed by
Marsh McLennan) a Restrictive Covenants Agreement. Failure to (a) execute or reaffirm such an
agreement by the date specified by the Company, which shall be in no event later than 60 days
following the occurrence of your Permanent Disability as described in Section III.B. or your
termination of employment as described in Section III.C. or III.D. (b) comply with the Restrictive
Covenants Agreement or to continue to be in compliance with the Restrictive Covenants Agreement
as of the delivery date for Performance Stock Units (as described in Section II.B.4.) or, at the
Company’s discretion, to reaffirm compliance prior to the delivery date, will result in the cancellation
or forfeiture of any rights, title and interest in and to the Award without any liability to the Company.
2. Waiver and Release and Restrictive Covenants Agreement. In the event of your termination
of employment by the Company other than for Cause as described in Section III.E., you will be
required to (i) execute or reaffirm, as determined by Marsh McLennan in its sole discretion, and
return to Marsh McLennan (or an agent appointed by Marsh McLennan) a Restrictive Covenants
Agreement and (ii) execute and not revoke a waiver and release agreement, if provided to you by
the Company at the time of your termination of employment. Failure to meet these requirements by
the date specified by the Company, which shall be in no event later than 60 days following your
termination of employment, or failure to comply with the waiver and release agreement or the
Restrictive Covenants Agreement, as applicable, or failure to continue to be in compliance with the
applicable agreement as of the delivery date for Performance Stock Units (as described in Section
II.B.4.) and, at the Company’s discretion, to reaffirm compliance prior to the delivery date, will result
in the cancellation or forfeiture of any rights, title and interest in and to the Award without any
liability to the Company.
I. Determination of Pro-Rata Calculation upon Termination of Employment.
The pro-rata portion of the unvested PSUs and accrued dividend equivalents that are outstanding as of
a termination of employment that will become distributable under certain circumstances described in
Section III. will be determined using the following formula:
where
A = the number of PSUs/accrued dividend equivalents covered by the Award;
B = the number of days in the period beginning on the grant date of the Award and ending on the
date of your termination of employment, as determined in accordance with Section III.G;
C = the number of days in the period beginning on the grant date of the Award and ending on the
PSU Scheduled Vesting Date, as applicable; and
D = the number of PSUs/accrued dividend equivalents that have previously vested, as determined in
accordance with Section III.G.
7
-- 115 of 139 --
J. Section 409A of the Code for Award Recipients Subject to U.S. Federal Income Tax (whether or
not the recipient is a U.S. citizen or employed in the U.S.).
1. For Award recipients subject to U.S. federal income tax, notwithstanding any other provision
herein, the Award may be subject to additional restrictions to ensure compliance with (or continued
exemption from) the requirements of Section 409A of the Code (as defined in Section V.). The
Committee intends to administer the Award in accordance with Section 409A of the Code and
reserves the right to make changes in the terms or operations of the Award (including changes that
may have retroactive effect) deemed necessary or desirable to comply with Section 409A of the
Code. This means, for example, that the timing of distributions may be different from those
described in the Award Documentation that do not reflect Section 409A of the Code. If the Award is
not in compliance with Section 409A of the Code, you may be subject to immediate taxation of all
unpaid awards under the Plan that are subject to Section 409A of the Code at your regular federal
income tax rate, plus a 20% additional tax, plus interest at the underpayment rate plus 1%, as well
as any state and local taxes, penalties, additional taxes and interest, if applicable, imposed under
any state tax law similar to Section 409A of the Code.
2. Notwithstanding any other provision herein, if any portion of the Award is determined to be
nonqualified deferred compensation subject to Section 409A of the Code, any references to
“termination of employment,” or “when you are no longer employed” in these Terms and Conditions
shall have the following meaning:
Your “termination of employment” (or similar terms) shall occur when you have incurred a
“separation from service” within the meaning of Section 409A of the Code and as further defined
herein. Specifically, you will have incurred a “separation from service” when the level of services you
provide to the Company in any capacity, including as an employee, director, independent contractor
or consultant, does not exceed 20% of the average level of services that you provided to the
Company in the preceding 36 months (or shorter period of service if, for example, your total service
with the Company is less than 36 months), all as determined in accordance with Section 409A of the
Code. In determining whether a “separation from service” has occurred, any period of up to six
months during which you are on a bona fide leave of absence or up to 29 months during which you
are absent from work due to a disability for which you are receiving Marsh McLennan long-term
disability benefits will be ignored.
3. Notwithstanding any other provision herein, if at the time of your termination of employment you
are a “specified employee” (as defined in Section 409A of the Code), no portion of the Award that is
determined to be nonqualified deferred compensation subject to Section 409A of the Code can be
distributed prior to the first day of the seventh month after your termination of employment and any
such distributions to which you would otherwise be entitled during the first six months following your
termination of employment will be accumulated and paid without interest on the first day of the
seventh month after your termination of employment, except to the extent that earlier distribution
would not result in your incurring interest or additional tax under Section 409A of the Code.
4. Notwithstanding any provision herein, if (i) a Change in Control occurs on or prior to December 31
of the second year of the three-year Performance Period and (ii) no earlier than in the third year of
the three-year Performance Period, (A) you satisfy the Age and Service Criteria for Pro-Rata Vesting,
(B) you satisfy the Age and Service
8
-- 116 of 139 --
Criteria for Full Vesting, (C) you are terminated by the Company other than for Cause, or (D) the
occurrence of your Permanent Disability, then shares of Common Stock deliverable on the PSU
Scheduled Vesting Date in respect of the PSUs covered by the Award shall be distributed to you as
soon as practicable following the PSU Scheduled Vesting Date, and in no event later than March 15
of the year in which the PSU Scheduled Vesting Date occurs.
5. Special 409A Distribution Provisions for Performance Stock Units and payments
attributable to Performance Stock Units.
a. Notwithstanding any provision herein, with respect to distributions of PSUs or cash attributable
to such PSUs (i) where, prior to [DATE], you have satisfied or would satisfy the Age and Service
Criteria either for Full Vesting or Pro-Rata Vesting and (ii) where such distributions are subject to
one or more Employment-Related Actions (as defined in Section V.):
i. With respect to PSUs, no later than December 31 of the year in which the PSU Scheduled
Vesting Date occurs, shares of Common Stock underlying such PSUs that relate to the PSU
Scheduled Vesting Date, shall be delivered to you (to the extent not previously delivered),
subject to a stop transfer order and subject to withholding of any applicable tax obligations, as
described in Section II.C. at the time of such delivery. Upon your timely satisfaction of all
applicable Employment-Related Actions, Marsh McLennan will remove or cause to be removed
such stop transfer order; and
ii. With respect to a cash payment attributable to PSUs, to the extent any such payment will
not be made by December 31 of the year in which the PSU Scheduled Vesting Date occurs,
any payment that relates to the PSU Scheduled Vesting Date shall be placed in escrow or
contributed to a secular trust (in the sole discretion of Marsh McLennan) for your benefit on or
before such December 31 and subject to withholding of any applicable tax obligations, as
described in Section II.C. at the time of such placement or contribution. Upon your timely
satisfaction of all applicable Employment-Related Actions, Marsh McLennan shall cause such
amounts to be released from escrow or paid to you out of such trust.
In either case, if any Employment-Related Action is not timely satisfied, the shares of Common
Stock or the cash payment shall revert to Marsh McLennan with no further compensation due to
you.
6. Nothing in this Section III.J. is intended to nor does it guarantee that the Award will not be subject
to “additional tax” or other adverse tax consequences under Section 409A of the Code or any similar
state tax law. In no event will the Company be liable for all or any portion of any taxes, penalties,
interest or other expenses that may be incurred on account of non-compliance with Section 409A of
the Code.
IV. CHANGE IN CONTROL PROVISIONS
A. Treatment of Performance Stock Units.
1. General. Upon the occurrence of a Change in Control the PSUs will continue to vest in accordance
with the vesting schedule specified in Sections II.B.2., subject to earlier vesting or forfeiture
pursuant to Section III.; provided that upon your termination of employment by the Company other
than for Cause, or by you for Good Reason (as defined in Section V.), during the 24-month period
following such Change in Control, all unvested PSUs that are outstanding as of your
st
st
st
9
-- 117 of 139 --
termination of employment will remain outstanding and will be distributed as soon as practicable
following the PSU Scheduled Vesting Date, as described in Section II.B.4., as applicable; provided
that you have satisfied the conditions described in Section IV.B. and provided further that the
number of shares distributable with respect to PSUs is as described in Section IV.A.3.
2. Awards Not Assumed. Notwithstanding the foregoing, if the PSUs are not assumed, converted or
replaced in connection with a Change in Control on an equivalent basis, such PSUs as described in
Section IV.A.3 (to the extent permitted in accordance with the requirements of Treas. Reg. § 1.409A-
3(j)(4)(ix)(B)) will fully vest immediately prior to the Change in Control and will be distributed as
soon as practicable following vesting and in no event later than 60 days following vesting.
3. Calculation of Shares Distributable with Respect to PSUs. Upon the occurrence of a “Change
in Control”, the Performance Period shall be deemed to have ended on (i) December 31 of the year
preceding the year in which the Change in Control occurs for determination of the EPS Performance
Factor and (ii) the date of the occurrence of the Change in Control for determination of the Relative
TSR Modifier, and the number of shares of Common Stock distributable in respect of the PSUs
(subject to the vesting conditions applicable thereto) will be determined in accordance with Section
II.B.1.; provided that, in the event that the Change in Control occurs on or prior to December 31 of
the year in which the PSUs are granted, the number of shares of Common Stock distributable with
respect to the PSUs will be determined based on (i) the “target” EPS Performance Factor and (ii) the
actual Relative TSR modifier, determined as of the date of the occurrence of the Change in Control.
B. Waiver and Release
In the event of your termination of employment by the Company other than for Cause or by you for Good
Reason during the 24-month period following such Change in Control, you will be required to execute
and not revoke a waiver and release agreement, if provided by the Company at the time of your
termination of employment. Failure to meet these requirements by the date specified by the Company,
which shall be in no event later than 60 days following your termination of employment, or failure to
comply with the waiver and release agreement, and be in compliance with the agreement, if applicable,
as of the delivery date Performance Stock Units (as described in Section II.B.4.), will result in the
cancellation or forfeiture of any rights, title and interest in and to the Award.
C. Other Matters
For the avoidance of doubt, in the event of your termination of employment by the Company other than for
Cause or by you for Good Reason during the 24-month period following such Change in Control and, on
or before the date of your termination of employment you satisfy the Age and Service Criteria for Pro-
Rata Vesting or the Age and Service Criteria for Full Vesting as described in Sections III.C. and D.,
respectively, any unvested PSUs covered by the Award will be treated as described in this Section IV.;
provided that you satisfy or have satisfied, as applicable, the conditions described in Section IV.B.
V. DEFINITIONS
As used in these Terms and Conditions:
10
-- 118 of 139 --
A. “Age and Service Criteria for Full Vesting” shall mean you are at least age 62 and have a minimum of five
years of service with the Company.
B. “Age and Service Criteria for Pro-Rata Vesting” shall mean you are at least age 55 but are not yet age 62
and have a minimum of five years of service with the Company.
C. “Cause” shall mean:
1. willful failure to substantially perform the duties consistent with your position which is not remedied
within 30 days after receipt of written notice from the Company specifying such failure;
2. willful violation of any written Company policies, including but not limited to, The Marsh McLennan
Code of Conduct, The Greater Good;
3. commission at any time of any act or omission that results in a conviction, plea of no contest, plea
of nolo contendere, or imposition of unadjudicated probation for any felony or crime involving moral
turpitude;
4. unlawful use (including being under the influence) or possession of illegal drugs;
5. any gross negligence or willful misconduct resulting in a material loss to the Company, or material
damage to the reputation of the Company; or
6. any violation of any statutory or common law duty of loyalty to the Company, including the
commission at any time of any act of fraud, embezzlement, or material breach of fiduciary duty
against the Company.
D. “Change in Control” shall have the meaning set forth in the Plan.
E. “Company” shall mean Marsh McLennan or any of its subsidiaries or affiliates.
F. “Employment-Related Action” shall mean the execution and effectiveness of a release of claims and/or a
restrictive covenant.
G. “Good Reason” shall mean any one of the following events without your written consent:
1. material reduction in your base salary;
2. material reduction in your annual incentive opportunity (including a material adverse change in the
method of calculating your annual incentive);
3. material diminution of your duties, responsibilities or authority; or
4. relocation of more than 50 miles from your principal place of employment immediately prior to the
Change in Control; provided that you provide Marsh McLennan with written notice of your intent to
terminate your employment for Good Reason within 60 days of your becoming aware of any
circumstances set forth above (with such notice indicating the specific termination provision above
on which you are relying and describing in reasonable detail the facts and circumstances claimed to
provide a basis for termination of your employment under the indicated provision) and that you
provide Marsh McLennan with at least 30 days following receipt of such notice to remedy such
circumstances.
H. “Performance Period” shall mean the period that begins on [DATE] and ends on [DATE]; provided that in
the event of a termination of your
11
-- 119 of 139 --
employment due to death prior to a Change in Control, such period will end on December 31 of the year
prior to such termination of employment for the PSUs covered by the Award; and provided further that
in the event of a Change in Control, such period will end on (i) December 31 of the year prior to the
occurrence of such Change in Control for determination of the EPS Performance Factor and (ii) the date
of the occurrence of such Change in Control for determination of the Relative TSR Modifier.
I. “Permanent Disability” will be deemed to occur when it is determined (by Marsh McLennan’s disability
carrier for the primary long-term disability plan or program applicable to you because of your
employment with the Company) that you are unable to engage in any substantial gainful activity by
reason of any medically determinable physical or mental impairment that can be expected to result in
death or can be expected to last for a continuous period of not less than 12 months.
J. “Section 409A of the Code” shall mean Section 409A of the U.S. Internal Revenue Code of 1986, as
amended, and the regulations and guidance thereunder (regarding nonqualified deferred
compensation).
K. “Tax-Related Items” shall have the meaning ascribed to such term in the Plan.
VI. ADDITIONAL PROVISIONS
A. Additional Provisions—General
1. Administrative Rules. The Award shall be subject to such additional administrative regulations as
the Committee may, from time to time, adopt. All decisions of the Committee upon any questions
arising under the Award Documentation shall be conclusive and binding. The Committee may
delegate to any other individual or entity the authority to perform any or all of the functions of the
Committee under the Award, and references to the Committee shall be deemed to include any such
delegate.
2. Amendment. The Committee may, in its sole discretion, amend the terms of the Award, including,
without limitation, to impose additional requirements on the Award and on any shares of Common
Stock acquired with respect to the Award; provided, however, that if the Committee concludes, in its
sole discretion, that such amendment is likely to materially impair your rights with respect to the
Award, such amendment shall not be implemented with respect to the Award without your consent,
except to the extent that any such action is made to cause the Award to comply with applicable law,
currency controls, stock market or exchange rules and regulations, or accounting or tax rules and
regulations, or is otherwise made in accordance with Section VI.A.4.
3. Limitations. Payment of the Award is not secured by trust, insurance contract or other funding
medium, and you do not have any interest in any fund or specific asset of Marsh McLennan by
reason of the Award. Your right to payment of the Award is the same as the right of an unsecured
general creditor of Marsh McLennan.
4. Cancellation or Clawback of Awards.
a. Marsh McLennan may, to the extent permitted or required by any applicable law, stock
exchange rules, currency controls, the Company Incentive Compensation Clawback Policy or any
other applicable Company policy or arrangement in effect prior to the vesting of any unvested
portion of the Award, or as specified in the Award Documentation, cancel, reduce or require
reimbursement of
12
-- 120 of 139 --
the Award in the event of fraud, financial restatements, or other events as may be determined by
the Committee.
b. If you fail to repay any amount due pursuant to this Section VI.A.4., the Company may bring an
action in court to recover the amount due. You acknowledge that, by accepting the Award, you
agree to pay all costs, expenses and attorney’s fees incurred by the Company in any proceeding
for the collection of amounts due pursuant to this Section VI.A.4., provided that the Company
prevails in whole or in part in any such proceeding. The Company may also, to the extent
permitted by applicable law, reduce any amounts owed to you by the Company in an amount up
to the full amount of the repayment due.
5. Governing Law; Choice of Forum. The Award and the Award Documentation applicable to the
Award are governed by and subject to the laws of the State of Delaware, without regard to the
conflict of law provisions, as set forth in Section 10.K of the Plan. For purposes of any action,
lawsuit, or other proceedings arising out of or relating to this Award, including without limitation, to
enforce the Award Documentation, the Company and you each hereby irrevocably and
unconditionally submits to the exclusive jurisdiction of any New York state court or federal court of
the United States of America sitting in the State of New York, and any appellate court thereof. The
Company and you agree that a final judgment in any such action or proceeding shall be conclusive
and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided
by law.
6. Severability; Captions. In the event that any provision of this Award is determined to be invalid
or unenforceable, in whole or in part, the remaining provisions of this Award will be unaffected
thereby and will remain in full force and effect to the fullest extent permitted by law. The captions of
this Award are not part of the provisions of this Award and will have no force or effect.
7. Electronic Delivery and Acceptance. Marsh McLennan may, in its sole discretion, decide to
deliver any documents related to the Award and/or your current or future participation in the Plan by
electronic means. You hereby consent to receive such documents by electronic delivery and agree to
participate in the Plan through an on-line or electronic system established and maintained by Marsh
McLennan or an agent appointed by Marsh McLennan.
8. Waiver. You acknowledge that neither a waiver by Marsh McLennan of your breach of any
provision of the Award Documentation nor a prior waiver by Marsh McLennan of a breach of any
provision of the Award Documentation by any other participant of the Plan shall operate or be
construed as a waiver of any other provision of the Award Documentation, or of any subsequent
breach by you.
9. Eligibility for Award. In order to be granted an Award, you must satisfy the eligibility criteria for
grantees set forth in the Plan as of the grant date.
B. Additional Provisions—Outside of the United States
1. Changes to Delivery. In the event that Marsh McLennan considers that due to legal, regulatory or
tax issues the normal delivery of an Award (as described in these Terms and Conditions) to a
participant outside the United States would not be appropriate, then Marsh McLennan may, in its sole
discretion, determine how and when the value of the Award will be delivered. Without limitation, this
may include making any payments due under the Award in cash instead of shares of Common Stock,
or in shares of Common Stock instead of cash or vesting after payment of applicable Tax- Related
Items and
13
-- 121 of 139 --
fees or, delivering or paying out the Award as soon as practicable following a termination of
employment. If the value of an Award is to be delivered in cash instead of shares of Common Stock,
Marsh McLennan may sell any shares of Common Stock distributable in respect of the Award on your
behalf and use the proceeds (after payment of applicable Tax-Related Items and fees) to satisfy the
Award.
2. Amendment and Modification. The Committee may modify the terms of any Award under the
Plan granted to you in any manner deemed by the Committee to be necessary or appropriate in
order for such Award to conform to laws, regulations and customs of the country (other than the
United States) in which you are then resident or primarily employed or were resident or primarily
employed at the time of grant or during the term of the Award, or so that the value and other
benefits of the Award to you, as affected by non-U.S. tax laws and other restrictions applicable as a
result of your residence or employment outside of the United States, shall be comparable to the
value of such an Award to an individual who is resident or primarily employed in the United States.
VII. QUESTIONS AND ADDITIONAL INFORMATION
Please retain this document in your permanent records. If you have any questions regarding the Award
Documentation or if you would like an account statement detailing each type of equity-based award and the number
of shares of Common Stock covered by such equity-based award that comprises the Award, and the vesting date(s)
of such equity-based awards that comprise the Award, or any other information, please contact:
Executive Compensation
Marsh & McLennan Companies, Inc.
1166 Avenue of the Americas
New York, NY 10036-2774
United States of America
Telephone Number: +1 212 345-9722
Facsimile Number: +1 212 948-8481
Email: mmc.compensation@mmc.com
14
-- 122 of 139 --
IN WITNESS WHEREOF, Marsh McLennan has caused these Terms & Conditions to be duly executed by the facsimile
signature of its Senior Vice President, Chief People Officer as of the day and year first above written. By consenting
to these Terms and Conditions, you agree to the following: (i) you have carefully read, fully understand and agree to
all of the terms and conditions described herein and in the Award Documentation; and (ii) you understand and agree
that these Terms & Conditions and the Award Documentation constitute the entire understanding between you and
Marsh McLennan regarding the Award, and that any prior agreements, commitments or negotiations concerning the
Award are replaced and superseded. The grant of the Award is contingent upon your acceptance of these Terms and
Conditions, Country-Specific Notices and Restrictive Covenants Agreement (if applicable) by the date and in the
manner specified in materials provided to you by Executive Compensation and/or the Company’s stock plan service
provider. If you decline the Award or you do not accept the Award and any applicable documents described in the
preceding sentence by the date and in the manner specified, the Award will be cancelled as of the grant date of the
Award.
/s/Carmen Fernandez
Carmen Fernandez
SVP, Chief People Officer
15
-- 123 of 139 --
MARSH & McLENNAN COMPANIES, INC.
2020 INCENTIVE AND STOCK AWARD PLAN
TERMS AND CONDITIONS
OF
STOCK OPTION AWARDS
GRANTED ON [DATE], 2022
-- 124 of 139 --
TABLE OF CONTENTS
Page
I. BACKGROUND 1
II. AWARDS 1
III. EMPLOYMENT EVENTS 3
IV. CHANGE IN CONTROL PROVISIONS 6
V. DEFINITIONS 7
VI. ADDITIONAL PROVISIONS 8
VII. QUESTIONS AND ADDITIONAL INFORMATION 10
-- 125 of 139 --
I. BACKGROUND
A Stock Option award (“Award”) has been granted to you under the Marsh & McLennan Companies, Inc. 2020
Incentive and Stock Award Plan (the “Plan”), subject to your acceptance as described in Section II.A.1. The
number of shares of Marsh & McLennan Companies, Inc. (“Marsh McLennan”) common stock covered by the
Award, instructions on how to accept or decline the Award and the deadline for accepting the Award will be
provided to you by Executive Compensation and/or the stock plan service provider of the Company (as defined
in Section V). The Award is also subject to the terms and conditions set forth herein (the “Terms and
Conditions”) and to additional terms and conditions as set forth in the country-specific notices (the “Country-
Specific Notices”). The Prospectus dated [DATE], also describes important information about the Plan. The
Terms and Conditions, the Country-Specific Notices and the Plan will be referred to herein as the “Award
Documentation”. As used herein, “Common Stock” means common stock of Marsh McLennan.
Capitalized terms in these Terms and Conditions are defined in Section V.
II. AWARDS
A. General.
1. Award Acceptance. The grant of this Award is contingent upon your acceptance, by the date and
in the manner specified by Executive Compensation and/or the Company’s stock plan service
provider, of these Terms and Conditions, the Country-Specific Notices and Restrictive Covenants
Agreement as described in Section II.A.3. If you decline the Award or if you do not accept the Award
and any applicable documents described in the preceding sentence by the deadline date and in the
manner specified, then the Award will be cancelled as of the grant date of the Award.
2. Rights of Award Holders. Unless and until the vesting conditions of the Award have been
satisfied and shares of Common Stock, as applicable, have been delivered to you upon your exercise
of the Award in accordance with the Award Documentation, you have none of the rights of ownership
to such shares (e.g., Options cannot be transferred or assigned; Options have no voting rights, etc.).
3. Restrictive Covenants Agreement. As described in Section II.A.1., a Restrictive Covenants
Agreement (“Restrictive Covenants Agreement”) in a form determined by Marsh McLennan must be
in place in order to accept the Award, you must execute or reaffirm, as determined by Marsh
McLennan, in its sole discretion, the Restrictive Covenants Agreement in order for the Award to vest
pursuant to certain employment events as described in Section III., and you must further execute or
reaffirm, as determined by Marsh McLennan, in its sole discretion, and be in compliance with the
Restrictive Covenants Agreement in order to exercise an Option whether or not you are employed by
the Company at that time. Failure to timely execute the Restrictive Covenants Agreement by the
date specified by the Company or failure to timely execute or reaffirm and comply with the
Restrictive Covenants Agreement as described in Section III.G.1. or 2., as applicable, will result in
cancellation or forfeiture of any rights, title and interest in and to the Award, without any liability to
the Company.
B. Stock Options.
1. General. A stock option (“Option”) represents the right to purchase a number of shares of
Common Stock (the “Option Shares”) at a specified exercise price for a specified period.
2. Vesting. Subject to your continued employment, 25% of the Option Shares covered by the Option
will vest on each of the first four anniversaries of the grant date of the Award. Each date on which an
1
-- 126 of 139 --
Option Share covered by the Option is scheduled to vest is an “Option Scheduled Vesting Date.” In
the event of your termination of employment or occurrence of your Permanent Disability (as defined
in Section V.) prior to an Option Scheduled Vesting Date, your right to any Option Shares covered by
the Option that are unvested immediately prior to your termination of employment or occurrence of
your Permanent Disability, as applicable, will be determined in accordance with Section III. For the
avoidance of doubt, the date of your termination of employment for purposes of this Section II.B.2.
will be determined in accordance with Section III.F.
3. Term. Subject to your continued employment, the Option will expire on the day immediately
preceding the tenth anniversary of the grant date of the Award (“Option Expiration Date”). If your
employment terminates before the Option Expiration Date, your right to exercise any vested Option
Shares covered by the Option will be determined in accordance with Section III.
4. Exercisability. The Option Shares covered by the Option will become exercisable when they vest.
You are responsible for keeping track of exercise periods while actively employed and, if applicable,
any post-termination exercise periods.
5. Method of Exercise of an Option.
a. General Procedures. An Option may be exercised by written notice (or other notice as required
by the Company and/or its stock plan service provider) to Marsh McLennan or an agent appointed
by Marsh McLennan, in form and substance satisfactory to Marsh McLennan, which must state the
election to exercise such Option, the number of Option Shares for which such Option is being
exercised and such other representations and agreements as may be required pursuant to the
provisions of the Award Documentation (the “Exercise Notice”). The Exercise Notice must be
accompanied by (i) any required income tax forms and (ii) any required reaffirmation of the
Restrictive Covenants Agreement, unless (A) the Option is being exercised after your death in
accordance with Section III. or (B) as otherwise determined by Marsh McLennan.
b. Payment of Exercise Price. Payment of the aggregate exercise price may be made with U.S.
dollars or by tendering shares of Common Stock (including shares of Common Stock acquired
from a stock option exercise or a stock unit award vesting) at your election.
c. Distribution of Option Shares. The shares of Common Stock from the Option exercise will be
distributed as specified in the Exercise Notice, after you have satisfied applicable tax obligations,
as described in Section II.C., and fees.
C. Satisfaction of Tax Obligations.
1. Personal Tax Advisor. Neither the Company nor any Company employee is authorized to provide
personal tax advice to you. It is recommended that you consult with your personal tax advisor for
more detailed information regarding the tax treatment of the Award, especially before making any
decisions that rely on that tax treatment.
2. U.S. Employees. Applicable taxes (including employment taxes) are required by law to be
withheld when a nonqualified Option is exercised. A sufficient number of whole shares of Common
Stock resulting from the Option exercise will be retained by Marsh McLennan to satisfy the tax-
withholding obligation unless you elect in the Exercise Notice to satisfy all applicable tax withholding
in another manner.
2
-- 127 of 139 --
3. Non-U.S. Employees.
a. In most countries, the value of an Option is generally not taxable on the grant date. If the value
of the Option is not taxable on the grant date, it will, in most countries, be taxed at a later time,
for example, upon exercise of the Option and delivery of shares of Common Stock in respect of
the Option, and/or the subsequent sale of the shares of Common Stock.
b. Withholding. Marsh McLennan and/or your employer shall have the power and the right to
deduct and withhold from the Award and other compensation or to require you to remit to Marsh
McLennan and/or to your employer, an amount sufficient to satisfy any Tax-Related Items (as
defined in Section V.) that Marsh McLennan expects to be payable under the laws of any country,
state, province, city or other jurisdiction. If applicable, Marsh McLennan and/or your employer
will, to the extent permissible under applicable law or otherwise agreed between you and Marsh
McLennan and/or your employer, retain and sell a sufficient number of whole shares of Common
Stock distributable in respect of the Award for purposes of satisfying applicable obligations with
respect to Tax-Related Items.
III. EMPLOYMENT EVENTS
A. Death. In the event your employment is terminated because of your death, the Option will fully vest with
respect to any unvested Option Shares and will become exercisable as of the date of your death. The
person or persons to whom your rights under the Option shall pass by will or the laws of descent and
distribution shall be entitled to exercise such Option with respect to any Option Shares that vest (and
any Option Shares that were already vested at the time of your death) within two years after the date
of death, but in no event shall the Option be exercisable after the Option Expiration Date.
B. Permanent Disability. Upon the occurrence of your Permanent Disability, the Option will fully vest with
respect to any unvested Option Shares and will become exercisable; provided that you satisfy the
conditions described in Section III.G.1; and provided further that any such Option Shares that vest in
accordance with this Section III.B. (and any Option Shares that were already vested at the time your
Permanent Disability occurred) shall be exercisable for two years following the occurrence of your
Permanent Disability, but in no event shall the Option be exercisable after the Option Expiration Date.
C. Termination by You – Age and Service Treatment. If you have satisfied Age and Service Criteria I
(as defined in Section V.) or Age and Service Criteria II (as defined in Section V.) on or before the date
you terminate your employment with the Company for any reason other than death or the occurrence of
your Permanent Disability, then:
1. If you have satisfied Age and Service Criteria I but not Age and Service Criteria II, your rights, title
and interest in and to any unvested Option Shares will be canceled upon such termination of
employment. Provided that you satisfy the conditions described in Section III.G.1., any Option
Shares that were vested at the time of your termination of employment shall be exercisable until the
earlier of the fifth anniversary of your termination of employment and the Option Expiration Date.
2. If you have satisfied Age and Service Criteria II, the Option will continue to vest with respect to
any unvested Option Shares as provided in Section II.B.2. as if your employment had not terminated
and the Option Shares will become exercisable as provided in Section II.B.4., provided that you
satisfy the conditions described in Section
3
-- 128 of 139 --
III.G.1. Provided that you satisfy the conditions described in Section III.G.1., any such Option
Shares that vest (and any Option Shares that were already vested at the time of your termination of
employment) shall be exercisable until the earlier of the fifth anniversary of your termination of
employment and the Option Expiration Date.
For the avoidance of doubt, Section III.D. will govern the treatment of the Award in the event your
employment is terminated by the Company other than for Cause (as defined in Section V.).
For the avoidance of doubt, the date of your termination of employment for purposes of determining
whether you have satisfied either Age and Service Criteria I or Age and Service Criteria II under this
Section III.C. will be determined in accordance with Section III.F.
Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it has received an
opinion of counsel that there has been a legal judgment and/or legal development in the jurisdiction
where you are employed that would likely result in the favorable treatment applicable to the Option
pursuant to this Section III.C. being deemed unlawful and/or discriminatory, then the Company will not
apply this favorable treatment upon your termination of employment, and the Option will be treated as
set forth in the other subparagraphs of this Section III., as applicable.
D. Termination by the Company Other Than for Cause.
1. Treatment of Stock Options.
a. General. Except as otherwise provided in Sections III.D.1.b., III.D.1.c., and IV., in the event
the Company, in its sole discretion, determines that your employment is terminated other than
for Cause, your rights, title and interest in and to any unvested Option Shares will be canceled
upon such termination of employment. Provided that you satisfy the conditions described in
Section III.G.2., any Option Shares that were vested at the time of your termination of
employment shall be exercisable until the earlier of 90 days following your termination of
employment and the Option Expiration Date.
b. Termination by the Company Other Than for Cause After Satisfaction of Age and
Service Criteria I but not Age and Service Criteria II. In the event the Company, in its sole
discretion, determines that your employment is terminated other than for Cause, and on or
before such time you satisfy Age and Service Criteria I but not Age and Service Criteria II, your
rights, title and interest in and to any unvested Option Shares will be canceled upon such
termination of employment. Provided that you satisfy the conditions described in Section III.G.2.,
any Option Shares that were vested at the time of your termination of employment shall be
exercisable until the earlier of the fifth anniversary of your termination of employment and the
Option Expiration Date.
4
-- 129 of 139 --
c. Termination by the Company Other Than for Cause After Satisfaction of Age and
Service Criteria II. In the event the Company, in its sole discretion, determines that your
employment is terminated other than for Cause, and on or before such time you satisfy Age and
Service Criteria II, the Option will continue to vest with respect to any unvested Option Shares as
provided in Section II.B.2. as if your employment had not terminated and the Option Shares will
become exercisable as provided in Section II.B.4.; provided that you satisfy the conditions
described in Section III.G.2. Provided that you satisfy the conditions described in Section III.G.2.,
any such Option Shares that vest (and any Option Shares that were already vested at the time of
your termination of employment) shall be exercisable until the earlier of the fifth anniversary of
your termination of employment and the Option Expiration Date.
2. Important Notes.
a. Sale of Business Unit. For purposes of this Award, in the event of a sale or similar transaction
involving the business unit for which you work (“Employing Company”) as a result of which the
Employing Company ceases to be a subsidiary or affiliate of Marsh McLennan, your employment
will be deemed terminated by the Company other than for Cause, even if your employment with
the Employing Company continues after the sale or similar transaction.
b. Constructive Discharge. The Award will not vest upon a constructive discharge, including if
any court or regulatory agency retroactively concludes or interprets events to have constituted a
constructive discharge.
E. All Other Terminations. For all other terminations of employment not described in Sections III.A.
through D. or Section IV. (including, but not limited to, a termination by the Company for Cause, or
your resignation without having satisfied either Age and Service Criteria I or Age and Service Criteria II
as described in Section III.C), any rights, title and interest in and to any remaining unvested portion of
the Award shall be cancelled as of the date your employment is treated as having terminated as
described in Section III.F. Provided that you satisfy the conditions described in Section III.G.1., any
Option Shares that were vested at the time of your termination of employment (except if you are
terminated by the Company for Cause) shall be exercisable until the earlier of 90 days following your
termination of employment and the Option Expiration Date. If you are terminated by the Company for
Cause, any rights, title and interest in and to any remaining vested or unvested portion of the Award
shall be cancelled as of the date your employment is treated as having terminated as described in
Section III.F.
F. Date of Termination of Employment.
1. If Section III.F.2 does not apply to you, then for purposes of determining vesting under Section
II.B.2., your employment will be treated as having terminated on your last day of employment with
the Company.
2. If you are obligated (whether by law or contract) to provide the Company advance notice of your
intention to terminate your employment or service relationship then, in the event you terminate your
employment pursuant to Section III.C., or III.E. (regardless of the reason for such termination and
whether or not later found to be invalid or in breach of employment laws in the jurisdiction where
you are employed or the terms of your employment agreement, if any), for purposes of determining
vesting under Section II.B.2., your employment will be treated as having terminated on your last day
of
5
-- 130 of 139 --
active service with the Company, as determined by the Company in its sole discretion.
You shall be deemed to have ceased active service with the Company when you are no longer
required by the Company to provide regular services to the Company even if you remain legally
employed by the Company, such as may occur if the Company were to place you on “garden leave”,
a terminal leave of absence or any similar period mandated under employment laws in the
jurisdiction where you are employed or the terms of your employment agreement, if any (in each
case as determined by the Company in its sole discretion).
G. Conditions for All or a Portion of an Award to Remain Outstanding Following a Termination of
Employment and Exercisability of Options Following a Termination of Employment.
1. Restrictive Covenants Agreement. In the event of (i) the occurrence of your Permanent
Disability as described in Section III.B., (ii) your termination of employment after satisfying either
Age and Service Criteria I or Age and Service Criteria II as described in Sections III.C., or (iii) your
termination of employment (other than a termination by the Company for Cause) as described in
Section III.E., you will be required to execute or reaffirm, as determined by Marsh McLennan in its
sole discretion, and return to Marsh McLennan (or an agent appointed by Marsh McLennan) a
Restrictive Covenants Agreement. Failure to (a) execute or reaffirm such an agreement by the date
specified by the Company, which shall be in no event later than 60 days following the occurrence of
your Permanent Disability as described in Section III.B. or your termination of employment as
described in Section III.C. or III.E., or (b) comply with the Restrictive Covenants Agreement will
result in the cancellation or forfeiture of any rights, title and interest in and to the Award without any
liability to the Company.
2. Waiver and Release and Restrictive Covenants Agreement. In the event of your termination
of employment by the Company other than for Cause as described in Section III.D., you will be
required to (i) execute or reaffirm, as determined by Marsh McLennan in its sole discretion, and
return to Marsh McLennan (or an agent appointed by Marsh McLennan) a Restrictive Covenants
Agreement and (ii) execute and not revoke a waiver and release agreement, if provided to you by
the Company at the time of your termination of employment. Failure to meet these requirements by
the date specified by the Company, which shall be in no event later than 60 days following your
termination of employment, or failure to comply with the waiver and release agreement or the
Restrictive Covenants Agreement, as applicable, or failure to continue to be in compliance with the
applicable agreement will result in the cancellation or forfeiture of any rights, title and interest in and
to the Award without any liability to the Company.
IV. CHANGE IN CONTROL PROVISIONS
A. Treatment of Stock Options. Upon the occurrence of a Change in Control (as defined in Section V.), the
Option Shares will continue to vest in accordance with the vesting schedule specified in Section II.B.2
and subject to earlier vesting or forfeiture pursuant to Section III.; provided that the Option Shares will
become fully vested at your termination of employment by the Company other than for Cause, or by
you for Good Reason (as defined in Section V.), during the 24-month period following such Change in
Control and will be treated as set forth below, provided that you satisfy the conditions described in
Section IV.B. Notwithstanding
6
-- 131 of 139 --
the foregoing, if the Option Share is not assumed, converted or replaced in connection with a Change in
Control on an equivalent basis, the Option Shares will fully vest immediately prior to the Change in
Control and will be treated as follows:
Provided that you satisfy the conditions described in Section IV.B., any such Option Shares that vest
(and any Option Shares that were already vested at the time of your termination of employment) shall
be exercisable until the earlier of (a) 90 days following your termination of employment or the
occurrence of the Change in Control, as applicable, and (b) the Option Expiration Date.
B. Waiver and Release. In the event of your termination of employment by the Company other than for
Cause or by you for Good Reason during the 24-month period following such Change in Control, you will
be required to execute and not revoke a waiver and release agreement, if provided by the Company at
the time of your termination of employment. Failure to meet these requirements by the date specified
by the Company, which shall be in no event later than 60 days following your termination of
employment, or failure to comply with the waiver and release agreement, and be in compliance with the
agreement, if applicable, will result in the cancellation or forfeiture of any rights, title and interest in and
to the Award.
C. Other Matters. For the avoidance of doubt, in the event of your termination of employment by the
Company other than for Cause or by you for Good Reason during the 24-month period following such
Change in Control and, on or before the date of your termination of employment you satisfy either Age
and Service Criteria I or Age and Service Criteria II as described in Section III.C., any unvested Options
covered by the Award will be treated as described in this Section IV.; provided that you satisfy or have
satisfied, as applicable, the conditions described in Section IV.B.; provided further that (i) if you satisfy
Age and Service Criteria II, any such Option Shares that vest (and any Option Shares that were already
vested at the time of your termination of employment) shall be exercisable until the earlier of the fifth
anniversary of your termination of employment and the Option Expiration Date, and (ii) if you satisfy
Age and Service Criteria I but not Age and Service Criteria II, any such Option Shares that were already
vested at the time of your termination of employment shall be exercisable until the earlier of the fifth
anniversary of your termination of employment and the Option Expiration Date.
V. DEFINITIONS
As used in these Terms and Conditions:
A. “Age and Service Criteria I” shall mean you are at least age 55 but are not yet age 62 and have a
minimum of five years of service with the Company.
B. “Age and Service Criteria II” shall mean you are at least age 62 and have a minimum of five years
of service with the Company.
C. “Cause” shall mean:
1. willful failure to substantially perform the duties consistent with your position which is not
remedied within 30 days after receipt of written notice from the Company specifying such failure;
2. willful violation of any written Company policies, including but not limited to, The Marsh McLennan
Code of Conduct, The Greater Good;
3. commission at any time of any act or omission that results in a conviction, plea of no contest, plea
of nolo contendere, or imposition of unadjudicated probation for any felony or crime involving moral
turpitude;
7
-- 132 of 139 --
4. unlawful use (including being under the influence) or possession of illegal drugs;
5. any gross negligence or willful misconduct resulting in a material loss to the Company, or material
damage to the reputation of the Company; or
6. any violation of any statutory or common law duty of loyalty to the Company, including the
commission at any time of any act of fraud, embezzlement, or material breach of fiduciary duty
against the Company.
D. “Change in Control” shall have the meaning set forth in the Plan.
E. “Committee” shall mean the Compensation Committee of the Board of Directors of Marsh McLennan.
F. “Company” shall mean Marsh McLennan or any of its subsidiaries or affiliates.
G. “Good Reason” shall mean any one of the following events without your written consent:
1. material reduction in your base salary;
2. material reduction in your annual incentive opportunity (including a material adverse change in the
method of calculating your annual incentive);
3. material diminution of your duties, responsibilities or authority; or
4. relocation of more than 50 miles from your principal place of employment immediately prior to the
Change in Control; provided that you provide Marsh McLennan with written notice of your intent to
terminate your employment for Good Reason within 60 days of your becoming aware of any
circumstances set forth above (with such notice indicating the specific termination provision above
on which you are relying and describing in reasonable detail the facts and circumstances claimed to
provide a basis for termination of your employment under the indicated provision) and that you
provide Marsh McLennan with at least 30 days following receipt of such notice to remedy such
circumstances.
H. “Permanent Disability” will be deemed to occur when it is determined (by Marsh McLennan’s disability
carrier for the primary long-term disability plan or program applicable to you because of your
employment with the Company) that you are unable to engage in any substantial gainful activity by
reason of any medically determinable physical or mental impairment that can be expected to result in
death or can be expected to last for a continuous period of not less than 12 months.
I. “Tax-Related Items” shall have the meaning ascribed to such term in the Plan.
VI. ADDITIONAL PROVISIONS
A. Additional Provisions—General
1. Administrative Rules. The Award shall be subject to such additional administrative regulations as
the Committee (as defined in Section V.) may, from time to time, adopt. All decisions of the
Committee upon any questions arising under the Award Documentation shall be conclusive and
binding. The Committee may delegate to any other individual or entity the authority to perform any
or all of the functions of the Committee under the Award, and references to the Committee shall be
deemed to include any such delegate.
8
-- 133 of 139 --
2. Amendment. The Committee may, in its sole discretion, amend the terms of the Award, including,
without limitation, to impose additional requirements on the Award and on any shares of Common
Stock acquired with respect to the Award; provided, however, that if the Committee concludes, in its
sole discretion, that such amendment is likely to materially impair your rights with respect to the
Award, such amendment shall not be implemented with respect to the Award without your consent,
except to the extent that any such action is made to cause the Award to comply with applicable law,
currency controls, stock market or exchange rules and regulations, or accounting or tax rules and
regulations, or is otherwise made in accordance with Section VI.A.4.
3. Limitations. Payment of the Award is not secured by trust, insurance contract or other funding
medium, and you do not have any interest in any fund or specific asset of Marsh McLennan by
reason of the Award. Your right to payment of the Award is the same as the right of an unsecured
general creditor of Marsh McLennan.
4. Cancellation or Clawback of Awards.
a. Marsh McLennan may, to the extent permitted or required by any applicable law, stock
exchange rules, currency controls, or the Company Incentive Compensation Clawback Policy or
any other applicable Company policy or arrangement in effect prior to the vesting of any
unvested portion of the Award, or as specified in the Award Documentation, cancel, reduce or
require reimbursement of the Award in the event of fraud, financial restatements, or other events
as may be determined by the Committee.
b. If you fail to repay any amount due pursuant to this Section VI.A.4., the Company may bring an
action in court to recover the amount due. You acknowledge that, by accepting the Award, you
agree to pay all costs, expenses and attorney’s fees incurred by the Company in any proceeding
for the collection of amounts due pursuant to this Section VI.A.4., provided that the Company
prevails in whole or in part in any such proceeding. The Company may also, to the extent
permitted by applicable law, reduce any amounts owed to you by the Company in an amount up
to the full amount of the repayment due.
5. Governing Law; Choice of Forum. The Award and the Award Documentation applicable to the
Award are governed by and subject to the laws of the State of Delaware, without regard to the
conflict of law provisions, as set forth in Section 10.K of the Plan. For purposes of any action,
lawsuit, or other proceedings arising out of or relating to this Award, including without limitation, to
enforce the Award Documentation, the Company and you each hereby irrevocably and
unconditionally submits to the exclusive jurisdiction of any New York state court or federal court of
the United States of America sitting in the State of New York, and any appellate court thereof. The
Company and you agree that a final judgment in any such action or proceeding shall be conclusive
and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided
by law.
6. Severability; Captions. In the event that any provision of this Award is determined to be invalid
or unenforceable, in whole or in part, the remaining provisions of this Award will be unaffected
thereby and will remain in full force and effect to the fullest extent permitted by law. The captions of
this Award are not part of the provisions of this Award and will have no force or effect.
7. Electronic Delivery and Acceptance. Marsh McLennan may, in its sole discretion, decide to
deliver any documents related to the Award and/or your current or future participation in the Plan by
electronic
9
-- 134 of 139 --
means. You hereby consent to receive such documents by electronic delivery and agree to
participate in the Plan through an on-line or electronic system established and maintained by Marsh
McLennan or an agent appointed by Marsh McLennan.
8. Waiver. You acknowledge that neither a waiver by Marsh McLennan of your breach of any
provision of the Award Documentation nor a prior waiver by Marsh McLennan of a breach of any
provision of the Award Documentation by any other participant of the Plan shall operate or be
construed as a waiver of any other provision of the Award Documentation, or of any subsequent
breach by you.
9. Eligibility for Award. In order to be granted an Award, you must satisfy the eligibility criteria for
grantees set forth in the Plan as of the grant date.
B. Additional Provisions—Outside of the United States
1. Changes to Delivery. In the event that Marsh McLennan considers that due to legal, regulatory or
tax issues the normal exercise of an Award (as described in these Terms and Conditions) by a
participant outside the United States would not be appropriate, then Marsh McLennan may, in its sole
discretion, determine how and when the value of the Award will be delivered. Without limitation, this
may include making any payments due under the Award in an amount equivalent to the value of the
Award on the date of exercise after payment of applicable Tax-Related Items and fees and any
exercise price. If the value of an Award is to be delivered in cash instead of shares of Common
Stock, Marsh McLennan may sell any shares of Common Stock distributable in respect of the Award
on your behalf and use the proceeds (after payment of applicable Tax-Related Items, fees and any
exercise price) to satisfy the Award.
2. Amendment and Modification. The Committee may modify the terms of any Award under the
Plan granted to you in any manner deemed by the Committee to be necessary or appropriate in
order for such Award to conform to laws, regulations and customs of the country (other than the
United States) in which you are then resident or primarily employed or were resident or primarily
employed at the time of grant or during the term of the Award, or so that the value and other
benefits of the Award to you, as affected by non-U.S. tax laws and other restrictions applicable as a
result of your residence or employment outside of the United States, shall be comparable to the
value of such an Award to an individual who is resident or primarily employed in the United States.
VII. QUESTIONS AND ADDITIONAL INFORMATION
Please retain this document in your permanent records. If you have any questions regarding the Award
Documentation or if you would like an account statement detailing each type of equity-based award and the number
of shares of Common Stock covered by such equity-based award that comprises the Award, and the exercise price,
vesting date(s) and expiration date of such equity-based awards that comprise the Award, or any other information,
please contact:
Executive Compensation
Marsh & McLennan Companies, Inc.
1166 Avenue of the Americas
New York, NY 10036-2774
United States of America
Telephone Number: +1 212 345-9722
Facsimile Number: +1 212 948-8481
Email: mmc.compensation@mmc.com
10
-- 135 of 139 --
IN WITNESS WHEREOF, Marsh McLennan has caused these Terms & Conditions to be duly executed by the facsimile
signature of its Senior Vice President, Chief People Officer as of the day and year first above written. By consenting
to these Terms and Conditions, you agree to the following: (i) you have carefully read, fully understand and agree to
all of the terms and conditions described herein and in the Award Documentation; and (ii) you understand and agree
that these Terms & Conditions and the Award Documentation constitute the entire understanding between you and
Marsh McLennan regarding the Award, and that any prior agreements, commitments or negotiations concerning the
Award are replaced and superseded. The grant of the Award is contingent upon your acceptance of these Terms and
Conditions, Country-Specific Notices and Restrictive Covenants Agreement (if applicable) by the date and in the
manner specified in materials provided to you by Executive Compensation and/or the Company’s stock plan service
provider. If you decline the Award or you do not accept the Award and any applicable documents described in the
preceding sentence by the date and in the manner specified, the Award will be cancelled as of the grant date of the
Award.
/s/Carmen Fernandez
Carmen Fernandez
SVP, Chief People Officer
11
-- 136 of 139 --
Exhibit 31.1
CERTIFICATIONS
I, Daniel S. Glaser, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Marsh & McLennan Companies, Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
internal control over financial reporting.
Date: April 21, 2022 /s/ Daniel S. Glaser
Daniel S. Glaser
President and Chief Executive Officer
-- 137 of 139 --
Exhibit 31.2
CERTIFICATIONS
I, Mark C. McGivney, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Marsh & McLennan Companies, Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
internal control over financial reporting.
Date: April 21, 2022 /s/ Mark C. McGivney
Mark C. McGivney
Chief Financial Officer
-- 138 of 139 --
Exhibit 32.1
Certification of Chief Executive Officer and Chief Financial Officer
The certification set forth below is being submitted in connection with the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31,
2022 of Marsh & McLennan Companies, Inc. (the "Report") for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) under the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 1350 of Chapter 63 of Title 18 of the United States Code.
Daniel S. Glaser, the President and Chief Executive Officer, and Mark C. McGivney, Chief Financial Officer, of Marsh & McLennan Companies, Inc.
each certifies that, to the best of his knowledge:
1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Marsh &
McLennan Companies, Inc.
Date: April 21, 2022 /s/ Daniel S. Glaser
Daniel S. Glaser
President and Chief Executive Officer
Date: April 21, 2022 /s/ Mark C. McGivney
Mark C. McGivney
Chief Financial Officer
-- 139 of 139 --